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Background: Chronic rhinosinusitis (CRS) is a prevalent upper respiratory condition 
characterized by inflammation of the paranasal sinuses. Few epidemiologic studies of 
CRS have been performed outside of tertiary care settings (e.g., surgical referral 
centers), likely representing the most severe end of the disease spectrum.  
Objectives: 1) compare several definitions of acute exacerbations of nasal and sinus 
symptoms (AENSS) by prevalence and risk factors; 2) quantify the workplace indirect 
costs of CRS, related conditions, and nasal and sinus and related symptoms; and 3) 
investigate measurement properties of two commonly used sinus computed tomography 
(CT) opacification scoring procedures (Lund-Mackay [LM] and modified Lund-Mackay 
[mLM]).  
Methods: We selected individuals from the electronic health record (EHR) of Geisinger 
to participate in a longitudinal questionnaire-based study of CRS. Of the 23,700 
individuals selected from the EHR, 7847 responded to the baseline questionnaire. Self-
reported NSS and physician diagnoses were used to operationalize AENSS. Measures 
of workplace absenteeism, presenteeism, and lost productive time (LPT) were derived 
from responses based on the Work and Health Interview. Sinus CT scans were 
completed for a subset of 646 individuals and opacification was quantified by LM and 
mLM. Measurement properties were assessed by EFA and further characterized by LCA 
for LM only.   
Results: AENSS were common in the general population with seasonal trends in 
exacerbation dependent on operationalization. AENSS based on timing of symptoms 
and worsening mucopurulence (AENSS-Sx-Pur) had risk factors consistent with 
literature and less seasonal trends in prevalence. Workplace LPT was driven by three 




constitutional symptoms, which mediated the associations of diagnoses with LPT. Lastly, 
LM and mLM appeared to measure the same underlying construct (i.e. sinus 
inflammation). However, latent class analysis (LCA) identified three homogeneous 
subgroups of individuals based on patterns of sinus opacification.  
Conclusions: AENSS was common in the general population and certain NSS domains 
were associated with workplace LPT. Further, single score approaches to quantifying 
sinus opacification are likely incorrect and location and patterns of opacification should 
be taken into consideration. Further studies of CRS are needed to validate these 
findings.  
 
Thesis readers: Brian S. Schwartz, Karen Bandeen-Roche, Jessie P. Buckley, and 
Ghassan B. Hamra 
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Chapter 1: Introduction 
1.0 Rationale 
 Chronic rhinosinusitis (CRS) is a prevalent upper-respiratory condition of the 
paranasal sinuses, significantly affecting quality of life and incurring large societal 
burdens.1 Few epidemiologic studies of CRS have occurred outside of the tertiary care 
setting; as such, our knowledge of CRS etiology, risk factors, and outcomes are limited 
to individuals likely comprising the most severe end of a broad spectrum of sinus 
disease. Therefore, the purpose of this dissertation was to perform one of the first 
general population-based epidemiologic studies of CRS to address critical gaps in our 
understanding of: 1) risk factors for exacerbations of CRS; 2) workplace impacts of CRS, 
comorbidities, and overlapping symptoms; and 3) measurement and correlates of 
radiologic inflammation in sinus disease. 
1.1 Rhinosinusitis and related conditions terminology 
Rhinosinusitis is a broad term used to designate conditions characterized by 
inflammation of the nasal cavities as well as the paranasal sinuses. It is a portmanteau 
created from two common medical terms: rhino (meaning “of the nose”) and sinus, with 
the suffix -itis indicating inflammation. Below, we introduce and define several related 
conditions characterized by rhinosinusitis.   
1.1.1 Acute rhinosinusitis 
Acute rhinosinusitis (ARS) is defined by several consensus groups, including the 
European Position Paper on Rhinosinusitis and Nasal Polyps (EPOS),1 the American 
Academy of Otolaryngology–Head and Neck Surgery (AAO–HNS),2 and the International 
Consensus Statement on Allergy and Rhinology (ICAR)3 by presence of the following 
symptoms: nasal blockage, congestion, or stuffiness; nasal discharge or postnasal drip 
(could be mucopurulent); reduction (hyposmia) or loss of smell (anosmia); and facial 




present and there must be at least two symptoms total.1 While symptomatology 
requirements are the same across consensus groups, they differ in establishing which 
durations are indicative of ARS with EPOS using a duration of less than 12 weeks,1 
while AAO–HNS and ICAR use a duration of 4 weeks or less.2,3  
ARS is often further sub-sectioned based on origin of inflammation (e.g., viral or 
bacterial) or recurrence in a defined period of time. For example, acute viral 
rhinosinusitis (AVRS) i.e., the common cold, generally has a symptomatic duration of 
less than 10 days.1,2 Acute post-viral rhinosinusitis (APVRS) is defined by an increase in 
number of symptoms after five days or persistent symptoms after 10 days, with 
symptoms not lasting beyond 12 weeks.1 Acute bacterial rhinosinusitis (ABRS) is defined 
differently by EPOS and AAO–HNS, though both agree that inflammation is of bacterial 
origin.1,2 EPOS defines ABRS as any combination of three or more symptoms or signs 
of: discolored discharge (with unilateral predominance) and purulent secretion in the 
casum navi (nasal cavity); severe local pain (with unilateral predominance); fever (>38°C 
or 100.4°F); elevated erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP); 
and, “double-sickening” which is a worsening of symptoms after an initial improvement 
or mild phase of symptoms.1 AAO–HNS, however, defines ABRS by ARS with 
suspected or confirmed bacterial infection in the nasal cavity or paranasal sinuses and 
either persistence or worsening of symptoms after 10 days.2 Lastly, recurrent ARS 
(RARS) is defined as ARS episodes occurring at least four times per year with complete 
remission of symptoms between episodes.2,3  
1.1.2 Chronic rhinosinusitis 
Several consensus groups define chronic rhinosinusitis (CRS) by subjective 
symptoms and objective evidence, both of which are required to clinically diagnose an 




however, these symptoms must have a duration of at least 12 weeks.1-3 Objective 
evidence, used to confirm the subjective symptoms, includes: endoscopic confirmation 
of nasal polyps, mucopurulent discharge of the middle meatus, and/or edema with or 
without mucosal obstruction in the middle meatus; and/or computed tomography (CT) 
scans of the osteomeatal complex and sinuses.1-3 EPOS proposed a definition for 
epidemiologic research based solely on the aforementioned subjective symptoms 
(CRSS) and duration criteria, since objective evidence is often difficult to obtain in large-
scale studies.1 However, other operationalizations of CRS definitions exist, including 
those based on: objective evidence only (CRSO); International Classification of Diseases 
(ICD) codes in medical records (CRSICD); electronic health records (EHR; CRSEHR), 
extending CRSICD to also include other aspects of the EHR (e.g., current procedural 
terminology [CPT] codes and laboratory diagnostics); and self-reported physician 
diagnosis of CRS (CRSSR).  
Throughout this dissertation, we make note of which definition of CRS is being 
described, saving the general use of “CRS” (with no clarifying subscript) for broad 
discussions of the underlying disease.  
1.1.3 Related conditions 
1.1.3.1 Allergic and non-allergic rhinitis 
Rhinitis, inflammation of the nasal mucosa, is differentiated by cause of symptoms 
onset. Allergic rhinitis (often referred to as “hay fever”) is characterized by an 
immunoglobulin E (IgE)-mediated immune response to external stimuli (e.g., animal 
dander, fungi, pollens) interacting with nasal mucosa.4,5 This atopic sensitization to 
certain external stimuli represents the hallmark of allergic responses in general; 
however, in allergic rhinitis this results in symptoms of: itching (nasal or ocular [i.e. eye]), 




Non-allergic rhinitis, while encompassing the same set of symptoms, is distinct from 
allergic rhinitis because the symptoms are not induced by an atopic response to external 
stimuli.6 Instead, symptoms are induced by a combination of biologic pathways, 
including: classic inflammatory, neurogenic, and idiopathic (unknown).7 
1.1.3.2 Asthma 
  Asthma is a heterogeneous chronic inflammatory condition of the lower airways 
characterized by diverse and recurrent symptoms (e.g., wheeze, shortness of breath, 
chest tightness), airflow obstruction, and bronchial hyperresponsiveness.8  
1.1.3.3 Aspirin exacerbated respiratory disease/Samter’s triad 
Aspirin exacerbated respiratory disease (AERD), sometimes referred to as Samter’s 
triad, is a culmination of three distinct conditions, including: nasal polyposis, aspirin (and 
other cyclooxygenase 1 [COX-1] inhibitors) allergy, and asthma.9   
1.1.3.4 Acute exacerbation of chronic rhinosinusitis 
Acute exacerbation of chronic rhinosinusitis (AECRS), sometimes referred to as 
“acute on chronic” CRS, is a sudden worsening of CRS-relevant nasal and sinus 
symptoms (NSS). While closely related to ARS, AECRS is not believed to simply be a 
viral cold in someone with CRS, but rather a separate pathologic phenomenon. The 
difficulty in formally defining AECRS stems from the fact that no universal or consensus-
recognized definition exists. To date, only 13 studies of AECRS have been completed, 
nearly all using a different operationalized definition. A summary of the studies, their 
respective samples, definitions, and conclusions is provided in Table 1.1.3.4.1. The 
majority of the few existing AECRS studies have focused on medical interventions and 
treatments, microbiology, or immunology of—as opposed to understanding the broad set 
of risk factors for—AECRS. As such, ICAR has declared a need for more extensive 




better understand and define this phenomenon. The first aim of this dissertation was a 




Table 1.1.3.4.1. Overview of prior studies of acute exacerbations of CRS (AECRS) 
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criteria: meet clinical 
definition of CRS which 
is 12 weeks with at 
least 2 of the major 
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within the past 5 years 
with a Lund-Mackay 
score >5; nasal polyps 
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physical exam; and 
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1.2 Etiology, pathogenesis, and pathophysiology of CRS 
While we did not formally assess etiology or pathogenesis of CRS as part of this 
dissertation, understanding the biological sequelae promulgating in observed sinus 
disease was important in understanding the possible risk factors for CRS. As such, we 
briefly introduce the etiology, pathogenesis, and pathophysiology of CRS in this section.  
CRS has often been considered to manifest as two divergent phenotypes—with 
nasal polyps (wNP) and without nasal polyps (sNP)—with diagnosis dependent on polyp 
identification in the middle meatus during nasal endoscopy.1,10 Conventionally, CRSwNP 
was thought to be an exaggerated atopic response while CRSSNP was due to persistent 
bacterial infection1,11; however, recent evidence suggests that both phenotypes share 
common etiologic and pathogenic characteristics.1,12-16 To better understand CRS 
etiology and pathogenesis, Tan et al.17 developed a conceptual framework to help 
elucidate underlying mechanisms involving CRS (Figure 1.2.1). It has been 
Figure 1.2.1. Rhinosinusitis framework. Adapted from: Tan et al. 2013. 
Chronic rhinosinusitis: the unrecognized epidemic. Am J Respir Crit Care 




hypothesized that CRS originates as NSS—caused (completely or partially) by a 
combination of previous and current exposures, co-morbidities, and genetic 
susceptibility—which promotes rhinitis and/or ARS, which could be recurrent (i.e. 
RARS).17 Pursuant with this concept, several hypotheses regarding the origins of CRS 
have been articulated.  
 Microbes (e.g., bacteria and fungi) and deficient host-immune barriers have been 
proposed as causative agents in CRS development. However, no single etiologic source 
has been identified in all individuals diagnosed with CRS. Further, individuals have 
varied immunological and inflammatory responses to the same agents, thus the field of 
CRS research has shifted away from viewing this disease as strictly phenotypic, but 
rather one of many endotypes (unique subgroups of individuals identified by specific 
biological mechanisms or processes associated with the observed disease) culminating 
in the known phenotypes (CRSSNP and CRSwNP).7 Below, we consider each potentially 
causative agent or source of CRS, noting associations with specific phenotypes where 
available information exists. We end this section with an overview of the proposed CRS 
endotypes and how they relate to the various causative agents or sources as well as the 
major phenotypes of CRS. 
1.2.1 Bacteria 
The most commonly reported bacteria associated with CRS include: Haemophilus, 
Moraxella, Pseudomonas, Staphylococcus aureus, and Streptococcus 1,7,18; however, 
Staphylococcus aureus is the most observed and/or elucidated.12,19-25 To date, there are 
at least three major hypotheses regarding the role of bacteria in CRS development, 
involving superantigens, biofilms, and microbiomes.12  
1.2.1.1 Superantigens 
The superantigen hypothesis primarily concerns infection by Staphylococcus 




produces—in an effort to exaggerate local eosinophilic immune responses.26-28 Though 
the presence of S. aureus in nasal and sinus cavities has been shown in both 
phenotypes of CRS,28 the role of superantigens has been extensively implicated in the 
immune responses associated with CRSwNP.26,27,29 The current understanding is that 
Staphylococcus aureus superantigens, particularly superantigen B (SEB), binds the T-
cell receptor outside of the antigen-binding groove and human leukocyte antigen (HLA) 
major histocompatibility complex II (MHC-II), present on antigen presenting cells 
(APCs).26-28 By doing so, there is a highly robust polyclonal T-cell expansion, which 
leads to increased pro-inflammatory cytokine release consistent with T-helper 2 cells (IL-
2, IL-4, IL-5), while inhibiting T-regulatory cells and their respective cytokines (IL-10 and 
TGF-β), leading to a T-helper 2 dominant immune response.27,29 This T-helper 2 biased 
immune response promotes immunoglobulin E (IgE) production from plasma cells 
(antibody secreting B-cells), which further promotes local inflammation by evoking mast 
cell degranulation.30 Despite this clear eosinophilic and T-helper 2 driven inflammatory 
response in CRSwNP, recent evidence suggests that the immune responses are not 
quite so homogeneous.1,16 In fact, studies have shown that western (Caucasian) 
individuals with CRSwNP tend to display the aforementioned eosinophilic/T-helper 2 
responses, whereas eastern (Asian) individuals have a tendency towards a neutrophilic 
and T-helper 1/T-helper 17 responses.1,16,31,32 Therefore, the utility of superantigens (and 
the immune responses they invoke) as an underlying mechanism for CRSwNP is 
debatable, and may be better described as a modifying factor or disease promoter.12  
1.2.1.2 Biofilms  
Biofilms, collective communities of bacteria organized within an extracellular matrix, 
are a survival mechanism for bacteria to resist host defense mechanisms and antibiotic 
treatments.33 The presence of biofilms has been detected in both phenotypes of CRS 




dependent on detection methodology.1,35 The specific role biofilms play in causing CRS 
is debatable and not fully understood.12,39,40  
1.2.1.3 Microbiomes 
Similarly, the role of the nasal and sinus microbiomes has been the topic of recent 
research in CRS. Results from prior studies have been incredibly divergent, with no clear 
associations between microbiome diversity and richness/abundance with either 
phenotype. The clearest observation across relevant studies is that bacterial diversity in 
the sinonasal microbiome is reduced when Staphylococcus aureus is abundant, with the 
latter bacteria often observed in individuals with CRSwNP.41-46 However, inconsistent 
use of sensitive molecular techniques (e.g., 16s RNA), differences in sampling locations, 
and difficulties in extracting samples from the target areas (e.g., from within sinus rather 
than from nasal cavity without contamination from the latter), makes this concept an 
issue of much needed advancement.12 
1.2.2 Fungi 
The role of fungi in CRS has been an issue of initial acclaim and subsequent 
dismissal.12 Early studies evaluating the role of fungal infections in CRS development 
found nearly all subjects with active CRS were predominantly colonized with Alternaria 
fungi, with colonization either absent in controls47 or in reduced concentration.48 
However, later studies, including a double-blind randomized controlled trial, found little 
efficacy of antifungals in treating CRS.49,50 Even if fungal infections are not the primary 
etiologic cause of CRS, however, they are thought to be important in characterizing 
individuals who transition from allergic fungal rhinosinusitis (AFRS) to CRS17 with 
Alternaria and Aspergillus being most often implicated.1,47,51 
1.2.3 Immune barriers: 
Lastly, a concept which seeks to support each of the aforementioned hypotheses 




exposures to foreign materials are generally handled via mucociliary clearance with no 
subsequent ensuing illness; however, inadequate mucociliary clearance and mechanical 
barriers (e.g. tight junctions) results in increased biologically relevant contact with these 
various foreign agents, resulting in inflammation, inadequate host responses, and 
ultimately sinus disease.52-54 It is also believed that imbalances in innate antimicrobials 
(defensins, lysozymes, S100s, lactoferrin, complement, collectins),1 altered pattern 
recognition receptor (PRR) signaling,12 and (most recently) defective T2R bitter taste 
receptors in the nose55 may play a role in CRS etiology.  
1.2.4 Endotypes of CRS 
 As previously mentioned, the field of CRS research has shifted away from viewing 
this disease as strictly phenotypic. Several recent studies have attempted to identify 
endotypes of CRS, though few are consistent across studies, and none were completed 
using individuals from a general population-based sample. A joint consensus group of 
the European Academy of Allergy and Clinical Immunology (EAACI) and American 
Academy of Allergy, Asthma & Immunology (AAAAI) outlined a potential framework for 
associating phenotypes of CRS with endotypes (Figure 1.2.4.1).7 However, the 




 Several studies have identified chemokines (namely 
CCL-1856 and CCL-2357), proteins which are chemotactic (engender movement and 
recruitment of neighboring cells) and bring inflammatory cells to target sites in tissue,58 
as potentially important biomarkers in (western) nasal polyposis (CRSwNP).56,57 
Similarly, a prior study of participants with CRSwNP, CRSSNP, and AERD found several 
T-helper (Th)-2 cytokines (proteins secreted by cells59) were associated with CRSwNP 
and AERD, but no differences were observed for CRSSNP.60 Specifically, increased 
levels of interleukin (IL)-5, IL-13, eotaxin-2, and monocyte chemoattractant protein 
(MCP)-4 were associated with CRSwNP while increased levels of eosinophil cationic 
protein (ECP), granulocyte macrophage-colony stimulating factor (GM-CSF), and MCP-1 
were associated with AERD. Decreased expression of tissue plasminogen activator 
(tPA) was also associated with AERD.60 
 In the same vein, a multi-center study identified as many as 10 endotypes 
represented by participants with CRSSNP, CRSwNP, and controls (individuals 
undergoing sinus surgery but who did not have diagnosis of CRS).61 This study 
observed IL-5 to be a key component in broadly differentiating two classes of endotypes, 
Figure 1.2.4.1. Key 
phenotypes and proposed 
endotypes of CRS and 
their possible associations. 
ASA, aspirin; CRS, chronic 
rhinosinusitis; IL, 
interleukin; IgE, 
immunoglobulin E; Th, T-
helper. Akdis et al. 2013. 
Endotypes and 
phenotypes of chronic 
rhinosinusitis: a 
PRACTALL document of 
the European Academy of 
Allergy and Clinical 
Immunology and the 
American Academy of 
Allergy, Asthma & 
Immunology. J Allergy Clin 





with low IL-5 levels identifying four endotypes: three representing CRSSNP with low 
prevalence of comorbid asthma and one representing a Th17 with a mix of CRSSNP and 
CRSwNP phenotypes. The remaining six endotypes were further differentiated based on 
medium or high IL-5 levels, comorbid asthma prevalence, and Staphylococcus aureus 
enterotoxin-specific IgE.61 
 While an endotype-driven approach to classification (and certainly treatment) of CRS 
is useful in accounting for the high variability in inflammation profiles represented by this 
one condition, no studies have replicated findings or found consistent endotypes across 
geographies and racial/ethnic groups.62 
1.3 Epidemiology of CRS 
1.3.1 Estimates of prevalence and risk 
Although CRS has been diagnosed in children,1,10,63,64 the majority of cases and 
epidemiologic research are from adults.1 Several studies have attempted to assess the 
prevalence of CRS across multiple countries; however, the shared symptoms between 
CRS and other conditions (e.g. acute rhinosinusitis, allergic rhinitis, and migraine 
headache) makes differential diagnosis difficult without objective evidence of 
inflammation.17 We detail prior epidemiologic studies of CRS, noting the definition used 
in the study (e.g., CRSS, CRSO, CRSC), to aid in comparisons. 
A 1996 study in Korea estimated the prevalence of CRSC to be 1.0%, which is the 
lowest prevalence of CRS estimated across all definitions.65 A recent study in Europe, 
using a sample of participants with indication for CT scans of the sinuses (but did not 
have prior diagnosis of CRS), estimated the prevalence of CRSC to be 3.0%.66  
Studies of CRSO have most frequently utilized participants receiving sinus surgery or 
had a clinical indication (other than CRS) requiring CT or nasal endoscopy.66-68 It is 




studied participants across studies and different methods of ascertaining and quantifying 
objective evidence were used for each. One study assessed CT scans of the sinuses to 
estimate the prevalence of “abnormal” sinuses (including mucosal thickening, polyps, 
opacification, and bone destruction) among non-CRS participants (but had other 
indication for CT), finding 42.5% of participants had at least one abnormality in one of 
the sinuses.67 Another study, using a sample of participants undergoing sinus surgery for 
CRS, found a prevalence of 79% for CRSO. The most recent study estimated a 
prevalence of 14% using a sample of participants with indication for CT scans, but did 
not have a prior diagnosis of CRS.66  
Prevalence estimates of CRSS are almost always considerably larger than those of 
CRSC, with geographic variation in prevalence also observed. For example, population-
based studies conducted in Europe and the U.S. estimated the adult prevalence of 
CRSS to be 10.9%69 and 11.9%,70 respectively. However, a study in Brazil estimated a 
prevalence of 5.51%71 while a Chinese study observed intra-county geographic variation 
in CRSS prevalence, with estimates ranging from 4.8% to 9.7% (overall prevalence was 
8.0%).64 
Geographic variation is similarly observed with self-reported CRS. The frequently 
cited10,17,72 1996 National Health Interview Survey similarly estimated the prevalence of 
CRSSR to be 12.5% of the U.S. population73; yet, the analogous 1996 National 
Population Health Survey in Canada only found a prevalence of 5.16%.53  
Lastly, a study in Omsted, MN estimated the local prevalence of CRSICD to be 1.95%, 
while a recent study using primary care visits from the electronic health record (EHR) of 
a large health system in Pennsylvania, estimated the incidence of CRS to be 1.1 cases 




specific incidence rates, observing 83 CRSwNP and 1048 CRSSNP cases per 100,000 
person-years at risk.74  
1.4 Pre- and post-morbidities associated with CRS 
 While we did not explicitly study the “unified airway” in this dissertation, we studied 
CRS and its comorbidities, including asthma and allergic rhinitis, which are comprised 
within the concept of unified airway disease (UAD).75-85 Therefore, we frame this section 
around the UAD model. We briefly define UAD, then we describe epidemiologic 
evidence in support of UAD (especially as it relates to CRS) and pathogenesis of 
morbidities related to CRS and how they connect to CRS pathogenesis.  
1.4.1 Unified airway disease  
The UAD is a model of disease suggesting the upper and lower respiratory tracts are 
distinct regions of the same organ.75-85 As such, conditions localized to one region (e.g., 
middle ear, sinuses, bronchioles) could impact physiological mechanisms in another, as 
long as they are both connected by the unified airway (Figure 1.4.1.1). Early research 
attempting to validate UAD have posited three major criteria to which it must account: 1) 
individuals with lower respiratory conditions (e.g., asthma, bronchiectasis, chronic 
obstructive pulmonary disease [COPD]) should have a greater risk of developing upper 
respiratory conditions (e.g., allergic rhinitis and CRS), and vice versa; 2) 
pathophysiological mechanisms within each level of the respiratory tract should explain 




condition (or conditions) in one region should improve symptoms or management in the 
other.77  
1.4.1.1 Epidemiologic evidence for UAD 
Several studies have provided evidence supporting the first criterion.9,70,74,83,86-98 For 
example, a prior study of CRSICD found several pre-morbid conditions were associated 
with increased risk of incident CRSICD  (Figure 1.4.1.1.1).74 Conditions suggestive of the 
UAD, specifically acute sinusitis (i.e. ARS), otitis media (i.e. ear infection), allergic 
rhinitis, asthma, pneumonia (i.e. infection in the lungs), and gastroesophageal reflux 
disease (GERD), conferred increased risk of CRSICD in both phenotypes (CRSSNP and 
CRSwNP). Another study in the same source population observed incident cases of 
CRSICD were associated with increased hazard of subsequently developing upper 
Figure 1.4.1.1. Common conditions of the (A) upper and (B) lower respiratory system. 
ABRS, acute bacterial rhinosinusitis; COPD, chronic obstructive pulmonary disease; 





respiratory conditions – ARS, otitis media, acute upper respiratory infection (URI), 
allergic rhinitis – as well as lower respiratory conditions – asthma, COPD, GERD, and 
pneumonia (Figure 1.4.1.1.2).98  
Yet another study in the same source population similarly observed current CRSS 
was associated with increased odds of self-reported physician diagnoses of asthma and 
allergic rhinitis as well as migraine headaches.70 Comparable findings were also 
observed in two European population-based epidemiologic studies of CRSS, as part of 
the Global Allergy and Asthma European Network (GA2LEN).99,100  
 
Figure 1.4.1.1.1. Adjusted associations comparing CRSwNP and CRSSNP with 
control patients (represented by the dotted red line) using selected provider 
coded diagnoses for the entire observed duration prior to CRS diagnosis. Tan et 
al. 2013. Incidence and associated pre-morbid diagnoses of patients with 





1.4.2 Pathogenesis of allergic rhinitis 
The hallmark of allergic rhinitis, as previously mentioned, is an exaggerated IgE-
specific immune response upon exposure to foreign materials, i.e. allergens, classically 
representing type I hypersensitivity. This process of “sensitization” begins when APCs 
(e.g., dendritic cells) in nasal mucosa interact with allergens, presenting portions of the 
allergens (i.e. peptides) on the MHC-II, and forming a ligand to which naïve 
(undifferentiated) CD4+ T-cells bind and begin differentiation into allergen-specific Th2 
cells.101 Cytokines secreted by Th2 cells induce isotype switching of B cells, the antibody 
producing cells of the adaptive immune system, to which allergen-specific IgE is 
produced. Additionally, proliferation of eosinophils, neutrophils, and mast cells occurs in 
tandem, mounting the atopic response to the allergen.101  
Figure 1.4.1.1.2. Adjusted hazard ratios comparing incident disease among patients 
with CRSwNP and patients with CRSSNP compared to control patients (dotted red 
line). GERD, gastrointestinal esophageal reflux disease; UTI, urinary tract infection; 
COPD, chronic obstructive pulmonary disease. *P < 0.05. Hirsch et al. 2015. Five-





 The priming of mast cells comprises the “early” reaction to an allergen, with 
symptoms of sneezing, epiphora, and rhinorrhea ensuing due to an influx of histamine, 
prostaglandin, and leukotrienes. This is followed by the “late” reaction which is marked 
by expansion of eosinophils, resulting in nasal obstruction as a consequence of nasal 
tissue damage and remodeling.101 
1.4.3 Pathogenesis of asthma 
The hallmarks of asthma include airway inflammation, airway hyperresponsiveness 
(AHR), airway remodeling, and bronchoconstriction.8,102 The classic paradigm of asthma 
suggested that disease manifested due to a skewed Th2/Th1 polarization of the immune 
system, with Th2-mediated (type 2) inflammation dominating. However, individuals with 
a low Th2 profile have been shown to develop asthma, too.102-105 We limit our discussion 
of asthma to the major phenotype of Th2-mediated (allergic) asthma.  
 Among the Th2-dominant individuals, similarly to allergic rhinitis, there is a 
dominance of allergen-specific IgE as well as eosinophilia.8,102 These eosinophils move 
into lung tissue via Th2 cytokine (e.g. IL-4 and IL5) mediation, adherence to vascular 
endothelia, and migration aided by eotaxin chemokines (e.g., CCL11, CCL24, 
CCL26).102 Tissue-implanted eosinophils release several proteins, including those which 
induce lung damage (eosinophil cationic protein [ECP], eosinophil-derived neurotoxin 
[EDN], eosinophil peroxidase [EPO], and major basic protein [MBP]),106,107 airway 
hyperresponsiveness (MBP),107 and bronchoconstriction.106 
1.4.4 Interrelations of biological mechanisms 
We limit our discussion of interrelated biological mechanisms for allergic rhinitis, 




  Inflammatory crosstalk, the ability of stimuli in one site to induce inflammation in a 
distal site, has been previously demonstrated in individuals with asthma and allergic 
rhinitis.109 Bronchoscopy-directed antigen placement onto bronchial mucosa induced 
nasal inflammation within a short period of time. The same inflammatory consequence 
occurred in pulmonary tissue when antigen was placed on nasal mucosa.109 This may be 
expected considering the immune cells and inflammatory mechanisms invoked by 
allergic rhinitis, asthma, and CRS (especially Th2-mediated CRS) are nearly identical, 
though acting on different tissues and distal sites of the body. Therefore, localized 
inflammation may be responsible for pathogenesis of one particular condition; however, 
diffuse, systemic inflammatory processes may be responsible for sequelae related to 
development of subsequent morbidities. This concept is supported by improvements in, 




















1.5 Risk factors for CRS 
 In this section, we provide an overview of the risk factors for CRS, identified in 
previous studies. We first introduce the demographic (e.g., sex, race/ethnicity, age) risk 
factors followed by lifestyle/social (e.g., smoking status, alcohol use, socioeconomic 
status [SES]) risk factors, but we primarily focus on sex differences in CRS prevalence 
and risk. We do not discuss allergic rhinitis or asthma as these have already been 
covered in sections above. We specify which definition of CRS was used in the study as 
well as phenotype, if reported.  
1.5.1 Demographic and lifestyle risk factors 
Sex differences in CRS have been reported with respect to prevalence, reported 
symptoms, comorbidities, and phenotypes.112 First considering self-reported physician-
diagnosed CRS (CRSSR), large North American surveys have estimated the prevalence 
of CRSSR to be two-fold greater among females than males.53,113,114 This sex difference 
in prevalence, however, was not observed in a comparable survey analysis in Korea.115 
CRSICD has yielded mixed results regarding sex differences in prevalence. For example, 
a study of individuals in Pennsylvania showed males were more likely than females to 
have ICD-9 codes for CRSSNP and CRSwNP.74 However, a smaller study in Minnesota 
estimated 67.7% of ICD-9 codes for CRS were among females.116 Lastly, a study in 
Taiwan found no differences in CRSICD prevalence by sex.117 A GA2LEN study in Europe 
estimated an 8% increase in odds of CRSS in females than males,69 whereas a study in 
Pennsylvania similarly estimated increased odds of CRSS in females, especially if they 
reported facial pain or pressure (odds ratio: 1.81; 95% confidence interval: 1.32, 2.49).70 
In a separate GA2LEN publication, males had nearly twice the odds of CRSO compared 
to females.66 Considering CRSC, the majority of studies have shown either no sex 





 Few studies of CRS (any definition) have assessed racial/ethnic differences in 
prevalence or risk. One study observed whites/Caucasians were more likely to have 
CRSSR than non-whites70; however, a different study from the same source population 
saw no differences in CRSICD incidence by racial/ethnic groups.74 A large U.S. national 
survey observed greater prevalence of CRSSR among American Indians compared to 
other race groups, while Hispanics were less likely to report CRS than non-Hispanic 
ethnic groups.113 
 Considering differences in CRS risk or prevalence by age, studies have largely 
shown a positive relation between increased age and CRSSR,53,69,113,114 CRSICD 
(CRSwNP only),74 CRSS,69 and CRSC115 (CRSwNP120-122). However, one study of CRSS 
observed a negative overall association with age (though, peak prevalence was 
observed between ages 50–59)70 while a study of CRSC observed no association with 
age.65 
 Active tobacco smoking (as opposed to passive or secondhand smoking) has been 
associated with increased odds of CRSS64,69,70,99 as well as CRSO,66 but not with CRSC.65 
Similar to sex differences, associations of SES, education, insurance status, and 
race/ethnicity have been mixed. A study of CRSS in Pennsylvania observed a positive 
association with receipt of Medical Assistance (a proxy for family socioeconomic 
status),70 while a study in China observed no association of education level with CRSS.64 
A prior study of CRSSR similarly observed no association with low income status.53 
Considering CRSC, studies have shown positive associations with lower education 
status,115,122 while others have observed no associations with education65,123 and 




1.5.2 Environmental and occupational risk factors 
Pursuant with the immune-barrier hypothesis, the mucosa of the nose and paranasal 
sinuses are likely to have the first contact with various exposures (e.g. secondhand 
smoke, dust, fumes, allergens); therefore, it is believed that environmental and 
occupational exposures may not only be the driving forces behind disease transition 
from acute to chronic rhinosinusitis, but for acute exacerbation, too.124 A recent 
systematic review found 41 peer-reviewed articles that evaluated environmental and/or 
occupational exposures in relation to CRS (excluded from the review were studies of 
secondhand smoke exposure, since this had been reviewed extensively in previous 
literature, and which did appear to be associated with CRS prevalence, persistence, or 
response to treatment).125,126 Of the reviewed studies, the vast majority (40 articles) 
evaluated occupational exposures, with only one focusing solely on environmental 
exposures.127 Only five of the 41 included studies were cohort-studies, four of which 
were occupational cohorts,128-131 with the remaining study only focusing on CRSwNP.132 
Only two of the studies used a case definition which was “probable CRS” (a definition 
which specifically mentioned use of objective evidence of inflammation by CT or nasal 
endoscopy, i.e. CRSC).129,132 Considering all occupational studies with a “probable CRS” 
case definition, significant exposures included: employment as a deep sea fisherman133; 
dust from cotton textile plant134; grain farming135; low molecular weight (LMW) 
compounds136; and diving/barotrauma.129 Of the studies with a “possible CRS” case 
definition (i.e. CRSS), significant exposures/occupations included: garage work137; 
plant/machine operators, assemblers, and craft/related trades workers138; exposure to 
gases, fumes, dust or smoke131,139; glass-blowing140; and pickling and mustard factory 
work.141 A recent cross-sectional study in China similarly found occupational exposures 
to dust, poisonous gas, and carpets to be significant risk factors for CRSS.142 Importantly, 




establish exposure metrics, as opposed to primary measurement of toxicants in 
environmental media. 
A study in Norway, using self-reported occupational exposures, observed paper dust, 
cleaning agents, metal dust, animals, moisture/mold/mildew, and “physically strenuous 
work” were all associated with CRSS.143 A U.S. study using a more formal assessment of 
exposure to air pollutants (specifically fine particulate matter [PM2.5] and black carbon 
[BC]) via Pittsburgh-area air pollution monitoring stations, observed associations 
between increased PM2.5 exposures and number of functional endoscopic sinus 
surgeries (FESS) as well as increased BC exposure and increased sinonasal outcome 
test (SNOT)-22 scores (indicating greater reporting of symptoms), among individuals 
with clinically diagnosed CRSSNP.144 
Additional studies investigating environmental and occupational risk factors for CRS, 
especially CRSC, and among individuals selected from a general population sample, are 
needed to better identify and understand the roles they may play in CRS etiology. 
1.6 Cost of illness 
 Costs of an illness (COI), often referred to as “burden of disease” (BOD), are 
generally broken into three components: direct, indirect, and intangible costs.145 While 
the methodologies employed in COI studies vary considerably from field to field, their 
primary purpose is to provide quantifiable estimates of the impact illnesses have on 
society, employers, and individuals.146 Below, we define and describe the two largest 
components of COI, direct and indirect costs, followed by these costs as they relate to 
CRS. We do not discuss intangible costs as there is no consensus about what 
constitutes these costs.145 
 Direct costs are those which are immediately related to the diagnosis, management, 




medical products, health care services, and medications are all direct costs of 
illness.145,146 Indirect costs are those which relate to impacts of the condition on daily 
functioning and livelihood. For example, missing work due to illness (i.e. absenteeism) 
and reduced productivity while at work due to illness (i.e. presenteeism) are the biggest 
contributors to indirect costs of illness.146-148 While it may be intuitive for direct costs of 
illness to be greater than indirect costs, the converse is generally true, with indirect costs 
amounting to an average of  2.3-times more than direct costs.148  
1.6.1 Workplace impacts of CRS 
A recent systematic review focused on characterizing the economic impact of adult 
CRS in the United States.149 Of the 44 papers selected for inclusion, four studies 
assessed the direct costs of CRS150-153 while only two assessed the indirect costs.154,155 
Considering direct medical costs only, the most commonly referenced estimate 
suggested adult CRSICD incurred an incremental cost of $8.6 billion,152 which 
approximates $9.9 billion in 2014, accounting for inflation.149 However, a study published 
in 2015—using the same data source as well as regression models and selection 
weights, estimated the national incremental cost (additive costs due to illness; derived by 
subtracting costs in those with illness from those in otherwise comparable individuals 
without illness) of CRSICD to be $12.5 billion per year.156 Authors assumed a national 
prevalence of CRS to be 3.5%, estimating the total national expense of the condition to 
be $60.6 billion, annually.156  
Indirect costs of CRS have received much less attention, compared to the direct 
costs. A previous study used a prospective cohort of CRSC patients to assess indirect 
costs by measuring workplace lost productivity time (LPT), an overall estimate of 
workplace impacts combining absenteeism and presenteeism,157 finding annual costs of 




study to estimate indirect costs of CRS, though restricted to refractory (recalcitrant) 
CRSC cases, used a small prospective cohort and estimated a cost of $10,077 per 
patient per year—$12.8 billion overall—using lost productivity costs.155 
Importantly, no prior studies of the workplace impacts of CRS have been completed 
using individuals selected from the general population, which was an aim of this 
dissertation. Further, no prior studies have included individuals across the broad 
spectrum of sinus disease (most have been of individuals from tertiary referral clinics), 
nor have they accounted for comorbidities with overlapping symptomatology (e.g., 
allergic rhinitis, asthma, migraine headache).  
1.7 Clinical diagnoses 
While we did not study healthcare economics, resource utilization, or disparities in 
healthcare access and referral in this dissertation, it was important to understand the 
general process by which an individual receives a clinical diagnosis of a condition, as we 
used self-reported physician diagnosed comorbidities in our analyses. Therefore, in this 
section, we introduce a broad framework to understand how an individual receives a 
clinical diagnosis, followed by a framework specific to the diagnosis of CRS. We extend 
the latter by discussing the role of subjective measures in relation to CRS and 
associated conditions; and the role of objective measures (i.e., endoscopy, MRI, and CT 
imaging) in the diagnosis and study of CRS. 
1.7.1 Framework for clinical diagnosis 
 The Committee on Diagnostic Error in Health Care of the National Academies of 
Sciences, Engineering, and Medicine developed a framework to better understand the 
process of clinical diagnosis, with the broader lens of improving diagnosis through 
reduction in diagnostic errors.158 The process of diagnosis is inherently patient-centered, 




clinician, stresses that patient education and self-advocacy are critical,158,159 and is highly 
iterative (Figure 1.7.1.1).158 
 As represented by the framework, the first step in receiving a diagnosis is an 
individual experiencing symptoms. The second step occurs if and when the individual 
seeks medical care for their symptoms. While the committee did not include the factors 
related to whether an individual seeks medical care for symptoms in their framework or 
explanation, there are additional considerations between the first two steps: 1) Is this the 
first time these symptoms have been experienced? 2) Are they (subjectively) severe 
enough to prompt seeking of medical care? 3) Are there barriers to receiving medical 
care even if the need for it is presented? The next step is actually a series of iterative 
and co-dependent steps wherein information is gathered, integrated, and interpreted to 
culminate in a working diagnosis or several working diagnoses. Information gathered 
includes clinical history and interview, physical exam, objective diagnostic testing, and 
perhaps referral or consultation with other clinicians/specialists. As diagnoses are ruled 
Figure 1.7.1.1. Framework of clinical diagnosis proposed by the Committee on 
Diagnostic Error in Health Care of the National Academies of Sciences, 
Engineering, and Medicine. Ball J, Balogh E, Miller BT. Improving diagnosis in 




out by subjective and objective measures, the remaining working diagnoses are 
comparatively verified against the individual’s contextual influences (e.g., physiology, 
demographics, comorbidities, other risk factors) until a (tentatively) final diagnosis is 
made. At that point, the clinician communicates to the individual the diagnosis, its 
implications, course of treatment, and next steps. Treatment is then initiated with follow-
up being critical to determine if the initial diagnosis was accurate and whether positive 
outcomes are observed for the individual.158 
1.7.2 Clinical diagnosis of CRS 
 As previously mentioned, several consensus groups have advised a clinical definition 
of CRS (i.e. CRSC) to not only include a certain combination of reported symptoms, but 
confirmation of inflammation via objective measures, too.1-3 While it has been argued 
that symptom-based definitions of CRS (i.e. CRSS) are useful because symptoms are 
what drive individuals to seek care (and thus, receive a diagnosis), objective evidence is 
necessary to provide differential diagnosis and targeted treatment for symptoms.1  
 In general, individuals transition from being asymptomatic to experiencing NSS.17 
Individuals with NSS, depending on the duration, severity, or bother of symptoms may 
first use over-the-counter products, and then, if there isn’t sufficient relief, seek medical 
care whereby presumptive treatment (active measures at treating symptoms without 
formal diagnosis) could include antibiotics, oral (systemic) or inhaled corticosteroids, 
antihistamines, and nasal irrigation or nasal saline spray.1,10 These symptoms may 
resolve, be recurrent, or persist with duration and frequency of symptoms narrowing 
possible diagnoses.1-3,10 Whereas infrequent or readily remitted symptoms may be an 
indication of ARS or allergic rhinitis,1,160 persistent symptoms over required periods of 
time (i.e. 12 weeks) may indicate CRS.1-3,10 Considering individuals with “true CRS” (not 




be presumptively treated, remit, develop symptoms, and start the process again.17 After 
several rounds of long-term unsuccessful treatment, they may receive further diagnostic 
testing to begin ruling in/out possible diagnoses, with endoscopy, MRI, or CT used for 
confirmation of CRSC as diagnosed by an otorhinolaryngologist or the primary care 
physician.1-3,10 However, these objective measures are usually only performed on 
individuals where surgical intervention is likely to be initiated, representing a small 
percentage of individuals on the spectrum of sinus disease. Below, we present a series 
of flow-diagrams highlighting the clinical process by which diagnosis of ARS (Figures 
1.7.2.1 and 1.7.2.2) or CRS (Figures 1.7.2.3–1.7.2.5) occurs. Although this 
consideration is not directly relevant to the research presented herein, it is helpful to 
understand the clinical decision-making process and how it may influence the range of 
conditions that have been labeled as “CRS” in the literature. 
Diagnosis of ARS in the primary-care setting is common and generally 
uncomplicated1; however, severe or recalcitrant ARS (e.g. ABRS) is often referred to an 
otorhinolaryngologist (Figure 1.7.2.1).1,10 In a specialist-care setting, severe ARS often 
results in directed medical therapies, including culture-based antibiotics (if bacterial 
presence confirmed) and oral steroids, as well as endoscopy, MRI, or CT imaging for 
ruling-in surgical intervention (Figure 1.7.2.2).1,10  
The diagnostic process for CRS in a primary-care setting is similar to that of ARS, 
albeit with different definitional operationalization, though referral to an ENT is 
recommended more often in CRS than ARS (Figure 1.7.2.3).1 In a specialist-care 
setting, phenotyping of CRS is usually performed via nasal endoscopy (to confirm 
presence of nasal polyps), with subsequent medical and surgical therapies tailored to 
the observed phenotype (CRSwNP or CRSSNP). While both phenotypes often receive 




surgical interventions are more readily performed in those with nasal polyps (Figure 
1.7.2.4), compared to those without (Figure 1.7.2.5).161 
  
Figure 1.7.2.1. Flow diagram of ARS clinical diagnosis and recommended 
treatments and courses of action, in a primary-care setting. Adapted from 
Fokkens WJ, Lund VJ, Mullol J, et al. European Position Paper on 
Rhinosinusitis and Nasal Polyps 2012. Rhinol Suppl 2012(23):3 p preceding 







Figure 1.7.2.2. Flow diagram of ARS clinical diagnosis and recommended 
treatments and courses of action, in a specialist-care setting. Adapted from 
Fokkens WJ, Lund VJ, Mullol J, et al. European Position Paper on 
Rhinosinusitis and Nasal Polyps 2012. Rhinol Suppl 2012(23):3 preceding 
table of contents, 1-298. [published Online First: 2012/07/07 
Figure 1.7.2.3. Flow diagram of CRS clinical diagnosis and recommended 
treatments and courses of action, in a primary-care setting. Adapted from 
Fokkens WJ, Lund VJ, Mullol J, et al. European Position Paper on 
Rhinosinusitis and Nasal Polyps 2012. Rhinol Suppl 2012(23):3 p preceding 






Figure 1.7.2.4. Flow diagram of CRSwNP clinical diagnosis and recommended 
treatments and courses of action, in a specialist-care setting. Adapted from Fokkens 
WJ, Lund VJ, Mullol J, et al. European Position Paper on Rhinosinusitis and Nasal 
Polyps 2012. Rhinol Suppl 2012(23):3 p preceding table of contents, 1-298. 





1.7.3 Subjective measures of disease 
Following the argument in the previous section, symptoms are the manifestation of 
underlying pathology, which are usually the reason why an individual seeks medical 
care.158 Some conditions have diagnostic criteria based solely on symptoms. For 
example, migraine headache is primarily based on the reporting of three specific 
symptoms during headache episodes: nausea, photophobia (sensitivity to light), and 
disability (inability to function productively, as usual).162 Similarly, viral colds (i.e. ARS) 
are diagnosed based on duration and frequency of specific symptoms.1 While clinical 
diagnosis of allergic rhinitis,160 asthma,163 and CRS1-3 is usually done based on 
presentation of signs and symptoms alone, consensus guidelines recommend using 
Figure 1.7.2.5 Flow diagram of CRSsNP clinical diagnosis and recommended 
treatments and courses of action, in a specialist-care setting. Adapted from 
Fokkens WJ, Lund VJ, Mullol J, et al. European Position Paper on Rhinosinusitis 
and Nasal Polyps 2012. Rhinol Suppl 2012(23):3 p preceding table of contents, 1-




objective measures in order to guide therapies and prognostication. Below, we outline 
the symptom-based components of these overlapping conditions. 
1.7.3.1 Allergic rhinitis 
Allergic rhinitis is often diagnosed by the presence of two or more symptoms, with 
near daily frequency and duration of at least one hour, including nasal congestion, nasal 
itching, sneezing, and rhinorrhea.160  
1.7.3.2 Asthma 
Asthma is often diagnosed by history of wheeze, shortness of breath, chest 
tightness, and cough. These symptoms should vary in intensity and severity over time 
(i.e. should not be persistent).163  
1.7.3.3 Chronic rhinosinusitis 
As previously described, CRS is characterized by symptoms of nasal 
blockage/congestion, nasal discharge (anterior and/or posterior), smell loss, and facial 
pain/pressure. These symptoms must have a duration of at least 12 weeks.1 
1.7.4 Utility of symptoms in diagnosis and study of CRS 
 Symptoms are critically important not only in the accurate diagnosis of CRS,1 but in 
the study of CRS, too. As shown in previous sections, symptoms are the driving force 
behind an individual seeking medical care in the first place. Further, individuals generally 
care most about the treatment and abatement of their symptoms, as opposed to 
underlying pathogenesis or pathophysiology. This highlights an important dichotomy in 
medical care, one which was highlighted in the aforementioned discussion of patient-
centered care158,159: patients care about symptoms, physicians care about underlying 
processes resulting in those symptoms that can direct care. This dichotomy is 
manifested in research settings, too. Studies of CRSS are important in that they can 
provide deeper understanding of the risk factors for—and implications of—
symptoms.69,70,164 However, symptom-based definitions like CRSS are limited in their 




symptoms, without careful consideration for overlapping symptomatology with other 
morbidities. In essence, epidemiologic studies of CRSS are likely more prone to 
misclassification of disease than CRSO or CRSC, given the commonality of qualifying 
CRSS symptoms with other (often) comorbid conditions, thus biasing observed 
associations. Therefore, studies of CRSS are perhaps best at exploration and hypothesis 
generation, as opposed to causal inference. 
1.7.5 Objective measures of inflammation and disease 
 Objective measures of inflammation and/or disease help to narrow potential 
diagnoses, guide medical and surgical therapies as well as prognostication, and 
establish potential etiologic sources of disease onset. In that sense, objective measures 
can compensate for the measurement error induced by high-sensitivity/low-specificity 
subjective measures (i.e. symptoms), assuming they both measure the same underlying 
phenomenon (e.g. CRS).165  
 Several conditions include objective measures as part of a clinical diagnosis. Asthma 
diagnosis, for example, requires evidence of airway obstruction and demonstration of 
variability in degree of obstruction, both usually measured by spirometry.163 CRS, as 
aforementioned, requires confirmation of sinus inflammation and/or nasal polyps via 
endoscopy, MRI, or CT.1-3 
1.7.6 Utility of endoscopy, MRI, and CT in diagnosis and study of CRS 
 While we only utilized sinus CT scans in this dissertation, we discuss the other 
common modes of objective confirmation of inflammation in the presence of NSS in 




1.7.6.1 Endoscopy  
While the endoscope has been around since the 1950’s, nasal endoscopic findings 
were not considered as part of the diagnostic criteria for CRS until 2007, with the AAO-
HNS including it as sufficient objective evidence (next to the gold standard, sinus CT).166 
Nasal endoscopy, while not the gold standard because of high specificity but low 
sensitivity, does allow the direct visualization of the nasal cavity and nasopharynx, and is 
often used to confirm the presence of nasal polyps (which usually grow outward from the 
ethmoids down into the nasal cavity). Figure 1.7.6.1.1 shows an obstructive nasal polyp 
identified by nasal endoscopy.167 Several studies have shown the inter-rater agreement 
for polyps, purulence, or anatomical abnormalities to be high168-170; however, mucosal 
changes (e.g., edema and thickening) and middle turbinate obstruction require other 
forms of imaging (i.e., MRI or CT).168,170 
1.7.6.2 Magnetic resonance imaging  
While not often used in diagnosis of CRS, at least as a first-pass imaging choice, 
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infection with ocular and/or intracranial complications, or development lesions.10,171 
Contributing to the low use of MRI in cases of CRS are high cost, longer imaging time, 
and lack of bone detail.172-174 Figure 1.7.6.2.1 compares axial images of the paranasal 
sinuses obtained by CT (Figure 1.7.6.2.1a) and MRI (Figure 1.7.6.2.1b).171 The images 
demonstrate that the level of soft tissue characterization achieved by MRI is 
unparalleled; however, bony mass and structures are more clearly identified on CT.  
1.7.6.3 Computed tomography  
As previously mentioned, sinus CT is the gold standard in imaging for suspected 
CRS because of its speed and resolution of bony structures and mucosal 
thickening.10,171 In brief, a CT leverages variability in X-ray absorption by tissues of 
differing densities, taking several cross-sectional images during the process.1 Sinus 
inflammation appears on CT as opaque regions in normally void sinuses, which appear 
black on CT (Figure 1.7.6.3.1).171 In addition to mucosal thickening (i.e. submucosal 
Figure 1.7.6.2.1. Comparison of sinus CT and sinus MRI. (a) Axial CT images 
showing a polypoid soft tissue mass centered in the right sinonasal cavity, crossing 
midline to the left, with extrasinus extension into the right orbit and destructive non-
expansile bony changes (arrow). This is concerning for an aggressive process 
(malignancy or aggressive infection in the appropriate clinical scenario). MRI should 
be obtained. (b) Axial T2w MR images showing an infi ltrative mass centered in the 
right ethmoid air cells, extending into the right orbit, relatively T2 hypointense 
compared to the benign post-obstructive sinonasal secretions in the sphenoid sinus 
(black arrow). Flanagan CE, Baugnon KL, DelGaudio JM. Radiographic Diagnosis of 
Chronic Rhinosinusitis. In: Batra PS, Han JK, eds. Practical Medical and Surgical 





edema), partial or complete opacification, and nasal polyps, changes to bony regions of 
the sinuses (e.g., thickened, sclerotic, and hyperostotic bone) can also be observed on 
CT (Figure 1.7.6.3.2).10,171 
Figure 1.7.6.3.1. Varied appearance of chronic rhinosinusitis. (a) Coronal image 
showing bilateral maxillary sinus mucosal thickening, extending into the outflow tracts 
(thin arrows). Note the sclerosis and thickening of the surrounding maxillary sinus 
walls (thick arrow). Axial images in bone window (b) and soft tissue window (c), 
demonstrating chronic right sphenoid sinusitis, recurrent postoperatively, with 
opacification with high-density secretions extending through the sphenoid ostium and 
sclerosis and hyperostosis of the surrounding bone (thick arrow). Flanagan CE, 
Baugnon KL, DelGaudio JM. Radiographic Diagnosis of Chronic Rhinosinusitis. In: 
Batra PS, Han JK, eds. Practical Medical and Surgical Management of Chronic 




1.8 Limitations of current measurement practices 
1.8.1 Construct validity of CRSS  
 There are several possible sources of error in CRSS operationalization. For example, 
four symptom groups comprise CRSS (nasal blockage/congestion; nasal discharge 
[anterior or posterior]; smell loss; and facial pain/pressure), yet two of the symptom 
groups (nasal discharge and facial pain/pressure) pertain to multiple symptoms with 
possibly disparate etiologic and pathogenic origins. By assuming exchangeability of 
anterior nasal discharge for posterior, and facial pain for facial pressure, one assumes 
that these symptoms manifest from the same underlying biological process, which may 
or may not be true. Further, while nasal blockage/congestion and nasal discharge are 
anchoring symptoms (at least one is required for CRSS), secondary symptoms of smell 
loss and facial pain/pressure are also essentially exchangeable with one another (i.e. 
two people with nasal blockage—one with smell loss the other with facial pain—would 
 Figure 1.7.6.3.2. Bony changes with chronic sinusitis. Axial (a) and coronal (b) images 
of a patient with recurrent chronic sinusitis after endoscopic sinus surgery, with 
thickening and sclerosis surrounding chronic sinusitis within the sphenoid and the right 
greater than the left maxillary sinuses (thick arrows), as well as bony remodeling and 
expansion surrounding an opacified left ethmoid air cell, compatible with mucocele (thin 
arrow). Note the thinning and dehiscence of the left lateral lamella (black arrow) and the 
left lamina papyracea (arrowhead) from the expansion of the mucocele. Flanagan CE, 
Baugnon KL, DelGaudio JM. Radiographic Diagnosis of Chronic Rhinosinusitis. In: Batra 
PS, Han JK, eds. Practical Medical and Surgical Management of Chronic Rhinosinusitis. 





both be considered to have CRSS). Considering the evidence towards endotypes of 
CRS, as opposed to broad phenotypes, treating these symptoms as exchangeable may 
mask connections to relevant endotypes.175 For example, a prior study of tertiary care 
subjects receiving a sinus CT scan for CRS symptoms found substantial overlap 
between CRS and non-CRS groups, noting facial pain to be negatively predictive of CRS 
while smell loss was positively predictive.176 This is perhaps unsurprising given the 
nonspecific nature of facial pain, which is commonly reported in several conditions. For 
example, facial pain is often reported in migraine headache and orodental diseases.1 
 Only one study has assessed whether CRSS operationalization is consistent with the 
idea that these symptoms measure one underlying construct.175 Using exploratory factor 
analysis (EFA), authors tested whether multiple dimensions (i.e. underlying constructs) 
were measured by a set of 37 NSS, allergy, asthma, and constitutional symptoms (e.g., 
fatigue, fever, headache), in a general population sample.175 As many as three CRS-
relevant constructs, including nasal blockage/congestion, smell loss, and facial 
pain/pressure, were identified, further evidence of the weak rationale of current 
approaches to measurement of CRSS.  
1.8.2 Scoring radiologic inflammation 
 Radiologic inflammation obtained by CT is most commonly scored using the Lund-
Mackay (LM) scoring approach.177 With this method, opacification is quantified in five 
sinuses (maxillary, anterior ethmoid, posterior ethmoid, frontal, and sphenoid) by 
assigning a score of 0 for no opacification, 1 for partial opacification, and 2 for complete 
opacification, separately for each side (left and right). The OMC is scored as a 0 for less 
than complete opacification and 2 for complete opacification. These individual sinus 
scores are then summed to form a total score ranging from 0 to 24, with higher scores 




approach has received criticism for its generally poor ability for tracking disease 
progression and prognostication, with respect to CRS.178 As such, the modified Lund-
Mackay (mLM) scoring approach was developed.179 This approach expanded partial 
opacification (as measured by LM) into thirds, allowing sinus location to have a score 
ranging from 0 to 4, and a total score of 0 to 44. Despite its greater detail, it has not been 
shown to perform differently than LM.179 Importantly, these scoring approaches have not 
been comparatively assessed in a general population sample, one aim of the research 
presented herein. 
Considering LM, there is no clear indication for which score (or range of scores) 
constitutes a “positive” CT finding for CRS. However, a previous study of tertiary care 
patients, receiving sinus CT scans for indications other than CRS, had a mean LM score 
of 4.26 (95% confidence interval: 3.55, 4.97).180 The authors concluded that a LM cutoff 
of 4 (LM < 4) should be used to indicate “normal” sinus opacification. While this cutoff 
has been used in epidemiologic studies of CRS,66,181 the sample from which it was 
based was highly selected and does not likely represent the general population; 
therefore, this cutoff needs to be reassessed in a more representative sample, another 
aim of the research in this dissertation.  
 Additionally, there are several issues with the assumptions implicated by using a 
single score approach to quantifying or categorizing radiologic inflammation, i.e. LM or 
mLM. Most importantly, LM and mLM assume all sinus locations are of equal importance 
and therefore measure the same underlying construct (i.e. CRS). However, it is known 
that sinus opacification tends to follow known drainage routes (e.g., osteomeatal unit 
[OMU], sphenoethmoidal recess [SER]).182 As such, quantification of sinus opacification 
should likely take into consideration the location of opacification, not just severity. To 




location and patterns of opacification, in a general population sample representing a 
broad spectrum of sinus disease, another aim of this dissertation research. 




1.9 Specific aims 
As previously described, despite being a particularly burdensome condition,1-
3,70,155,156 previous studies of CRS have differed widely on the definition used to 
characterize CRS (e.g., CRSS, CRSSR, CRSC), making inferences about the condition 
difficult to assess across studies. Additionally, the majority of CRS epidemiologic studies 
have focused on individuals selected from tertiary care settings (e.g. surgical clinics), 
which only represent a small subset of the underlying spectrum of disease. Therefore, 
studies of individuals from the general population, representing the full spectrum of 
disease, are necessary.  
Like CRS, acute exacerbations of nasal and sinus symptoms (AENSS) related to 
CRS (i.e. AECRS) have lacked a unifying and consistent definition in prior studies. Of 
studies focused on AENSS among CRS subjects, most primarily focused on 
bacteriology and immunology—rather than risk factors—of exacerbation.20,183-186 As 
such, comparatively assessing several definitions of AENSS, estimating their 
prevalence, and identifying their risk factors is of critical importance.3  
Considering tangible impacts, no studies have assessed the workplace impacts (i.e. 
absenteeism, presenteeism, and lost productive time) of NSS across a full spectrum of 
sinus disease (including CRS), among individuals from a general population sample. 
Identifying which symptoms impart the greatest burden on workplace productivity may 
help educate clinicians and patients about the consequences of these symptoms and 
possibly guide further treatment and/or symptom management.  
Lastly, the quantification of radiologic inflammation in CRS warrants further 
investigation. A simple sum of LM opacification scores for six sinus locations is often 
used to guide a “positive” CT finding indicative of CRS, with a current recommended 




locations to be interchangeable, which goes against the newer thinking of CRS being 
represented by several endotypes culminating in few observable phenotypes.7,12,187 
Therefore, newer approaches to characterizing and measuring sinus inflammation are 
needed.  
Data from an existing population-based study70 was used to understand NSS in the 
general population. The studies that comprised this dissertation research utilized 
information from the electronic health record (EHR) of Geisinger, a large healthcare 
system whose patients are generalizable to the region EHR, longitudinal questionnaire 
data from 7847 individuals (selected from the EHR), and research sinus CT scans from 
646 subjects in the questionnaire study, to holistically understand this condition. The 
following specific aims were used to address the critical knowledge gaps outlined above:  
1. Comparatively assess several definitions of AENSS, estimate their prevalence, 
and identify risk factors for exacerbation.  
2. Estimate the workplace impacts of NSS related to CRS and related conditions.  
3. Rigorously assess and improve current approaches to measurement of radiologic 
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Chapter 2: Detailed methods 
In this chapter, we provide greater background and information about two broad 
classes of methods used in Chapters 4 and 5, specifically regarding exploratory factor 
analysis (EFA) and latent class analysis (LCA). We include this information to better 
provide context for why and how these methods were used. However, the following 
descriptions of these methods are not intended to be fully comprehensive, but rather a 
brief overview of salient issues relevant to the utility, methodologic decisions, and 
appropriateness of their use for our applications.  
2.0 Chapter 4 and Chapter 5: Factor analysis 
2.0.1 Concept and utility 
Unlike principal components analysis (PCA), which is often used in the creation of 
indices (i.e. composite measures formed by several observed indicators), factor analysis 
is commonly used in scale development, whereby observed indicators are 
manifestations of unobservable latent constructs. PCA seeks to create uncorrelated (i.e. 
orthogonal) and weighted combinations (composites) of observed indicators to maximize 
variance explained by these composites while factor analysis maximizes the common 
variance of the observed indicators.1 While two “flavors” of factor analysis are common 
in practice, confirmatory and exploratory, we restrict our discussions in this section to the 
latter. EFA is a method in which unobserved (i.e. latent variables that cannot be directly 
measured) variables are linearly related to manifest (i.e. observed) variables, with no 
hypothesized relations of the observed and manifest variables a priori (unlike 
confirmatory factor analysis which tests predetermined relations of observed indicators 
with latent constructs).1 A common goal of EFA is to reduce dimensionality in observed 
data, which is done by using covariances among the observed variables to express them 
in terms of fewer latent variables (i.e. factors), thereby identifying relations of observed 




series of linear regression-like models, with independent errors and conditional 
independence of observed variables (i.e. conditional on the factor, observed variables 
are independent of each other) (Equation 2.0.1.1). The observed variable indicators (Yk) 
are linearly related to factor loadings (λk), the latent factor (F), and random error (δk). The 
factor loadings are generally interpreted as the correlation of the factor with the observed 
indicator, though this interpretation is dependent on the rotation method used, with larger 
absolute values indicating a greater association with the factor.3 As an example of EFA 
“in action,” we used EFA in Chapter 5 to determine whether radiologic inflammation in 
six sinonasal locations were associated with a single underlying factor (i.e. construct), or 
if there were additional constructs represented by these locations (Figure 2.0.1.1). This 
analysis was directly relevant to the Lund-Mackay approach of treating all sinonasal 
locations equivalently in summing them to make a single index. 
Equation 2.0.1.1. Formulation of EFA as regression-like model 





2.0.2 Estimation procedures 
2.0.2.1 Pearson, tetrachoric, polychoric, biserial, and polyserial correlations 
Correlation matrices based on the observed variables are often used as inputs for 
EFA, as they are essentially standardized covariances, and therefore unitless and 
bounded by -1 and 1. Pearson correlations are found between sets of continuous 
observed variables, whereas inferred Pearson correlations are found for dichotomous 
and ordinal variables. Polychoric correlations were used in Chapters 4 and 5 as the 
sinus location indicator variables were observed to be ordinal. In brief, polychoric 
correlations are considered inferred Pearson correlations because the estimated 
correlation is that of two underlying (i.e. latent) normal random variables, which manifest 
as the observed ordinal variables.4 Extensions of this approach are available for sets of 
dichotomous variables (i.e. tetrachoric),5 ordinal and continuous variables (i.e. 
polyserial),6 and dichotomous and continuous variables (i.e. biserial).6  
2.0.2.2 Least squares and maximum likelihood 
2.0.2.2.1 Least squares 
Least squares estimation in EFA models aims to minimize the sum of squared 
differences between observed and estimated correlation matrices, thereby minimizing 
the residuals of the fitted model.7 This estimation approach was used in Cole et al.,8 from 
which factor scores were based upon in Chapter 4.  
2.0.2.2.2 Maximum likelihood 
Maximum likelihood estimation of EFA models, as the name suggests, aims to 
(iteratively) maximize the likelihood of producing the observed correlation matrix, 
assuming the distribution of the variables (observed and latent) are multivariate normal.2 
This estimation approach was used in Chapter 5 for all EFA models.   
2.0.2.3 Rotations 
Considering the formulation of the EFA model, there are an infinite number of 




better interpret the resulting factor loadings.2,3 In this dissertation, where multiple factor 
models were considered, oblique rotations were used to allow factors to correlate (which 
for our applications in evaluating correlations among sinonasal symptoms and also 
sinonasal opacification, and their factors, was clearly the case rather than treating the 
resultant factors as uncorrelated [i.e. orthogonal] factors).  
2.0.3 Factor scores and their estimation 
2.0.3.1 Factor scores, defined 
In the simplest sense, factor scores are estimated factor values which seek to distill 
the fitted factor analysis model into usable continuous variables, often in subsequent 
regression analysis.9  
2.0.3.2 Factor scores, estimated 
There are several approaches to estimation of factor scores, including Thurstone (i.e. 
regression),10 Bartlett,11 and item response theory (IRT)-based scores.12 In this 
dissertation, we estimated IRT-based scores via the expected a posteriori (EAP) 
method.13 The explicit details of EAP theta (θ; factor score) estimation are beyond the 
scope of this dissertation and will only briefly be covered. Theta estimation is an iterative 
procedure in which Newton-Raphson numerical integration is applied to the fitted EFA 
model in order to obtain the best estimate of theta, given the patterns of responses used 
as inputs to the EFA. This maximum likelihood-based estimate of theta is then combined 
with a normal prior distribution, thus resulting in an estimate of the mean of the 
combined posterior distribution.13  
2.1 Chapter 5: Latent class analysis 
2.1.1 Concept and utility 
Latent class analysis (LCA) is a statistical method in which patterns of responses to a 
set of categorical variables are used to identify mutually exclusive and homogeneous 
subgroups (i.e. classes).1 In Chapter 5, we applied LCA to binary indicators of 




1) Does sinus opacification occur randomly in the different locations, or are there 
subgroups of subjects who evidence site-specific patterns of opacification?  
2) If there are identifiable subgroups, how many are best represented by the data?  
2.1.2 Estimation procedure 
2.1.2.1 Maximum likelihood 
The general form of the LCA model is provided below (Equation 2.1.2.1.1).14 
Equation 2.1.2.1.1. General form of LCA model. Adapted from Collins LM. Latent Class 
and Latent Transition Analysis With Applications in the Social, Behavioral, and Health 
Sciences. In: Lanza ST, ed. Hoboken :: John Wiley & Sons, 2010. 









In Equation 2.1.2.1.1, Yj is a variable with Rj categories taking generic value rj = 
1,…Rj; I (yj = rj) represents a binary variable that is equal to 1 when variable j = rj , and 0 
otherwise; γC represents the probabilities of membership in each latent class; and p 
represents the probability of observing a particular response conditional on latent class 
membership (c).14 Model parameters are estimated by maximum likelihood estimation 
via an expectation-maximization algorithm,15 with the exact likelihood function being 
maximized defined as the product over individuals of the likelihood components given 
the equation just above. 
2.1.2.2 Goodness of fit 
There are several absolute and relative measures of model fit useful in guiding the 
best LCA solution (i.e. the appropriate number of latent classes to extract). While not an 
exhaustive list, we briefly summarize the tests and indices used in Chapter 5.  
2.1.2.2.1 Akaike’s information criterion 
Akaike’s information criterion (AIC) is simply expressed as -2LL + 2m, where LL is the 
log-likelihood from the estimated model and m is the number of estimated parameters, 




2.1.2.2.2 Bayesian information criterion 
Similar to AIC, Bayesian information criterion (BIC) is -2LL + m * ln(n), where LL and 
m are the same as above and n is the sample size (i.e. number of observations).  
2.1.2.2.3 Vuong-Lo-Mendell-Rubin likelihood ratio test 
The Vuong-Lo-Mendell-Rubin (VLMR) likelihood ratio test (LRT) addresses the issue 
of non-nested models for which traditional LRT approaches faulter.16,17 In brief, VLMR 
uses the derivatives from a k class model and k-1 class model to compute the p-value 
associated with the difference in log-likelihoods from these models. If the p-value is not 
significant (i.e. p ≥ 0.05), then the null hypothesis of k-1 class model being appropriate is 
failed to be rejected. Said differently, a significant p-value (i.e. p < 0.05) would reject the 
null hypothesis and favor the model with a higher number of latent classes.  
2.1.2.2.4 Bootstrapped likelihood ratio test 
The bootstrapped LRT (BLRT) similarly addresses the issue of non-nested models by 
a series of four steps: 1) the k and k-1 class models are estimated and -2LL is 
calculated; 2) a bootstrap sample is generated from the k-1 class model and -2LL is 
calculated (by using estimated k class model in step 1); 3) this process is repeated 
several hundred times (we used 500 bootstrap samples in Chapter 5 analyses) allowing 
estimation of the “true” distribution of -2LL; and 4) the p-value is obtained by comparing 
the “true” distribution in step 3 to the -2LL calculated in step 1.18 As with VLMR, a 
significant p-value would indicate rejection of the null hypothesis that the k-1 class model 
is sufficient, therefore favoring the k class model.  
2.1.3 Checking for local maxima 
A well-known problem in LCA is that of local maxima in the likelihood.19 Given the 
estimation procedure, it is possible for local solutions to be obtained, as opposed to 
global solutions. A local maximum solution is the best solution in a neighborhood of the 
parameter space, but not the global maximum. We used several strategies to more 




fitting model). We first used several thousand random starts (5,000) in the first step of 
the estimation procedure and the best 500 in the second step. Next, after being assured 
that the model converged, we estimated the model again, but this time using twice as 
many random starts (first and second step) to determine if we converged to the same 
solution. Then, we assessed solutions for five of the starts (using their “seeds”) that had 
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Background: Nasal and sinus symptoms (NSS) are common to many health conditions, 
including chronic rhinosinusitis (CRS). Few studies have investigated the occurrence 
and severity of, and risk factors for, acute exacerbations of NSS (AENSS) by CRS status 
(current, past, or never met European Position Paper on Rhinosinusitis [EPOS] criteria 
for CRS).  
Methods:  Four seasonal questionnaires were mailed to a stratified random sample of 
Geisinger primary care patients. Logistic regression was used to identify individual 
characteristics associated with AENSS occurrence and severity by CRS status (current 
long-term, current recent, past, never) using EPOS subjective symptoms-only (EPOSS) 
CRS criteria. We operationalized three AENSS definitions based on prescribed 
antibiotics or oral corticosteroids, symptoms, and symptoms with purulence. 
Results: Baseline and at least one follow-up questionnaires were available from 4,736 
subjects. Self-reported NSS severity with exacerbation was worst in the current long-
term CRS group. AENSS was common in all subgroups examined and generally more 
common among those with current EPOSS CRS. Seasonal prevalence of AENSS 
differed by AENSS definition and CRS status. Associations of risk factors with AENSS 
differed by definition, but CRS status, body mass index, asthma, hay fever, sinus 
surgery history, and winter season consistently predicted AENSS.  
Conclusions: In this first longitudinal, population-based study of three AENSS 
definitions, NSS and AENSS were both common, sometimes severe, and differed by 
EPOSS CRS status. Contrasting associations of risk factors for AENSS by the different 





There are few prior longitudinal studies of nasal and sinus symptoms (NSS) and their 
acute exacerbation (AENSS) in general population samples and no standardized 
approaches to measurement of AENSS in epidemiologic studies. NSS are common to 
multiple health conditions, can be relapsing and remitting, can become chronic as in the 
case of chronic rhinosinusitis (CRS), and have a significant individual and population 
impact.1-8 The European Position Paper on Rhinosinusitis and Nasal Polyps (EPOS) has 
operationalized a clinical definition of CRS, requiring both subjective symptoms which 
must be present for 12 continuous weeks and objective confirmation of sinonasal 
mucosal inflammation (e.g. via sinus computed tomography [CT]). For epidemiologic 
studies, EPOS only requires the presence of subjective symptoms (we designate as 
EPOSS).1,2  
Difficulties in obtaining objective evidence of inflammation have been an impediment 
to large-scale, population-based epidemiologic studies. Depending on individual 
characteristics, onset, duration, and season, the sudden onset or worsening of NSS 
could be an indication for allergic rhinitis (AR), acute rhinosinusitis (ARS), an acute 
exacerbation of chronic rhinosinusitis (AECRS), or other related diagnoses. Published 
studies of exacerbation among CRS patients have primarily focused on bacteriology,9-11 
immunology,12,13 and medical treatments,14-17 as opposed to population-based 
occurrence, severity, risk factors, and natural history. The International Consensus 
Statement on Allergy and Rhinology (ICAR), therefore, has declared a need for 
prevalence estimates of AECRS and more prospective studies, especially those which 
compare several definitions of AECRS.2  
As such, the objectives of this study were to evaluate and compare seasonal 




definitions of AENSS; describe NSS severity by CRS and AENSS status; and identify 
self-reported individual characteristics associated with AENSS by CRS status. We 
addressed these objectives in a population-based longitudinal study using a sample of 
primary care patients from Geisinger who are representative of the general population in 
the area of central and northeastern Pennsylvania. 
3.3 Materials and methods 
3.3.1 Study overview 
Details of the study design have been published elsewhere.5,18 Briefly, in 2014, adult 
(at least 18 years of age) primary care patients were selected from the EHR of Geisinger 
to participate in a study of the epidemiology of CRS. Individuals who responded to the 
baseline questionnaire were additionally mailed four seasonal follow-up questionnaires 
over the course of 16-months, to evaluate seasonal exacerbations (Table 3.3.1.1; for 
example questionnaire see Supplemental material Figure 3.7.1). This study was 
approved by the Institutional Review Board (IRB) of Geisinger, which has an IRB 
Authorization Agreement with the Johns Hopkins Bloomberg School of Public Health. 
Health Insurance Portability and Accountability Act authorization and written informed 





Table 3.3.1.1. Description of longitudinal questionnaires and number of responders 
Description April 2014 October 2014 February 2015 May 2015 August 2015 
Questionnaire Baseline Fall Exacerbation Winter Exacerbation Spring Exacerbation Summer Exacerbation 
Mailings 3 (to August 2014) 2 (to January 2015) 1 1 2 (to December 2015) 
Items 94 87 15 15 79 
Sections 
 AENSS exacerbation AENSS exacerbation AENSS exacerbation AENSS exacerbation 
 CRS treatment (4wk) CRS treatment (4wk) CRS treatment (4wk) CRS treatment (4wk) 
Current CRS Current CRS   Current CRS 
Secondary CRS Secondary CRS*   Secondary CRS 
Minor symptoms Minor symptoms   Minor symptoms 
Doctor diagnoses 
Anxiety   






  SHS and farm contacts 
Responders 7847 4966 5094 4089 4600 
Abbreviations: CRS = chronic rhinosinusitis; SES = socioeconomic status; SHS = second-hand smoke 
*Secondary CRS indicates more specific questions about NSS frequency and severity not included as part of the diagnostic criteria for CRS 




3.3.2 Study population 
Geisinger provides primary care services to over 450,000 patients, with the majority 
residing in central and northeastern Pennsylvania. The source population for this study 
consisted of 200,769 adult primary care patients who had available EHR data, including 
race/ethnicity. Stratified sampling was utilized to over represent individuals more likely to 
have CRS, as well as racial/ethnic minorities (8% of Geisinger patients identify as non-
white race/ethnicity). From the source population, 23,700 individuals were selected to 
participate in the baseline survey and baseline responders (n = 7847) were mailed four 
follow-up questionnaires with four-month intervals in-between (Table 3.3.1.1).  
3.3.3 Description of sampling method 
The sampling method has been reported previously.5,18 Briefly, individuals with a 
greater likelihood of having CRS were over-sampled by using EHR data to categorize 
individuals into three groups, based on International Classification of Disease (ICD)-9 
codes as well as Current Procedural Terminology (CPT) codes from patient medical 
records for: CRS, asthma, allergic rhinitis, sinus procedures, and related information.18 
Oversampling of racial and ethnic minorities was also performed. Sampling proportions 
are reported elsewhere.5  
3.3.4 CRS classification 
Individuals were classified as having EPOSS CRS as previously reported.5,18 In brief, 
CRS status was determined using subject responses concerning the frequency of the 
cardinal symptoms of CRS (nasal congestion/blockage, green/yellow nasal discharge 
[purulence], post-nasal drip, smell loss, facial pain, and facial pressure), as defined by 
EPOS.1 Based on responses to these questions at the baseline and first follow-up 
questionnaires, subjects were classified as “current long-term” (current CRS at both 
questionnaires), “current recent” (past or never CRS at baseline, current CRS at follow-




questionnaire). Only these questionnaires were used for determining CRS status in this 
study because two of the follow-up questionnaires (winter and spring exacerbation) did 
not include questions about EPOS symptoms over the past three months and we did not 
want to induce reverse causality in the association of CRS status and exacerbation. We 
did not differentiate between CRS with and without nasal polyps since objective 
evidence of CRS was unavailable for all study participants and therefore no way to 
reliably phenotype these subjects. 
3.3.5 Operationalization of NSS severity and AENSS 
NSS severity was assessed in two different ways. The first used self-reported rating 
of NSS on a 10-point visual analog scale while the second used self-report of having 
“worse” or “much worse” NSS on a five-point Likert scale.1 
Using consensus recommendations1,2 and prior evidence on CRS exacerbations9-
11,13,15,19 we operationalized three definitions for the classification of AENSS (see 
Supplemental material Table 3.7.1). All definitions required participants to self-report 
worsened NSS in the past four weeks. “AENSS-Med” defined exacerbation was based 
on self-reported medication use for worsened NSS. We only used antibiotics and oral 
corticosteroids as qualifying medications as these are unlikely to be prescribed for viral 
infections, thereby minimizing potential misclassification of AENSS as common colds. 
This definition is also parallel to the medical management recommended for asthma 
control,1 since no evidence-based treatment recommendations exist for AECRS.2 We did 
not include inhaled corticosteroids because this would certainly misclassify AENSS as 
asthma exacerbations. “AENSS-Sx” was based on duration (≥ 1 week) of worsened 
aggregate NSS, again to minimize ascertainment of colds as AENSS, since these 
usually resolve within 1 week. Lastly, “AENSS-Sx-Pur” required the same criteria as 
“AENSS-Sx”, but additionally required self-reported worsened purulence in the past four 




worse for longer than four weeks, only a four week period was measured on 
questionnaires.  
3.3.6 Evaluation of risk factors for AENSS and confounding variables 
Based on previous studies,5,18 potential risk factors and confounding variables from 
the EHR included: current age (years); sex; race/ethnicity (white non-Hispanic vs. all 
other groups); smoking status (current, former, and never); body mass index (BMI, 
kg/m2); Charlson comorbidity index20; and history of receiving Medical Assistance, a 
surrogate for family socioeconomic status (SES)21. Individual self-reported information 
was ascertained from baseline and follow-up questionnaires (Table 3.3.1.1). 
Previous studies have shown asthma to be associated with CRS5,22,23, and was 
therefore hypothesized to be a risk factor for AENSS. As such, individuals who 
experienced ≥ 1 asthma symptom (awakening at night due to wheezing; wheezing, chest 
tightness, or whistling in the chest when not having cold or flu; chest wheezing during or 
after exercise; dry cough at night apart from a cold or chest infection) at least some of 
the time were classified as having asthma symptoms at baseline. Migraine headaches 
have similarly been associated with CRS,5,18 therefore a binary indicator for whether a 
subject had migraine headaches at baseline was determined as previously reported.18,24 
The continuous “Anxiety Sensitivity Index (ASI)”25 measures how much a person fears 
the symptoms of anxiety, believing them to be harmful, and was created from the fall 
exacerbation questionnaire and included in the analysis as quintiles to help control for 
confounding due to an individual’s propensity to be aware of and/or over-report 
symptoms. Questionnaire return dates were used to define the season in which 
exacerbations occurred as follows: autumn, September 22 through December 21; winter, 
December 22 through March 21; spring, March 22 through June 21; and summer, June 




3.3.7 Statistical analyses 
Given the paucity of information regarding NSS and AENSS by EPOSS CRS status, 
the goals of the analysis were to 1) assess differences in NSS severity by CRS status 
and AENSS definition, 2) estimate the seasonal prevalence of different subgroups of 
AENSS (e.g., by CRS status and AENSS definition) in the source population, and 3) 
evaluate associations of individual self-reported risk factors and season with AENSS by 
CRS status.  
Survey-corrected methods were used for all analyses to account for the sampling 
design. Design weights were the inverse product of the probability of being selected into 
the study and probability of responding to the baseline questionnaire. Additionally, 
survey weights were corrected for attrition by estimating inverse probability of censoring 
weights (IPCW; see Supplemental material Equation 3.7.1). Since CRS status was not 
ascertained at all time-points, CRS status at the first follow-up questionnaire was used 
for all follow-up questionnaires. Subjects who skipped a questionnaire (23.9%) were 
excluded from all subsequent questionnaires to avoid intermittent missingness. 
Risk factor analysis consisted of inverse-probability-weighted generalized estimating 
equations logistic regression models assuming an independence working correlation 
matrix and incorporated stabilized truncated survey weights. Final survey weights had a 
median of 2.81 and range 2.45 ‒ 43.03. Taylor linearization was used to estimate robust 
variances and standard errors. Lastly, item non-response for covariates was addressed 
by using multiple imputation by chained equations (25 imputed data sets).  
Covariates were identified as being a risk factor if they retained statistical significance 
in adjusted models and were not a priori determined to be a confounder. Methods for 
assessing model fit are limited in multiply-imputed survey-based regression models.  




predicted probabilities (from weighted candidate final models) and using. Archer-
Lemeshow tests for goodness of fit. To assess the utility of the multiple imputations, 
Monte Carlo error estimates were generated for all effect estimates and associated test 
statistics. All analyses were conducted in STATA 14.1 (StataCorp, College Station, 
Texas). 
3.4 Results 
3.4.1 Description of participants 
Baseline characteristics of the study population have been described elsewhere.5,18 A 
total of 558 current long-term, 273 current recent, 1,644 past, and 2,261 never EPOSS 
CRS individuals contributed at least one observation to the analysis (Table 3.4.1.1). The 
general trends in Table 3.4.1.1 suggests individuals with AENSS appeared to be 
younger, white, female, on medical assistance, and have greater Charlson comorbidity 
index values, compared to those without AENSS (Table 3.4.1.1). The prevalence of 
AENSS increased from the lowest in the never group, to intermediate in the past and 
current recent CRS groups, to the highest in the current long-term CRS status group 
(Table 3.4.1.1). AENSS recurrence, as identified through the four follow-up 
questionnaires, was the least common in the never group and the most common in the 





Table 3.4.1.1. Percentage (95% CI) of respondents and mean value (i.e., age, BMI) who ever met criteria for AENSS by operational 
criteria and by covariatesa 
Characteristic  













EPOSS CRS statuse 
 Current long-term, 
 n = 558 
 
 Current recent, n = 273 
 
 Past, n = 1,644 
 
 Never, n = 2,261 
 
74.1  
(65.2 – 83.0)f 
80.8  
(71.9 – 89.8) 
84.4  
(80.9 – 87.9) 
92.4  
(90.5 – 94.3) 
 
25.9  
(17.0 – 34.8) 
19.2  
(10.2 – 28.1) 
15.6  
(12.1 – 19.1) 
7.62  
(5.73 – 9.51) 
 
41.7  
(31.0 – 52.5) 
48.9  
(35.4 – 62.4) 
50.9  
(45.2 – 56.4) 
71.1  
(67.8 – 74.3) 
 
58.3  
(47.5 – 69.0) 
51.1  
(37.6 – 64.6) 
49.2  
(43.6 – 54.8) 
28.9  
(25.7 – 32.2) 
 
74.6  
(67.0 – 82.5) 
84.2  
(77.5 – 91.0) 
79.4  
(74.9 – 83.8) 
89.4  
(87.1 – 91.6) 
 
25.2  
(17.5 – 33.0) 
15.8  
(9.04 – 22.5) 
20.6  
(16.2 – 25.1) 
10.6  
(8.38 – 12.9) 
p-valueg < 0.001 < 0.001 < 0.001 
Age (years), mean 55.9  
(54.8 – 56.9) 
53.3  
(50.7 – 55.9) 
57.1  
(55.8 – 58.4) 
52.9  
(51.4 – 54.5) 
56.5  
(55.4 – 57.5) 
50.2  
(47.8 – 52.6) 
p-value 0.08 < 0.001 < 0.001 
Sex 
 Male, n = 1,741 
 
 Female, n = 2,995 
 
91.2  
(88.7 – 93.7) 
88.4  
(86.3 – 90.5) 
 
8.79  
(6.29 – 11.3) 
11.6  
(9.51 – 13.7) 
 
68.6  
(64.2 – 73.0) 
62.3  
(27.0 – 65.8) 
 
31.4  
(27.0 – 35.8) 
37.7  
(34.2 – 41.1) 
 
86.6  
(83.4 – 89.9) 
86.2  
(83.8 – 88.5) 
 
13.4  
(10.1 – 16.6) 
13.8  
(11.5 – 16.2) 
p-value 0.10 0.03 0.82 
Race/ethnicity 
 White, n = 4,399 
 
 Non-white, n = 337 
 
89.3  
(87.6 – 91.0) 
91.6  
(88.8 – 94.4) 
 
10.7  
(9.01 – 12.4) 
8.38  
(5.56 – 11.2) 
 
64.2  
(61.4 – 67.0) 
73.9  
(68.6 – 79.1) 
 
35.8  
(33.0 – 38.6) 
26.1  
(20.9 – 31.4) 
 
86.1  
(84.1 – 88.1) 
91.5  
(88.4 – 94.5) 
 
13.9  
(11.9 – 15.9) 
8.54  
(5.50 – 11.6) 






 Never received, n = 4,328 
 
 Ever received, n = 408 
 
89.9  
(88.2 – 91.6) 
84.0  
(77.4 – 90.5) 
 
10.1  
(8.44 – 11.8) 
16.0  
(9.52 – 22.6) 
 
64.6  
(61.8 – 67.4) 
64.6  
(54.7 – 74.5) 
 
35.4  
(32.6 – 38.2) 
35.4  
(25.5 – 45.3) 
 
86.6  
(84.6 – 88.6) 
83.7  
(76.5 – 90.8) 
 
13.4  
(11.4 – 15.4) 
16.3  
(9.19 – 23.5) 
p-value 0.04 1.00 0.41 
Body mass index 
(BMI; kg/m2), mean 
29.3  
(28.9 – 29.7) 
30.6  
(29.4 – 31.8) 
29.6  
(29.0 – 30.1) 
29.2  
(28.6 – 29.8) 
29.4  
(29.0 – 29.9) 
29.5  
(28.5 – 30.5) 
p-value 0.05 0.45 0.79 
Charlson comorbidity index, 
mean 
1.10  
(1.04 – 1.16) 
1.39  
(1.20 – 1.58) 
1.10  
(1.02 – 1.18) 
1.19  
(1.09 – 1.29) 
1.13  
(1.06 – 1.19) 
1.15  
(1.00 – 1.30) 
p-value < 0.01 0.20 0.83 
Smoking status 
 Current, n = 581 
 
 Former, n = 1,460 
 
 Never, n = 2,695 
 
87.1  
(82.0 – 92.1) 
91.4  
(88.9 – 93.9) 
88.9  
(86.6 – 91.1) 
 
12.9  
(7.86 – 18.0) 
8.62  
(6.14 – 11.1) 
11.1  
(8.87 – 13.4) 
 
64.5  
(56.3 – 72.7) 
65.9  
(61.0 – 70.7) 
65.0  
(60.4 – 67.5) 
 
35.5  
(27.3 – 43.7) 
34.1  
(29.3 – 39.0) 
36.0  
(32.5 – 39.6) 
 
88.2  
(83.2 – 93.3) 
87.1  
(83.6 – 90.6) 
85.6  
(83.0 – 88.1) 
 
11.8  
(6.69 – 16.8) 
12.9  
(9.43 – 16.4) 
14.4  
(11.9 – 17.0) 






Abbreviations: CI = confidence interval; CRS = chronic rhinosinusitis; EHR = electronic health record; EPOS = European Position 
Paper on Rhinosinusitis; SES = socioeconomic status 
a Unless otherwise noted, estimates are row percentages (within characteristic) of ever/never having an AENSS during follow-up  
b AENSS-Med= worse/much worse NSS in past 4 weeks + use of systemic corticosteroids or antibiotic prescription for worsened 
NSS 
c AENSS-Sx = worse/much worse NSS in past 4 weeks + worse over any time period up to 4 weeks + remained worse for ≥ 1-
week 
d AENSS-Sx-Pur = worse/much worse NSS in past 4 weeks + worse over any time period up to 4 weeks + remained worse for ≥ 1 
week + worse/much worse purulence 
e EPOSS CRS status determined using baseline and fall exacerbation questionnaires: current long-term CRS = EPOS 
epidemiologic criteria fulfilled at both questionnaires; current recent CRS = current CRS at fall questionnaire, but not at baseline;  
past CRS = EPOS epidemiologic criteria fulfilled in lifetime, but not during study; never CRS = EPOS epidemiologic criteria never 
met 
f Population-estimates were derived by using survey-corrected methods with robust standard error estimation 
g p-values represent differences in means (continuous variables) or Pearson’s chi-square (categorical variables) 




3.4.2 Severity of nasal and sinus symptoms 
Mean NSS severity scores varied by CRS group and exacerbation status (Figure 
3.4.2.1; Supplemental material Table 3.7.3). There were statistically significant 
associations between CRS status and NSS severity (Table 3.7.3). Mean NSS scores 
increased ordinally from the lowest score in the never CRS group to the highest score in 
the current long-term CRS group, where those who were having AENSS had higher 
NSS severity than those who were not (p < 0.001 for all CRS status groups). Mean NSS 
Figure 3.4.2.1. Mean nasal and sinus symptom severity score on a 10‐point visual 
analogue scale, by EPOSS defined CRS status (current long‐term, current recent, 
past, and never) and exacerbation definition. Nasal and sinus symptoms (NSS) 
severity in the past 4 weeks was ascertained by self-report at each follow-up 
questionnaire and estimated in the source population. Three definitions of AENSS 
were operationalized as follows: AENSS-Med, AENSS-Sx, and AENSS-Sx-Pur. Non-
overlapping confidence intervals indicate statistical significance (p < 0.05). Exact p-




severity scores by AENSS-Med and AENSS-Sx-Pur defined exacerbations were greater 
than in AENSS-Sx (Figure 3.4.2.1; Supplemental material Table 3.7.3).  
3.4.3 Seasonal prevalence of AENSS 
Prevalence estimates of AENSS by CRS status and AENSS definition were estimated 
for each season (Figure 3.4.3.1; Supplemental material Table 3.7.4). The seasonal 
peak prevalence for exacerbation consistently occurred in the winter for past CRS status 
and in spring for never CRS status. Seasonal trends were comparable between AENSS-
Sx and -Sx-Pur for the current long-term and current recent CRS groups, with peak 
prevalence occurring in the winter for the current recent CRS group, and a modest peak 
in the summer for the current long-term CRS group (Figure 3.4.3.1; Supplemental 
material Table 3.7.4).  
Figure 3.4.3.1. Population estimated prevalence of AENSS, by EPOSS defined CRS 
status (current long-term, current recent, past, and never), exacerbation definition, and 
season. Prevalence was estimated in the source population. Three definitions of AENSS 





3.4.4 Individual characteristic and seasonal risk factors for AENSS 
Risk factor analysis proceeded with two of the three AENSS definitions (AENSS-Med 
and -Sx-Pur). We did not include AENSS-Sx since prevalence estimates were much 
greater from this definition compared to AENSS-Med and -Sx-Pur, which were both 
comparable, indicating a low relative specificity of AENSS-Sx compared to the other 
definitions. Tables 3.4.4.1 and 3.4.4.2 show the adjusted odds ratios (aORs) and 95% 
CIs for several covariates estimated from logistic regression models.  
Several significant and elevated odds ratios were identified in relation to AENSS-Med 
(Table 3.4.4.1) for higher BMI, being a current smoker, having asthma or migraine 
symptoms at baseline, doctor diagnosed hay fever, having had two or more sinus 
surgeries, and winter season. As CRS status was found to modify associations of 
season with AENSS-Med, associations are displayed within strata of CRS status (Table 
3.4.4.1). 
Elevated odds ratios of risk factors with AENSS-Sx-Pur (Table 3.4.4.2) were found for 
white race/ethnicity, BMI, having asthma symptoms at baseline, doctor diagnosed hay 
fever, history of having two or more sinus surgeries, and season (winter and spring). Age 
modified associations of CRS status with AENSS, therefore CRS status associations are 
displayed at the grand mean age (55.1 years). Subjects with either past or current long-
term CRS had increased odds of AENSS-Sx-Pur. The interaction between age and CRS 
status was observed as a linear reduction in odds of AENSS-Sx-Pur with higher ages for 




Table 3.4.4.1. Associations with exacerbation of nasal and sinus symptoms defined by 
AENSS-Med 
Risk Factora 
Adjusted Odds Ratio 
(95% Confidence Interval)b 
EPOSS CRS statusc 
 Never 
  Fall 
  Winter 
  Spring 
  Summer 
 Past 
  Fall 
  Winter 
  Spring 
  Summer 
 Current recent 
  Fall 
  Winter 
  Spring 
  Summer 
 Current long-term 
  Fall 
  Winter 
  Spring 




1.48 (0.91 – 2.41) 
2.01 (1.22 – 3.32)** 
0.80 (0.42 – 1.55) 
 
1.28 (0.73 – 2.23) 
3.73 (2.30 – 6.06)*** 
2.18 (1.27 – 3.75)** 
0.94 (0.46 – 1.90) 
 
2.97 (1.30 – 6.77)* 
3.22 (1.59 – 6.51)** 
2.64 (1.11 – 6.26)* 
3.84 (1.33 – 11.07)* 
 
2.55 (1.41 – 4.62)** 
5.96 (3.33 – 10.66)*** 
1.82 (0.89 – 3.74) 
2.89 (1.43 – 5.84)** 






1.35 (1.05 – 1.74)* 
Race/ethnicity 




0.66 (0.43 – 1.00) 
Medical Assistanced 
 Never received 
 Ever received 
 
Ref 
1.37 (0.91 – 2.06) 
Body mass index (per 1 kg/m2 increase; BMI; 
kg/m2) 
1.03 (1.02 – 1.05)*** 
Charlson comorbidity index (per 1 unit 
increase in index value) 
1.09 (1.01 – 1.18)* 
Smoking status (baseline) 
 Never 
 Former 
 Current  
 
Ref 
1.01 (0.77 – 1.32) 
1.53 (1.08 – 2.18)* 
Asthma symptoms (baseline) 
 None 
 At least one 
 
Ref 
1.47 (1.14 – 1.88)** 














1.36 (1.07 – 1.74)* 
History of sinus surgeries (baseline) 
 None 
 1 
 2 or more 
 
Ref 
1.46 (1.04 – 2.05)* 
1.75 (1.11 – 2.76)* 








0.96 (0.65 – 1.42) 
0.78 (0.52 – 1.17) 
1.18 (0.80 – 1.75) 
1.29 (0.89 – 1.87) 
Abbreviations: AENSS = acute exacerbation of nasal and sinus symptoms; CRS = 
chronic rhinosinusitis; EHR = electronic health record; EPOS = European Position 
Paper on Rhinosinusitis; NSS = nasal and sinus symptoms 
*p-value<0.05, **p-value<0.01, ***p-value<0.001 
 aRisk factors selected from the electronic health record (EHR) include: age, sex, 
race/ethnicity, receival of Medical Assistance, and body mass index (BMI). Risk 
factors from self-report includes: asthma symptoms, Dr. diagnosed hay fever, history 
and number of sinus surgeries, and anxiety sensitivity. 
b Adjusted estimates from survey-corrected marginal logistic regression models with 
robust standard error estimation 
c EPOSS CRS status determined using baseline and fall exacerbation questionnaires: 
current long-term CRS = EPOS epidemiologic criteria fulfilled at both questionnaires; 
current recent CRS = current CRS at fall questionnaire, but not at baseline;  past CRS 
= EPOS epidemiologic criteria fulfilled in lifetime, but not during study; never CRS = 
EPOS epidemiologic criteria never met 
d Medical Assistance is a binary indicator of socioeconomic status (SES) 
e Season: Autumn = September 22 through December 21; Winter = December 22 





Table 3.4.4.2. Associations with exacerbation of nasal and sinus symptoms defined by 
AENSS-Sx-Pur 
Risk Factora 
Adjusted Odds Ratio 
(95% Confidence Interval)b 
EPOSS CRS statusc 
 Never 
 Past 
 Current recent 
 Current long-term 
 
Ref 
1.56 (1.18 – 2.06)** 
1.56 (0.97 – 2.50) 
2.33 (1.62 – 3.34)*** 
Age trend (per five-year increase; years) 
 Never 
 Past 
 Current Recent 
 Current Long-term 
 
0.85 (0.81 – 0.90)*** 
0.92 (0.87 – 0.97)** 
0.82 (0.71 – 0.94)** 






1.09 (0.86 – 1.38) 
Race/ethnicity 
 White  
 Non-white  
 
Ref 
0.52 (0.34 – 0.79)** 
Medical Assistanced 
 Never received 
 Ever received 
 
Ref 
0.95 (0.67 – 1.35) 
Body mass index (per 1 kg/m2 increase; BMI; 
kg/m2) 
1.02 (1.01 – 1.03)** 
Charlson comorbidity index (per 1 unit 
increase in index value) 
0.94 (0.88 – 1.02) 
Asthma symptoms (baseline) 
 None 
 At least one 
 
Ref 
1.68 (1.32 – 2.15)*** 





1.34 (1.00 – 1.79) 





1.36 (1.08 – 1.71)* 
History of sinus surgeries (baseline) 
 None 
 1 
 2 or more 
 
Ref 
1.30 (0.95 – 1.78) 
1.58 (1.06 – 2.35)* 








1.00 (0.69 – 1.44) 
0.92 (0.63 – 1.34) 
1.19 (0.83 – 1.71) 













2.17 (1.67 – 2.82)*** 
1.71 (1.28 – 2.29)*** 
0.88 (0.62 – 1.25) 
Abbreviations: AENSS = acute exacerbation of nasal and sinus symptoms; CRS = 
chronic rhinosinusitis; EHR = electronic health record; EPOS = European Position 
Paper on Rhinosinusitis; NSS = nasal and sinus symptoms 
*p-value<0.05, **p-value<0.01, ***p-value<0.001 
a Risk factors selected from the electronic health record (EHR) include: age, sex, 
race/ethnicity, receival of Medical Assistance, and body mass index (BMI). Risk 
factors from self-report includes: asthma symptoms, Dr. diagnosed hay fever, history 
and number of sinus surgeries, and anxiety sensitivity. 
b Adjusted estimates from survey-corrected marginal logistic regression models with 
robust standard error estimation 
c EPOSS CRS status determined using baseline and fall exacerbation questionnaires: 
current long-term CRS = EPOS epidemiologic criteria fulfilled at both questionnaires; 
current recent CRS = current CRS at fall questionnaire, but not at baseline;  past CRS 
= EPOS epidemiologic criteria fulfilled in lifetime, but not during study; never CRS = 
EPOS epidemiologic criteria never met 
d Medical Assistance is a binary indicator of socioeconomic status (SES) 
e Season: Autumn = September 22 through December 21; Winter = December 22 








To our knowledge, this is the first study of the epidemiology of AENSS by EPOSS 
CRS status, while evaluating three definitions of AENSS. There were several potentially 
important findings by season and CRS status, offering possible etiologic and diagnostic 
insights relevant to clinical management of AENSS. NSS and AENSS were common 
among all subjects; NSS and AENSS severity were worst in subjects with current, long-
term CRS; prevalence of AENSS as measured by AENSS-Sx was almost 2-fold higher 
than by -Sx-Pur and -Med; there were clear seasonal prevalence differences observed 
using the different definitions of AENSS; and risk factor analysis showed differing 
associations depending on the definition of AENSS, particularly that odds of AENSS-Sx-
Pur did not decline with increasing age in current long-term EPOSS subjects but did in all 
other EPOSS groups. 
In the absence of consensus on how to measure AENSS, we operationalized three 
definitions that first identified worsening of symptoms (e.g., NSS in past four weeks 
reported as worse or much worse than “usual”) and then applied criteria that would 
differentially maximize sensitivity (the proportion of people with an exacerbation who met 
the AENSS definition), positive predictive value (PPV; the proportion of people who met 
the AENSS definition who had an exacerbation), and clinical similarity to how asthma 
exacerbation is often defined in epidemiologic studies. AENSS-Sx was the most 
sensitive (and by definition, least specific) definition, and is useful for researchers 
wanting to estimate the prevalence of AENSS while avoiding under-estimation. Of the 
three definitions, AENSS-Sx-Pur should have the highest PPV, and therefore may be the 
best for risk factor analysis since its lower misclassification will minimize bias in effect 
estimates towards the null. Lastly, a medication-based AENSS definition (AENSS-Med) 




threatening, thus making a medication-based definition much more reliant on health care 
access and delivery.  
Although overall prevalence estimates for AENSS-Med and -Sx-Pur were 
comparable, there was little overlap in individuals ascertained by the two definitions, with 
only 31% of AENSS-Sx-Pur events additionally meeting criteria for AENSS-Med (see 
Supplemental material Table 3.7.5). Discordance could be due to AENSS-Med being 
influenced by an individual’s propensity to seek and be provided with medical care.  
AENSS occurred in all CRS status groups, but prevalence was higher and severity 
worse among subjects with past or current (long-term and recent) CRS. The absolute 
change in severity during an AENSS was largest among subjects who never met EPOSS 
CRS criteria, possibly due to a ceiling effect in NSS severity among individuals with 
current or past CRS.   
AENSS prevalence was greatest in the winter and spring for the past and never CRS 
groups, respectively, across all three AENSS definitions. This suggests exacerbations 
might be driven by viral infections in the winter (e.g. rhinoviruses26-30) or seasonal 
allergens and allergic rhinitis, for those with or without a history of CRS, respectively. No 
consistent seasonal patterns of AENSS were observed for the current CRS status 
groups across all three definitions of AENSS; however, a peak prevalence occurred in 
the winter or summer (AENSS-Med and AENSS-Sx/Sx-Pur, respectively) for the current 
recent CRS group. Prevalence of AENSS-Med was greatest in the current long-term 
CRS status group and occurred in the winter season, yet no major seasonal changes in 
AENSS-Sx/Sx-Pur were observed for this group, apart from modest associations with 
summer season. This could be due to residual selection bias due to loss-to-follow-up 
unaccounted for by the weighting procedure, or could reflect specific seasonal triggers 




history of current CRS are more likely to be prescribed medications for NSS in the 
winter, although NSS may not necessarily be more severe (given the lack of observed 
associations between season and AENSS-Sx/-Sx-Pur in this group). This may also 
reflect underlying pathobiology relevant to triggers of exacerbation in this group, since 
medical management would depend on the trigger (e.g. infections vs. grass pollen).  
We identified clinical and seasonal factors associated with AENSS. CRS status, 
increased BMI, asthma symptoms, hay fever, migraine symptoms, history of sinus 
surgeries, and season were associated with AENSS by both Med and Sx-Pur defined 
exacerbation. Our findings with BMI are similar to those found previously with CRS31,32 
and other otorhinolaryngological32 diseases, possibly due to chronic low-grade 
inflammation associated with obesity.33,34 Asthma1,2,22,23 and hay fever1,2,22,23 have been 
associated with CRS; however, symptom overlap between these conditions could 
indicate measurement error in EPOSS criteria. To address this issue, we evaluated 
whether hay fever or asthma modified associations of CRS status with AENSS. As we 
found no evidence for this, we included hay fever and asthma diagnoses as covariates in 
regression models without further stratification and statistical significance suggests 
indication of the unified airways disease concept. The relationship between migraines 
and NSS has been observed in previous studies,5,23 but could be due to misclassification 
of overlapping symptoms or biologic pathways, 35-37 or both. Sinus surgery was also 
associated with AENSS and could be due to bacterial infections in some CRS patients,38 
or be a proxy for individuals with recalcitrant CRS or persistent ARS, who are more likely 
to be aware of the severity of sinus symptoms over time.  
Females were more likely to have AENSS-Med than males, possibly due to residual 
confounding associated with medical-seeking and -prescribing behaviors,39 since this 




sex has been associated with CRS symptoms in other studies.5,40,41 Non-white 
race/ethnicity was associated with reduced odds of both AENSS definitions, though only 
statistically significant in the AENSS-Sx-Pur model. Lastly, never smokers were less 
likely to have AENSS-Med, compared to current smokers, although no association with 
smoking status and AENSS-Sx-Pur was observed. The odds of AENSS-Sx-Pur declined 
with higher ages, excluding the current long-term CRS status group, possibly due to 
differential susceptibility to viral infections which precede bacterial infections and 
decrease with increasing age.42 Yet, individuals with long-term CRS may be at risk of 
developing viral respiratory infections even at older ages due to compromised epithelial 
barrier function,43,44 which can accompany CRS,1,2,45 suggestive of a disease progressive 
model in those with persistent CRS. 
Our study had several strengths, including study of the general population in the 
region representing the full spectrum of diseases with NSS, longitudinal design (the first 
to our knowledge), large sample size, and evaluation of a relevant set of individual-
reported potential risk factors for AENSS, as well as season. We also used several 
definitions of AENSS to comparatively assess their utility in epidemiologic research, as 
advised by ICAR.2 Our study is not without limitations, however. We used a definition of 
CRS which did not include confirmation of inflammation by endoscopy or CT scan so we 
were unable to classify individuals with clinical CRS. Second, both CRS status and self-
reported individual characteristics were selected from the same questionnaires; as such 
there is the potential for spurious associations between them, since they are dependent 
on how an individual interprets and responds to the questions. However, a strength of 
this study is the inclusion of the ASI as a covariate, which adjusts for an individual’s 




associations from same source bias was mitigated. Furthermore, we used weighting 
methods and multiple imputation to adjust for non-response and potential selection bias.  
In summary, our study found that NSS and AENSS were common in the general 
population. NSS and AENSS severity were worse across categories of EPOSS CRS, 
peaking among current long-term CRS. Seasonal exacerbation prevalence depended on 
the AENSS definition and differed by EPOSS CRS status. Results suggest that a high 
PPV definition (e.g., AENSS-Sx-Pur) may provide the best balance between a sensitive 
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3.7 Supplemental material   





Table 3.7.1.  Definitions for acute exacerbations of nasal and sinus symptoms (AENSS) 













- ≥1 week - 
AENSS-
Sx-Purf 




Abbreviations: AENSS = acute exacerbation of nasal and sinus symptoms; CRS = 
chronic rhinosinusitis; NSS = nasal and sinus symptoms 
a Use of medications, including systemic corticosteroids and/or oral antibiotics, 
ascertained by self-report on each follow-up questionnaire 
b Timing of duration for worse/much worse NSS ascertained by self-report on each 
questionnaire from individuals who indicated worse/much worse NSS in past 4 weeks 
c Specifics for severity of cardinal CRS symptoms ascertained by self-report on each 
questionnaire from individuals who indicated worse/much worse NSS in the past 4 
weeks 
d AENSS-Med = worse/much worse NSS in past 4 weeks + use of systemic 
corticosteroids or antibiotic prescription for worsened NSS 
e AENSS-Sx = worse/much worse NSS in past 4 weeks + worse over any time period 
up to 4 weeks + remained worse for ≥ 1-week 
f AENSS-Sx-Pur = worse/much worse NSS in past 4 weeks + worse over any time 




IPCWs were calculated by using predicted probabilities from a pooled logistic 
regression model, in which the outcome (rij) was odds of remaining in the study at time t, 
and included a vector of baseline covariates (Zi0): age (centered), age2 (centered), sex, 
race/ethnicity, history of Medical Assistance, time (follow-up visit), Charlson comorbidity 
index (centered), as well as CRS status at the previous time-point (lagged CRS status; 
Zij-1). CRS status was only determined at two of the follow-up questionnaires (fall and 
summer exacerbation). As such, CRS status at the fall exacerbation questionnaire was 
carried forward until the summer exacerbation questionnaire. To account for large 
weights, which can lead to model instability, we used stabilized IPCWs. The stabilizing 
factor of the IPCW used as the numerator all baseline covariates included in original 
IPCW model, with the exclusion of age2 (Zio*).  
𝑆𝑡𝑎𝑏𝑖𝑙𝑖𝑧𝑒𝑑 𝐼𝑃𝐶𝑊 =
Pr(𝑟𝑖𝑗 = 1 | 𝑍𝑖0
∗ )
Pr(𝑟𝑖𝑗 = 1 | 𝑍𝑖0 +  𝑍𝑖𝑗−1)
 
The survey weights for these analyses were a product of the stabilized IPCW and a 
truncated design weight (where the strata with the largest weights were truncated to the 
next highest category), to further reduce model instability from extreme weights. 
𝑆𝑢𝑟𝑣𝑒𝑦 𝑤𝑒𝑖𝑔ℎ𝑡 =
Pr(𝑟𝑖𝑗 = 1 | 𝑍𝑖0)
Pr(𝑟𝑖𝑗 = 1 | 𝑍𝑖0 +  𝑍𝑖𝑗−1)
  𝑋 𝐷𝑒𝑠𝑖𝑔𝑛 𝑤𝑒𝑖𝑔ℎ𝑡𝑖 
 
  




Table 3.7.2.  Proportion (column percentages and 95% confidence intervals)a of recurrent AENSS events identified during four 
follow-up questionnaires 
EPOSS CRS statusb AENSS-Medc AENSS-Sxd AENSS-Sx-Pure 
Current long-term, n = 558 
 0 
 1 
 2  
 3 or 4 
 
74.1 (64.2 – 82.0) 
21.1 (13.6 – 31.1) 
3.27 (1.88 – 5.62) 
1.55 (0.58 – 4.08) 
 
41.7 (31.5 – 52.7) 
32.2 (23.2 – 42.7) 
15.0 (9.20 – 23.6) 
11.0 (6.66 – 17.8) 
 
74.5 (66.2 – 81.7) 
20.7 (14.2 – 29.0) 
3.34 (1.92 – 5.76) 
1.23 (0.53 – 2.83) 




 3 or 4 
 
80.8 (70.3 – 88.3) 
11.2 (6.80 – 18.0) 
7.10 (2.47 – 18.8) 
0.84 (0.14 – 4.89) 
 
48.9 (35.8 – 62.1) 
23.3 (13.9 – 36.5) 
17.1 (10.1 – 27.5) 
10.7 (4.93 – 21.6) 
 
84.2 (76.3 – 89.9) 
11.8 (7.12 – 19.0) 
2.76 (1.20 – 6.23) 
1.21 (0.21 – 6.73) 




 3 or 4 
 
84.4 (80.6 – 87.6) 
13.2 (10.3 – 16.8) 
2.15 (1.04 – 4.42) 
0.25 (0.15 – 0.40) 
 
50.8 (45.2 – 56.4) 
33.2 (28.1 – 38.7) 
11.4 (8.64 – 14.9) 
4.64 (3.08 – 6.94) 
 
79.4 (74.6 – 83.5) 
17.6 (13.7 – 22.3) 
2.82 (1.66 – 4.75) 
0.19 (0.12 – 0.31) 




 3 or 4 
 
92.4 (90.3 – 94.1) 
7.14 (5.49 – 9.24) 
0.43 (0.19 – 0.98) 
0 (0 – 0.22) 
 
71.1 (67.7 – 74.2) 
21.1 (18.3 – 24.3) 
5.86 (4.47 – 7.65) 
1.95 (1.21 – 3.15) 
 
89.4 (86.9 – 91.4) 
9.81 (7.81 – 12.3) 
0.39 (0.23 – 0.65) 






Abbreviations: AENSS = acute exacerbation of nasal and sinus symptoms; CRS = chronic rhinosinusitis; EPOS = 
European Position Paper on Rhinosinusitis; NSS = nasal and sinus symptoms 
a Column percentages estimated by survey-corrected methods and robust standard error estimation 
b EPOSS CRS status  determined using baseline and fall exacerbation questionnaires: current long-term CRS = 
EPOS epidemiologic criteria fulfilled at both questionnaires; current recent CRS = current CRS at fall questionnaire, 
but not at baseline;  past CRS = EPOS epidemiologic criteria fulfilled in lifetime, but not during study; never CRS = 
EPOS epidemiologic criteria never met 
c AENSS-Med = worse or much worse NSS in past 4 weeks and treated with either oral corticosteroids or antibiotics 
for worsened symptoms 
d AENSS-Sx = worse or much worse NSS in past 4 weeks and worsened symptoms lasting 1 week or more 
e AENSS-Sx-Pur = worse or much worse NSS in past 4 weeks, worsened symptoms lasting 1 week or more, and 








AENSS-Medb AENSS-Sxc AENSS-Sx-Purd 
No Exac Exac No Exac Exac No Exac Exac 
Current long-
term, 
 n = 558 
5.81  
(5.44 – 6.18) 
8.32  
(8.05 – 8.59)*** 
5.27  
(4.89 – 5.66) 
7.58  
(7.24 – 7.92)*** 
5.90  
(5.50 – 6.29) 
7.71  
(7.25 – 8.18)*** 
Current recent, 
n = 273 
4.88  
(4.38 – 5.38) 
7.69  
(7.10 – 8.28)*** 
4.33  
(3.74 – 4.92) 
7.00  
(6.59 – 7.40)*** 
4.98  
(4.42 – 5.55) 
7.13  
(6.53 – 7.73)*** 
Past, 
 n = 1,644 
4.24  
(4.02 – 4.47) 
7.22  
(6.88 – 7.56)*** 
3.67  
(3.44 – 3.91) 
6.76  
(6.55 – 6.96)*** 
4.20  
(3.97 – 4.24) 
7.09  
(6.76 – 7.41)*** 
Never,  
n = 2,261 
2.01  
(1.89 – 2.14) 
6.16 
 (5.61 – 6.71)*** 
1.65  
(1.54 – 1.76) 
5.42  
(5.17 – 5.68)*** 
1.97  
(1.85 – 2.10) 
5.87  
(5.39 – 6.35)*** 
Wald F-test 
 p-valuee 
 < 0.001  < 0.001  < 0.001  < 0.001  < 0.001  < 0.001 
Abbreviations: CRS = chronic rhinosinusitis; EPOS = European Position Paper on Rhinosinusitis; NSS = nasal and sinus 
symptoms  
*p-value<0.05, **p-value<0.01, ***p-value<0.001; p < 0.05 = statistically significant 
a Estimates determined by survey-corrected methods and robust standard error estimation; severity determined by use of visual 
analog scale (0-10), where higher scores indicate more severe NSS 
b EPOSS CRS status determined using baseline and fall exacerbation questionnaires: current long-term CRS = EPOS 
epidemiologic criteria fulfilled at both questionnaires; current recent CRS = current CRS at fall questionnaire, but not at baseline;  
past CRS = EPOS epidemiologic criteria fulfilled in lifetime, but not during study; never CRS = EPOS epidemiologic criteria never 
met 
c AENSS-Med = worse or much worse NSS in past 4 weeks and treated with either oral corticosteroids or antibiotics for worsened 
symptoms 
d AENSS-Sx = worse or much worse NSS in past 4 weeks and worsened symptoms lasting 1 week or more 
e AENSS-Sx-Pur = worse or much worse NSS in past 4 weeks, worsened symptoms lasting 1 week or more, and one of 
worsened symptoms was green/yellow nasal discharge (mucopurulence) 





Table 3.7.4. Figure 2 seasonal prevalence estimates of exacerbated nasal and sinus symptoms, by EPOSS CRS status and 
exacerbation definition 
EPOSS CRS status a Seasonb 
AENSS-Medc AENSS-Sxd AENSS-Sx-Pure 
Row Percentagef (95% Confidence Interval) 






7.77 (4.73 ‒ 12.53) 
20.6 (12.9 ‒ 31.2) 
5.94 (3.28 ‒ 10.5) 
9.15 (5.03 ‒ 16.1) 
29.7 (20.8 ‒ 40.6) 
35.1 (26.3 ‒ 45.1) 
33.5 (23.2 ‒ 45.6) 
45.3 (31.4 ‒ 59.9) 
10.9 (6.15 ‒ 18.5) 
10.4 (7.05 ‒ 15.0) 
10.8 (6.73 ‒ 16.9) 
11.71 (5.59 ‒ 22.9) 
 p-valueg 0.02 0.41 0.99 






7.63 (3.91 – 14.4) 
7.67 (4.18 – 13.6) 
8.95 (3.10 – 23.2) 
11.4 (3.83 – 29.2) 
27.7 (17.2 – 41.4) 
33.2 (22.4 – 46.2) 
31.5 (20.0 – 45.9) 
26.2 (13.6 – 44.6) 
6.01 (2.70 – 12.8) 
10.2 (5.96 – 17.0) 
4.83 (2.39 – 9.50) 
5.08 (1.55 – 15.4) 
 p-value 0.92 0.71 0.17 





4.08 (2.49 ‒ 6.62) 
9.29 (6.98 ‒ 12.3) 
6.67 (4.33 ‒ 10.1) 
3.89 (1.40 ‒ 10.3) 
16.3 (12.7 ‒ 20.7) 
30.0 (25.0 ‒ 35.5) 
29.0 (23.6 ‒ 35.1) 
21.2 (15.0 ‒ 29.1) 
4.99 (3.08 ‒ 7.97) 
13.5 (9.81 ‒ 18.2) 
7.89 (5.05 ‒ 12.1) 
3.91 (2.29 ‒ 6.58) 
 p-value 0.002 <0.001 <0.001 





1.92 (1.13 ‒ 3.23) 
2.67 (1.77 ‒ 4.02) 
3.98 (2.63 ‒ 5.99) 
1.54 (0.71 ‒ 3.27) 
8.29 (6.40 ‒ 10.7) 
13.3 (11.0 ‒ 15.9) 
19.6 (16.4 ‒ 23.2) 
7.76 (5.77 ‒ 10.4) 
3.40 (2.17 ‒ 5.29) 
4.11 (2.88 ‒ 5.83) 
6.06 (4.17 ‒ 8.73) 
1.29 (0.71 ‒ 2.33) 






Abbreviations: AENSS = acute exacerbation of nasal and sinus symptoms; CRS = chronic rhinosinusitis; 
EPOS = European Position Paper on Rhinosinusitis; NSS = nasal and sinus symptoms 
p-value < 0.05 is significant 
a EPOSS CRS status  determined using baseline and fall exacerbation questionnaires: current long-term 
CRS = EPOS epidemiologic criteria fulfilled at both questionnaires; current recent CRS = current CRS at 
fall questionnaire, but not at baseline;  past CRS = EPOS epidemiologic criteria fulfilled in lifetime, but not 
during study; never CRS = EPOS epidemiologic criteria never met 
b Season: Autumn = September 22 through December 21; Winter = December 22 through March 21; Spring 
= March 22 through June 21; Summer = June 22 through September 21 
c AENSS-Med = worse or much worse NSS in past 4 weeks and treated with either oral corticosteroids or 
antibiotics for worsened symptoms 
d AENSS-Sx = worse or much worse NSS in past 4 weeks and worsened symptoms lasting 1 week or more 
e AENSS-Sx-Pur = worse or much worse NSS in past 4 weeks, worsened symptoms lasting 1 week or 
more, and one of worsened symptoms was green/yellow nasal discharge (mucopurulence) 
f Estimates determined by survey-corrected methods and robust standard error estimation 






Table 3.7.5. Overlap of AENSS definitions (row/colum percentages and 95% confidence intervals)a 
 AENSS-Medb 
AENSS-Sxc No Yes 
 No 99.4 (98.9 – 99.6) / 86.3 (84.9 – 87.6) 0.6 (0.39 – 1.07) / 13.6 (8.67 – 20.8) 





 No 97.5 (96.9 – 98.0) / 96.3 (95.6 – 97.0) 2.5 (2.03 – 3.07) / 60.3 (53.1 – 67.0) 





 No 87.9 (86.6 – 89.1) / 100 12.1 (10.9 – 13.4) / 69.3 (65.4 – 73.0) 
 Yes 0 / 0 100 / 30.7 (27.0 – 34.6) 
Abbreviations: AENSS = acute exacerbation of nasal and sinus symptoms 
a Estimates determined by survey-corrected methods and robust standard error estimation 
b AENSS-Med = worse or much worse NSS in past 4 weeks and treated with either oral corticosteroids or 
antibiotics for worsened symptoms 
c AENSS-Sx = worse or much worse NSS in past 4 weeks and worsened symptoms lasting 1 week or more 
d AENSS-Sx-Pur = worse or much worse NSS in past 4 weeks, worsened symptoms lasting 1 week or more, 
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Objective: Evaluate associations of nasal and sinus and related symptoms, as well as 
selected health conditions which produce those symptoms, with total lost productive time 
(LPT) at work in the past two weeks. 
Methods: We used a cross-sectional analysis of 2402 currently working subjects. Self-
reported physician diagnoses, condition statuses measured with standardized 
instruments, and symptom-based factor scores from an exploratory factor analysis were 
used in survey weighted log-binomial regression.  
Results: Pain and pressure, nasal blockage and discharge, and asthma and 
constitutional symptom factor scores as well as self-reported allergic rhinitis were 
associated with higher total LPT. Individuals who met operationalized criteria for multiple 
health conditions, especially chronic rhinosinusitis, had the greatest total LPT.  
Conclusions: Better management of these symptoms, and awareness of how they 
impact an individual’s ability to perform job-functions in the workplace, could improve 






Cost is an important component in determining the overall burden of a disease,1 
often broken-down into two primary sources: direct and indirect. Direct costs include 
expenditures related to the medical treatment and care received for a condition while 
indirect costs are commonly characterized by daily life and employment impacts of a 
condition. In the workplace, indirect costs often include absenteeism (missing work due 
to health conditions) and presenteeism (reduced productivity and performance at work 
due to health conditions), which are jointly referred to as total lost productive time (LPT).2 
Acute conditions, like influenza, often have more indirect costs than direct costs,1,3 
whereas chronic conditions, like diabetes, have larger direct costs.4  
Chronic rhinosinusitis (CRS) is an upper respiratory condition characterized by 
inflammation of the nasal and paranasal sinuses,5-7  that is estimated to affect nearly 
12% of the adult US population,7 and incurs $22-$32 billion in total costs yearly.8,9 The 
European Position Paper on Rhinosinusitis and Nasal Polyps symptom-based criteria 
(CRSS) is commonly used for CRS classification in epidemiologic studies.5 Individuals with 
CRSS have been shown to have severe, persistent, and bothersome symptoms10 that 
would be expected to impact workplace productivity. Previous studies have shown CRS 
to result in increased absenteeism11-17 and presenteeism12,15,17,18 with estimates as high 
as 24.6 and 38.8 days per year, respectively.18 These studies have focused on 
individuals in the more severe spectrum of disease with many focused solely on 
recalcitrant or refractory CRS after surgery.15,17,18  
To date, no study has evaluated the workplace impacts of CRS across the full 
spectrum of disease in a general population representative sample. CRS is often 
comorbid with several conditions (e.g., allergic rhinitis [hay fever], asthma, migraine 




from these conditions as well. Further, these conditions have been shown to increase 
absenteeism,21-25 presenteeism,21-25 and total LPT.26,27 Several of these conditions with 
overlapping symptoms are diagnosed solely on the basis of symptoms (e.g. migraine 
headache), while others have additional evidence that can assist diagnosis (e.g., 
pulmonary function tests, skin allergy testing, sinus CT scan). Treatment for some of 
these conditions itself can have side effects that themselves impact work. Few prior 
studies have attempted to disentangle whether aspects of the diagnosis itself, which 
could capture the impact of treatment side effects, or the specific associated symptoms, 
were most associated with increased LPT.12,17  
Given the lack of general population-based epidemiologic studies of NSS due to 
CRS and related conditions with workplace impacts, the overarching objective of this 
study was to identify risk factors for LPT in a generalizable, population-based sample. To 
accomplish this objective, we used electronic health records (EHR) of subjects who had 
a primary care provider from Geisinger, a healthcare system in over 40 counties in 
central and northeastern Pennsylvania; these subjects are representative of the general 
population for the region.28 
4.3 Materials and methods 
4.3.1 Study overview 
We performed a cross-sectional analysis using responses to the final questionnaire 
in a longitudinal study of subjects focused on NSS and CRS, described elsewhere.7,29 
Briefly, we sequentially mailed five self-administered questionnaires from April 2014 
through December 2015 to a stratified random sample of primary care patients of 
Geisinger. Details of items included in questionnaires are described elsewhere.29 Briefly, 
the four questionnaires following baseline were used to understand seasonal 
exacerbations of NSS and were sent in approximately four month intervals. This study 




Authorization Agreement with the Johns Hopkins Bloomberg School of Public Health. 
Health Insurance and Accountability Act authorization and written informed consent 
waivers were approved by the IRB. 
4.3.2 Sampling method and study population 
A description of the sampling method has been previously reported.7 Electronic 
health records (EHR) were utilized to categorize individuals into three groups based on 
International Classification of Disease-9 and Current Procedural Terminology codes for 
allergic rhinitis, asthma, CRS, nasal polyps, and sinus procedures. We over-sampled 
individuals with CRS, nasal polyp, allergic rhinitis, and asthma diagnostic codes, as well 
as racial/ethnic minorities.7 Of the 23,700 individuals randomly selected to participate in 
the longitudinal study, 7847 responded to the baseline survey and 4600 responded to 
the final follow-up questionnaire. 
4.3.3 Primary independent variables 
We first operationalized definitions and analytic variables for the primary independent 
variables of interest, including condition statuses and symptoms. 
4.3.3.1 CRS classification 
We used the CRSS criteria for categorizing individuals with CRS as previously 
reported.7,10,29 CRSS status (referred to as CRS) was determined using self-reported 
frequency (in the past three months) of the cardinal CRS symptoms (nasal blockage, 
green or yellow discharge [anterior or posterior], smell loss, and facial pain or pressure) 
at each questionnaire. These symptoms were self-reported using a five-point Likert scale 
(“never”, “once in a while”, “some of the time”, “most of the time”, and “all of the time”). 
Symptoms reported at least “most of the time” were considered towards CRSS criteria. 
Individuals were assigned into three CRS status groups: “never” (did not meet current 
CRSS criteria at any questionnaire), “past” (met criteria at a prior questionnaire but not at 




4.3.3.2 Self-reported physician diagnoses and migraine headache status 
Self-reported physician diagnosis of hay fever and asthma were ascertained at 
baseline. Migraine status was operationalized as a binary indicator and determined 
using standardized and validated methods.29,30  
4.3.3.3 Symptom factor scores 
Factor scores were estimated from five factors using factor weights and methods 
previously described.31 Briefly, three EFA models were performed using 3535 subjects 
with responses to baseline, six month, and 16-month (final) questionnaires. Indicators 
included in the EFA were 37 self-reported symptoms in the categories of nasal and 
sinus; ear and eye; asthma; constitutional symptoms (i.e., fever, headache, fatigue); and 
allergy symptoms. Five factors were identified by the EFA models as pain and pressure; 
blockage and discharge; asthma and constitutional; smell loss; and ear and eye 
symptoms. Factor weights from the 16-month questionnaire EFA were used to estimate 
factor scores as previously reported.31 Larger scores indicated greater reporting of 
symptoms relevant to the specific factor and were standardized by z-transformation to 
allow for comparisons of factors.   
4.3.4 Dependent variables: absenteeism, presenteeism, and lost productive time 
Questions from the Work and Health Interview32 were only included in the 16-month 
questionnaire, using a two-week recall period. Subjects were instructed to complete the 
work-related questions only if they were currently working. Questions ascertained the 
average number of days worked per week and hours worked per day, which were then 
combined to calculate the average total hours worked in the prior two weeks. NSS-
specific absenteeism was operationalized from two questions: “How many workdays did 
you miss in the past two weeks because you were not feeling well?” and “How many of 
the workdays in the past two weeks were missed due to nasal and sinus symptoms?” 




components. We first estimated presenteeism days with responses to two questions: 
“On how many days in the past two weeks did you go to work when not feeling well?” 
and “On the days in the past two weeks you were not feeling well at work how many 
were due to your nasal and sinus symptoms?” We then estimated an “impact index” as 
workplace ability and function while having NSS using responses to five Likert scale 
questions (Supplemental material Table 4.7.1). Each of the five questions were scored 
from 0 to 1 (1 = all of the time; 0.75 = most of the time; 0.50 = about half of the time; 0.25 
= some of the time; 0 = none of the time) and the final index score was the mean of the 
five questions. Finally, the product of presenteeism days and the impact index provided 
the total number of NSS-specific presenteeism days. Both absenteeism and 
presenteeism were converted from days to hours using estimated hours worked per two-
week period. Lastly, total LPT was estimated by adding NSS-specific absenteeism and 
presenteeism for each subject.  
4.3.5 Statistical analyses 
The primary goals of the analysis were to evaluate whether: 1) symptom-based 
factor scores from an exploratory factor analysis (EFA)31 of a range of symptoms from 
several related conditions (i.e., asthma, CRS, hay fever, migraine headache) were more 
strongly associated with total LPT than were operationalized or self-reported physician 
diagnoses of these conditions; and 2) estimate and compare average total LPT within 
subgroups based on CRS and other health conditions to characterize subgroups with 
higher average total LPT.  
Of the 4600 subjects who responded to the final questionnaire, 2402 had classifiable 
CRS status and reported currently working and were therefore included in the analysis. 
Relations between variables as well as distributions were assessed and missing data on 
selected covariates were multiply imputed as done previously.29 For adjusted estimates 




symptom factors; model 2 evaluated condition statuses (e.g. physician-reported hay 
fever); and model 3 (fully-adjusted) evaluated symptoms and conditions. The outcome in 
these models was a proportion defined by: the number of work-hours attributed to LPT 
(numerator) over the average total number of hours worked (denominator), in a two 
week period.  
Potential covariates were selected from prior studies and a priori theory and included 
age (years, centered and scaled per five-years), sex, race/ethnicity (white vs. non-white), 
receipt of Medical Assistance (a surrogate for family socioeconomic status),33 body mass 
index (BMI, kg/m2), Charlson comorbidity index (centered),34 smoking status (never, 
former, current), and education (high school education or less, some college, four or 
more years of college). Non-linearity in continuous covariates was assessed, resulting in 
a cubic function for pain and pressure.  
To better understand associations observed in the regression models, we estimated 
LPT over a range of factor score values (Figure 4.4.2.1) and in subgroups based on 
CRS and health conditions using average adjusted predictions (i.e. predictive margins35) 
derived from the fully-adjusted model (Figure 4.4.2.2). Hereafter, we refer to these 
values as average expected total LPT (AET-LPT). While effect estimates from 
regression models are useful in understanding adjusted relations of covariates with the 
outcome, this latter approach provides tangible estimates of the expected outcome for, 
as examples, specific subgroups of people or for different values of specified covariates. 
Models were weighted using methods previously described29 and included use of 
sampling7,10 and inverse-probability of censoring weights (IPCW).29 As done 
previously,7,10,29 full weights were used in estimation of descriptive statistics whereas 
truncated weights were used in regression modeling. Adequacy of model fit was 




ultimately removed from final models. Models with and without this observation were 
substantively comparable, yet non-linearity of pain and pressure factor score was 
attenuated when the observation was included.  Statistical analyses were performed 
using STATA v15.1 (StataCorp, College Station, TX, USA) and R v3.4.1 (R Foundation 
for Statistical Computing, Vienna, Austria; www.r-project.org) software packages.    
4.3.6 Sensitivity analyses 
We did not include CRS status in model 3 since questions used to operationalize 
CRSS were also included in the factors, thereby inducing a linear dependency. However, 
we did test an additional model in which we included CRS status as a covariate. We also 
assessed sensitivity of observed effect estimates (for model 3) to sampling weights by 
comparing estimates from unweighted, truncated, and fully weighted models.  
4.4  Results 
4.4.1 Description of study population 
Of the 2402 working subjects, a total of 134, 775, and 790 subjects had any hours of 
absenteeism, presenteeism, and total LPT in the prior two weeks, respectively. The 
mean (standard error) absenteeism, presenteeism, and total LPT in the past two weeks 
was 0.40 (0.10), 1.45 (0.17), and 1.86 (0.21) hours, respectively. Compared to subjects 
included in the study, excluded subjects tended to be older, less healthy (i.e. larger 
Charlson comorbidity index), and more likely to receive Medical Assistance 
(Supplemental material Table 4.7.2).  
Population-estimated (survey weighted) descriptive information for the study sample 
showed persons with LPT were younger, more likely to be women, had more 
comorbidities, and were more likely to have past or current CRS (Table 4.4.1.1). 
Average factor scores were estimated in the source population, both overall and in CRS 
and health condition subgroups (i.e., migraine headache, hay fever, asthma, and 




Table 4.4.1.1. Population-estimated characteristics based on study sample (n = 2402) 
 Means (95% confidence intervals)/medians (IQR)a 
Selected variables No LPT (n = 1612)b LPT > 0 (n = 790) p-value 
 Hours worked per day; mean 8.33 (8.12 – 8.54) 8.52 (8.24 – 8.80) 0.31 
 Days worked per 2-week period; mean 9.68 (9.49 – 9.87) 10.2 (9.91 – 10.5) 0.003 
 Age (in years); mean  48.4 (47.0 – 49.8) 43.9 (41.7 – 46.0) 0.001 
 Body mass index (BMI; kg/m2); mean 29.4 (28.7 – 30.0) 29.0 (27.9 – 30.2) 0.62 
 Charlson comorbidity index; mean 0.79 (0.72 – 0.86) 1.16 (0.97 – 1.33) 0.001 
 Blockage and discharge; median (IQR) -0.77 (0.91) 0.18 (1.17) < 0.001 
 Pain and pressure; median (IQR) -0.82 (0.55) 0.15 (1.58) < 0.001 
 Asthma and constitutional; median (IQR) -0.75 (-0.71) 0.16 (1.31) < 0.001 
 Smell loss; median (IQR) -0.77 (0) 0.24 (2.19) < 0.001 
 Ear and eye; median (IQR) -0.71 (1.07) 0.22 (1.36) < 0.001 
 Column percentages (95% confidence intervals) 
 Sex (female), n = 1496 59.7 (55.0 – 64.4) 75.8 (69.1 – 82.4) < 0.001 
 Race/ethnicity (non-white), n = 157 3.73 (3.29 – 4.17) 5.59 (3.79 – 7.40) 0.09 
 Medical Assistance (ever received)c, n = 137 5.70 (3.09 – 8.32) 10.3 (5.43 – 15.1) 0.10 
 CRSS status (16-month)d 
  Never, n = 1034 
  Past, n = 915 
  Current, n = 453 
 
74.7 (70.9 – 78.4) 
19.5 (16.1 – 22.8) 
5.88 (3.89 – 7.87) 
 
45.4 (37.2 – 53.6) 
32.9 (25.7 – 40.0) 





 Physician diagnosed asthma, n = 573 8.82 (6.82 – 10.8) 23.6 (17.4 – 29.7) < 0.001 
 Physician diagnosed hay fever, n = 1169 26.2 (22.4 – 30.0) 54.4 (46.2 – 62.6) < 0.001 






Abbreviations: CRS = chronic rhinosinusitis; EHR = electronic health record; CRSS = symptoms that meet 
European Position Paper on Rhinosinusitis definition for CRS symptoms; LPT= lost productive time; NSS = 
nasal and sinus symptoms 
a Estimates derived using survey weighted methods; p-values based on F-ratios, except factor scores, which 
are based on Mann-Whitney-Wilcoxon U-test  
b LPT estimated using the sum of self-reported days missed and present while ill (in which work productivity 
was affected) due to NSS 
c Medical Assistance is determined from the EHR and is a proxy for family socioeconomic status 
d CRS status determined using self-reported symptoms relevant to CRSS at all observed time-points; never 
CRS = never met CRSS criteria over follow-up; past CRS = met CRSS criteria at some point in lifetime or over 





4.4.2 Adjusted estimates of workplace impacts 
In an adjusted model with symptom factor scores, three factors were associated with 
total LPT: pain and pressure, blockage and discharge, and asthma and constitutional 
(model 1, Table 4.4.2.1). In the next model, factor scores were removed and condition 
status for various health conditions were added; in this model, migraine, physician-
diagnosed hay fever, and past and current CRS were associated with increased hours of 
total LPT (model 2, Table 4.4.2.1). In the fully-adjusted model, factor scores and health 
condition status were included together; pain and pressure, blockage and discharge, and 
asthma and constitutional factors, as well as hay fever, remained associated with total 
LPT (model 3, Table 4.4.2.1). Generally, estimates and inferences were substantively 
unchanged when different sampling weights were used (or omitted) (Supplemental 





Table 4.4.2.1. Adjusted log-binomial regression models of total lost productive time (in hours) in two weeks, by symptom factor 
scores (model 1), selected conditions (model 2), and both (model 3), estimated in the source populationa 
Covariates 
Exponentiated β-coefficientsa (95% confidence interval) 
Model 1 Model 2 Model 3b 
Pain & pressure factor score (FS)c 
 Linear term 
 Squared termd 
 Cubic termd 
 
3.38 (2.42 – 4.71)*** 
0.47 (0.31 – 0.71)*** 
1.16 (1.02 – 1.32)* 
  
3.31 (2.37 – 4.61)*** 
0.48 (0.32 – 0.73)*** 
1.15 (1.02 – 1.31)* 
Blockage & discharge FS 1.21 (1.01 – 1.45)*  1.21 (1.02 – 1.43)* 
Asthma & constitutional FS 1.31 (1.16 – 1.50)***  1.30 (1.14 – 1.48)*** 
Smell loss FS 0.92 (0.80 – 1.06)  0.90 (0.78 – 1.04) 
Ear & eye FS 1.08 (0.91 – 1.28)  1.05 (0.89 – 1.24) 
Migraine status (Ref: no)  1.83 (1.31 – 2.55)*** 1.24 (0.94 – 1.64) 
Physician diagnosed hay fever (Ref: no)  1.61 (1.19 – 2.19)* 1.30 (1.00 – 1.70)* 
Physician diagnosed asthma (Ref: no)  1.22 (0.87 – 1.72) 1.20 (0.88 – 1.63) 




1.62 (1.10 – 2.38)* 








p-value: < 0.001***, 0.01**, < 0.05* 
Abbreviations: CRS = chronic rhinosinusitis; EHR = electronic health record; CRSS = symptoms that meet 
European Position Paper on Rhinosinusitis definition for CRS symptoms; LPT= lost productive time; NSS = 
nasal and sinus symptoms 
a Estimates derived using survey weighted methods; outcome is a proportion represented by total LPT as 
the numerator and average total hours worked in a two-week period as the denominator; all models 
additionally adjusted for: age (centered; scaled by five years), sex, race/ethnicity, Medical Assistance, body 
mass index (centered), Charlson comorbidity index (centered), smoking status, and education 
b To avoid linear dependency between current CRS status and the symptom factor scores, CRSS status was 
not retained in the final version of model 3 in which all other estimates are based on; estimates for CRS 
status are only derived from model 2 
c Factor scores were standardized (z-transformed) with units of SDs; entered model as continuous variables 
d Allowed for non-linearity in association 
e CRS status determined using self-reported symptoms relevant to CRSS at all observed time-points; never 
CRS = never met CRSS criteria over follow-up; past CRS = met CRSS criteria at some point in lifetime or 
over follow-up, but did not meet criteria at time of 16-month follow-up; current CRS = met CRSS criteria at 




We further evaluated associations of each factor with total LPT by estimating AET-
LPT using score values within ± 2 standard deviations, controlling for covariates (model 
3, Table 4.4.2.1 and Figures 4.4.2.1A-E). AET-LPT for a one standard deviation 
increase from the mean pain and pressure factor score would be 4.19 (95% CI: 3.25, 
5.13) hours, while a decrease would be 0.29 (95% CI: 0.08, 0.49) hours (Figure 
4.4.2.1A). Similarly, AET-LPT for a blockage and discharge factor score one standard 
deviation above or below the mean would be 2.76 (95% CI: 2.01, 3.52) and 1.90 (95% 
CI: 1.38, 2.42) hours, respectively (Figure 4.4.2.1B). AET-LPT for a one standard 
deviation increase from the mean asthma and constitutional factor score would be 2.98 
(95% CI: 2.24, 3.73) hours, while a decrease would be 1.76 (95% CI: 1.33, 2.19) hours 
(Figure 4.4.2.1C). Using the sum of all factor scores as an aggregate measure of all 
NSS and related symptoms, AET-LPT among subgroups with a score of 0, 5, or 10 
would be 2.29 (95% CI: 1.81, 2.78), 6.25 (95% CI: 5.00, 7.50), and 9.20 (95% CI: 6.24, 




Figure 4.4.2.1. Adjusted average total lost productive time (in hours) in two weeks, by standardized factor scores and sum of factor 
scores, estimated in the source population. LPT estimates are presented across ± 2 standard deviations for each of five symptom 
factors: (A) pain and pressure; (B) blockage and discharge; (C) asthma and constitutional; (D) smell loss; (E) ear and eye; and (F) 




Finally, to understand how associations with symptoms and LPT are represented in 
subgroups of individuals with these symptoms, we estimated AET-LPT within subgroups 
based on CRS and health conditions, using the fully-adjusted model (Figure 4.4.2.2). 
Overall, the current CRS subgroup would be expected to have the most AET-LPT, 7.47 
hours (95% CI: 6.11, 8.82) in two weeks. Current CRS subgroups with comorbid asthma, 
hay fever, or migraine would have an AET-LPT of 9.25 (95% CI: 3.34, 15.2), 6.40 (95% 
CI: 3.95, 8.85), and 7.42 (95% CI: 4.67, 10.2) hours, respectively. Lastly, the current 
CRS subgroup with all three comorbidities would have an AET-LPT of 15.4 (95% CI: 
10.3, 20.5) hours (Figure 4.4.2.2). 
4.5 Discussion 
In this first general population-based study of the workplace impacts of nasal, sinus, 
and related symptoms due to CRS and comorbid conditions, several findings were 
notable. We identified three symptom domains using factor scores that were associated 
with total LPT, specifically pain and pressure, blockage and discharge, and asthma and 
Figure 4.4.2.2 Adjusted average total lost productive time (in hours) in two weeks, by 
CRSS and health condition subgroups, estimated in the source population. Estimates 




constitutional, with the strongest association for pain and pressure. Before inclusion of 
these factor scores, past or current CRS, hay fever, and migraine were each associated 
with total LPT but only hay fever was associated with total LPT when factor scores were 
included.  
We attempted to determine which aspect of a condition was the key determinant of 
workplace impact by including both symptom factors and condition indicators in the 
same model. While condition status also encompasses symptoms (as they are generally 
the basis for diagnosis) it further includes willingness to seek medical care, disease 
control, medical or surgical treatments (which may affect reported symptoms), and side 
effects of treatments. By including both measures into a single model, we attempted to 
disentangle the workplace impacts of symptoms from the other aspects of the studied 
health conditions. Our results suggest that symptoms are more important than other 
features of these health conditions, with the symptoms of pain and pressure having a 
strong association with total LPT.  
The finding with the pain and pressure factor is consistent with that of a prior study of 
CRS and LPT in a tertiary care sample, in which facial pain was found to be highly 
correlated with workplace presenteeism and total LPT, even with adjustment for total 
sino-nasal outcomes test (SNOT)-22 scores (which includes nasal and sinus, fatigue, 
and allergy symptoms) and confounding variables.12 The results of both studies suggest 
that facial pain is associated with LPT even after accounting for differences in co-
occurring symptoms. Our observed association between nasal blockage and discharge 
and total LPT is also supported by a study of SNOT-22 domains and indirect costs 
among individuals with refractory CRS, where increases in monetary costs were 
associated with a one standard deviation increase in extra-nasal rhinologic symptoms 




associated with workplace impacts,23,24 and our association of the asthma and 
constitutional factor with total LPT is consistent with prior literature. Our lack of an 
association for the smell loss factor score is also consistent with a recent study of 
olfactory dysfunction and total LPT among individuals with recalcitrant CRS using an 
objective measure of smell loss.36  
Current CRS was associated with more total LPT than never or past CRS. 
Symptoms of blockage and discharge as well as facial pain and pressure are used in 
CRSS criteria for current CRS classification. Given this dependence on these symptoms 
for classification, it is perhaps unsurprising that current CRS was associated with total 
LPT in a model which only included conditions, since several studies of mainly tertiary 
care populations have shown CRS to influence workplace productivity among persons 
with it.12,15,18 It is important to note the association of current CRS was attenuated when 
symptom factor scores were included in the same model. While this could be due to 
modest collinearity, it may also imply that it was the symptom-based components of 
current CRS classification which drove its association with total LPT, as opposed to 
aspects of medical and/or surgical treatments. 
Hay fever was the only condition to remain associated with LPT in the fully-adjusted 
model. We speculate that only individuals with the most severe hay fever symptoms 
would seek medical care and thus have a physician diagnosis; however, the observation 
could also be due to side effects of some allergy medications, which have been 
associated with LPT.37  
Estimates of total LPT share similarities with previous findings. A prior study of total 
LPT among migraineurs found a range of 0.98 – 4.07 and 0.83 – 4.95 hours of total LPT 
per week among white females and males, respectively, ages 45-54 years.27 Our study 




deviation above average predicted 4.19 hours of total LPT per two weeks (~2.10 hours 
per week), while migraineurs with no history of CRS and other comorbidities were 
predicted to have 1.95 hours of total LPT per two weeks (~0.98 hours per week). Our 
study also found results differing from prior studies. For example, a study of CRS 
estimated an average workplace impact of 63.4 days of total LPT per year (507.2 hours 
assuming 8-hr work periods) among persons with CRS.18 The discrepancy is likely 
because the latter study was only of persons with refractory CRS selected from tertiary-
referral centers, so represents the most extreme end of the disease spectrum.  
Our study had several strengths. This is the first study, to our knowledge, to estimate 
and compare the workplace impacts of several conditions in a general population-based 
sample including CRS subjects with the full spectrum of disease, not only those cared 
for in tertiary care referral facilities. We examined symptom-based factors and evaluated 
their associations with total LPT with and without inclusion of specific health conditions in 
the models, disentangling the role of symptoms and other features of the health 
conditions on total LPT.  
This study also had limitations. We did not have occupational information (e.g. job 
title) for the subjects included in this study. We were thus unable to incorporate job type 
in analyses. We were also unable to account for differences in workplace culture and 
workplace policies (e.g., sick time, personal time off without having to provide medical 
documentation, light duty) that could differentially influence how symptomatic conditions 
could be translated into absence time and presenteeism. Finally, we studied self-
reported physician diagnoses, self-reported symptoms, and conditions based on 
standardized screening instruments, but were not able to include objective evidence of 




In this first population-based study of NSS and other symptoms from CRS and 
related health conditions, we found that rigorously estimated factor scores in the 
domains of pain and pressure, nasal blockage and discharge, and asthma and 
constitutional symptoms were associated with increased total LPT. Awareness for how 
these symptoms may impact a person’s ability to perform necessary job functions, as 
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4.7 Supplemental material 






On the day(s) you went to work with nasal and sinus symptoms, on 
average, how much of the time did you just do no work when you were 
supposed to be working? 
Q2 
On the day(s) you went to work with nasal and sinus symptoms, how 
much of the time did you spend doing a job over because you made a 
mistake or your supervisor told you to do a job over? 
Q3 
On the day(s) you went to work with nasal and sinus symptoms, how 
much of the time did you find it difficult to concentrate on what you 
needed to do?  
Q4 
On the day(s) you went to work with nasal and sinus symptoms, how 
much of the time did you work more slowly or take longer to complete 
tasks than usual or expected?  
Q5 
On the day(s) you went to work with nasal and sinus symptoms, how 
much of the time were you very tired, fell asleep at work or just felt too 
exhausted to do your work?  
Table 4.7.2. Comparison of subjects included and excluded from study (at 16-month 
follow up) 
 Means (95% confidence intervals)a 
Selected variables Not in study (n = 2198) In study (n = 2402) p-value 
Age (in years) 65.4 (64.8 – 65.9) 50.6 (50.1 – 51.1) < 0.001 
Body mass index 
(BMI; kg/m2) 




2.18 (2.11 – 2.25) 1.55 (1.49 – 1.60) 
< 0.001 
 Column Percentages (95% confidence intervals) 
Sex (female), n = 
2854 
61.8 (59.8 – 63.8) 62.3 (60.3 – 64.2) 
0.73 
Race/ethnicity 
(non-white), n = 
314 
7.14 (6.07 – 8.22) 6.53 (5.55 – 7.52) 
0.42 
Medical Assistance 
(ever received)b, n 
= 354  
9.87 (8.63 – 11.1) 5.70 (4.78 – 6.63) 
< 0.001 
Abbreviations: CRS = chronic rhinosinusitis; EHR = electronic health record; CRSS = 
symptoms that meet European Position Paper on Rhinosinusitis definition for CRS 
symptoms; LPT= lost productive time; NSS = nasal and sinus symptoms 
a P-values based on F-ratios  





Table 4.7.3.  Effect estimates for unweighted, truncated weighted, and fully weighted versions of model 3 
Covariates 
Exponentiated β-coefficientsa (95% confidence interval) 
Unweighted Truncated Full 
Pain & pressure FSb 
 Linear term 
 Squared termc 
 Cubic termc 
 
3.03 (2.39 – 3.84)*** 
0.51 (0.38 – 0.67)*** 
1.16 (1.06 – 1.26)** 
 
3.31 (2.37 – 4.61)*** 
0.48 (0.32 – 0.73)*** 
1.15 (1.02 – 1.31)* 
 
2.49 (1.54 – 4.03)*** 
0.66 (0.34 – 1.27) 
1.05 (0.86 – 1.28) 
Blockage & discharge FS 1.12 (0.97 – 1.28) 1.21 (1.02 – 1.43)* 1.20 (0.97 – 1.49) 
Asthma & constitutional FS 1.24 (1.12 – 1.38)*** 1.30 (1.14 – 1.48)*** 1.34 (1.15 – 1.55)*** 
Smell loss FS 1.02 (0.93 -1.12) 0.90 (0.78 – 1.04) 0.90 (0.75 – 1.07) 
Ear & eye FS 1.09 (0.97 – 1.23) 1.05 (0.89 – 1.24) 1.12 (0.89 – 1.41) 
Migraine status (Ref: no) 1.22 (1.01 – 1.47)* 1.24 (0.94 – 1.64) 1.48 (1.03 – 2.11)* 
Physician diagnosed hay fever (Ref: no) 1.08 (0.89 – 1.32) 1.30 (1.00 – 1.70)* 1.53 (1.07 – 2.19)* 
Physician diagnosed asthma (Ref: no) 0.82 (0.64 – 1.07) 1.20 (0.88 – 1.63) 1.13 (0.78 – 1.65) 
Abbreviations: CRS = chronic rhinosinusitis; EHR = electronic health record; CRSS = symptoms that meet 
European Position Paper on Rhinosinusitis definition for CRS symptoms; FS = factor score; LPT= lost 
productive time; NSS = nasal and sinus symptoms 
a Estimates derived using survey weighted methods; outcome is a proportion represented by total LPT as 
the numerator and average total hours worked in a two-week period as the denominator; all models 
additionally adjusted for: age (centered; scaled by five years), sex, race/ethnicity, Medical Assistance, body 
mass index (centered), Charlson comorbidity index (centered), smoking status, and education 
b Factor scores were standardized (z-transformed) with units of SDs; entered model as continuous variables 






Table 4.7.4. Effect estimates for model 3 which included CRSS status 
Covariates 
Exponentiated β-coefficientsa (95% confidence interval) 
Model 3 
Pain & pressure FSb 
 Linear term 
 Squared termc 
 Cubic termc 
 
3.42 (2.48 – 4.72)*** 
0.46 (0.31 – 0.70)*** 
1.16 (1.02 – 1.31)* 
Blockage & discharge FS 1.19 (0.98 – 1.45) 
Asthma & constitutional FS 1.29 (1.14 – 1.47)*** 
Smell loss FS 0.90 (0.78 – 1.04) 
Ear & eye FS 1.05 (0.89 – 1.23) 
Migraine status (Ref: no) 1.25 (0.94 – 1.67) 
Physician diagnosed hay fever (Ref: no) 1.30 (1.00 – 1.69) 
Physician diagnosed asthma (Ref: no) 1.22 (0.90 – 1.65) 




0.82 (0.58 – 1.16) 
1.05 (0.67 – 1.64) 
p-value: < 0.001***, 0.01**, < 0.05* 
Abbreviations: CRS = chronic rhinosinusitis; EHR = electronic health record; CRSS = symptoms that 
meet European Position Paper on Rhinosinusitis definition for CRS symptoms; FS = factor score; LPT= 
lost productive time; NSS = nasal and sinus symptoms 
a Estimates derived using survey weighted methods; outcome is a proportion represented by total LPT as 
the numerator and average total hours worked in a two-week period as the denominator; all models 
additionally adjusted for: age (centered; scaled by five years), sex, race/ethnicity, Medical Assistance, 
body mass index (centered), Charlson comorbidity index (centered), smoking status, and education 
b Factor scores were standardized (z-transformed) with units of SDs; entered model as continuous 
variables 
c Allowed for non-linearity in association 
d CRS status determined using self-reported symptoms relevant to CRSS at all observed time-points; 
never CRS = never met CRSS criteria over follow-up; past CRS = met CRSS criteria at some point in 
lifetime or over follow-up, but did not meet criteria at time of 16-month follow-up; current CRS = met 
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Background: Chronic rhinosinusitis (CRS) is a prevalent condition. Clinical diagnosis 
requires subjective evidence (i.e. symptoms) and objective evidence of inflammation 
(e.g. sinus computed tomography [CT]). Few studies have assessed differences in 
common CT scoring approaches for CRS, the Lund-Mackay (LM) system and its 
modified version (mLM); none in a general population sample.  
Objectives:  To answer the following: (1) Did mLM improve upon LM? (2) Should nasal 
cavity opacification be included as part of scores? (3) How should location-specific 
scores be utilized? (4) If location-specific scores are summed, what should be the 
cutoff? (5), Are associations of opacification with symptoms observed when using 
different approaches to measurement? 
Methods:  We used sinus CT scans scored using LM and mLM from 526 subjects 
selected from a larger CRS study. Exploratory factor analysis (EFA) assessed 
equivalence of mLM and LM. Latent class analysis (LCA) identified subgroups of sinus 
opacification patterns. Clinical relevance of latent classes was assessed by investigating 
associations with nasal and sinus symptoms (NSS) using least absolute deviation and 
multivariate ordered probit regression analyses. 
Results: EFA suggested all sinuses measured the same construct, with no differences 
between LM and mLM, or after addition of nasal cavity opacification. LCA identified three 
subgroups of opacification: no/mild, localized, and diffuse. An LM cutoff of 3 has similar 
performance to the currently used 4. Diffuse opacification was associated with nasal 
blockage, smell loss, and overall NSS burden.   
Conclusions: Latent classes of sinus opacification may have clinical relevance 





Chronic rhinosinusitis (CRS) is a prevalent condition of the paranasal sinuses.1 
Clinical diagnosis of CRS, suggested by American,2 European,1 and international3 
consensus groups, requires two components: 1) objective evidence of sinus 
inflammation by imaging (e.g. computed tomography [CT] scan) or nasal endoscopy, 
and 2) subjective evidence of self-reported nasal and sinus (NSS) symptoms. 
Considering the difficulty and cost associated with obtaining objective evidence of 
inflammation, EPOS has also proposed a symptom-based CRS definition (CRSS) to be 
used in epidemiologic research.1  
The Lund-Mackay (LM)4 scoring approach is recommended for CRS5 and measures 
opacification in three categories (none, partial, total) in five sinuses (maxillary, anterior 
and posterior ethmoids, frontal, and sphenoid) as well as the osteomeatal complex 
(OMC, none or total), with individual scores summed to a total of 0-24. A previous study 
of tertiary care patients with indications requiring sinus CT scans suggested a total score 
of LM < 4 be used as the cutoff for determining “normal” sinus opacification.6 The 
modified LM (mLM)7,8 is a variant of LM with finer gradation in sinus opacification (five 
categories) allowing for a total score of 0-44. Neither approach includes nasal cavity 
opacification as part of the total score, despite the fact that nasal polyposis, usually 
detected through endoscopic examination of the nasal cavity, causes nasal cavity 
opacification, and characterizes one phenotype of CRS (CRS with nasal polyps 
[CRSwNP]).1  
It has been well-documented that objective and subjective evidence of CRS correlate 
poorly;5,9-11 however, there are many potential reasons for the observed inconsistencies. 
NSS are common to several conditions e.g., acute rhinosinusitis (ARS), allergic rhinitis, 




CRSS while having no objective evidence of sinus inflammation. Further, symptom scoring 
approaches like CRSS consider NSS to be largely interchangeable; however, a recent 
study of NSS has shown the four symptom groups used in CRSS (nasal 
blockage/congestion/obstruction; anterior/posterior nasal discharge; smell loss; and 
facial pain/pressure), identify separate constructs, not one, which would be expected if 
they all represent the same underlying process or pathogenesis.12 Additionally, sinus 
opacification in the general population has not been studied so there have not been 
rigorous approaches to measurement across the broad spectrum of disease. 
Considering causation, inflammation causes manifestation of symptoms, not vice versa. 
Given the above, it is not surprising that NSS cannot be used to identify those likely to 
have sinus opacification. Given the widespread use of LM for diagnosis of sinus disease, 
this study had five primary objectives: 1) evaluate two common scoring approaches, 
mLM and LM, to determine whether mLM had better measurement properties compared 
to LM; 2) given that nasal polyps eventually extend to the nasal cavity, determine 
whether addition of nasal cavity opacification impacted scoring approaches; 3) assess 
whether sinus scores should be summed into one index, as current scoring proposes, or 
whether other approaches to measurement provide additional information; 4) if sinus 
locations are to be summed, determine if the current cutoff of LM ≥ 4 is suggested based 
on a general population sample; and 5) based on findings 1-4, determine whether new 
approaches to measurement of radiologic inflammation are associated with NSS.  
5.3 Materials and methods 
5.3.1 Study overview and participant selection 
Low-dose radiation sinus CT scans were completed on 646 subjects selected from a 
larger longitudinal study of CRS epidemiology. Details of the longitudinal study have 
been published elsewhere.13,14 Briefly, in 2014, primary care patients at least 18 years of 




health system in Pennsylvania and New Jersey in over 40 counties and whose primary 
care population is representative of the general population,15 to participate in the 
longitudinal study. Individuals who responded to the baseline questionnaire (n = 7847) 
were additionally mailed four seasonal follow-up questionnaires over the course of 16-
months. 
We used a stratified-random sampling approach to over-sample individuals with NSS 
as well as racial/ethnic minorities. NSS questionnaires were sent to subjects prior to their 
scheduled CT visit. Subjects who were pregnant were excluded and subjects reporting a 
cold or upper respiratory infection in the past 30 days were asked to postpone their CT 
visit. Of the 3269 subjects invited to participate in the CT study, 646 completed a sinus 
CT.  
This study was approved by Geisinger’s Radiation Safety Committee and Institutional 
Review Board (IRB), which has an IRB Authorization Agreement with the Johns Hopkins 
Bloomberg School of Public Health. Health Insurance Portability and Accountability Act 
authorization was approved and written informed consent was received from all 
participants.  
5.3.2 CT imaging, staging, and scoring 
Low-dose radiation, non-contrast sinus CT scans (coronal 3mm slices) were 
completed for all study subjects. CT images were de-identified and independently 
assessed by two otorhinolaryngologists who were blinded to CRS symptoms. CT images 
were scored using the mLM scoring approach.8 All locations were scored separately for 
the left and right sides with the OMC scored from 0-2 (0 = no occlusion, 1 = partial 
occlusion, 2 = complete occlusion) and sinuses scored from 0-4 (0 = 0% opacification, 1 
= 1-33%, 2 = 34-66%, 3 = 67-99%, or 4 = 100%). Nasal cavity opacification was also 




turbinate, 3 = at or below inferior turbinate, 4 = total opacification) per side. Average 
scores for locations were used when otorhinolaryngologists differed by only one point, 
whereas adjudication by discussion and agreement was required for scores differing by 
greater than one point. mLM scores were also converted to traditional LM scores4,5 
(sinuses: 0 = no opacification, 1 = partial opacification, 2 = complete opacification; OMC: 
0 = no occlusion and 2 = occlusion). Total LM scores were the sum of scores for all six 
locations.16 Lastly, evidence of prior sinus surgery based on CT images was recorded by 
the otolaryngologists. 
5.3.3 CRS symptoms and CRSS index 
The six core CRSS symptoms (four symptom groups) were self-reported using a five-
point Likert scale (0 = “never”, 1 = “once in a while”, 2 = “some of the time”, 3 = “most of 
the time”, and 4 = “all of the time”) detailing frequency of symptoms experienced in the 
past three months. We assessed symptoms individually and combined as a CRSS index to 
indicate overall NSS burden. The index followed the same logic of CRSS and collapsed 
the six symptoms into four symptom groups: nasal blockage; nasal discharge (average 
of self-reported nasal discharge and post-nasal drip); smell loss; facial symptoms 
(average of self-reported facial pain and pressure). These four symptom groups were 
then summed to create a score ranging from 0-16.  
5.3.4 Exploratory factor analysis 
 To evaluate whether sinus location opacification scores clustered,  we first applied 
exploratory factor analysis (EFA), a statistical technique often used in creation of scales 
in which a set of observed indicators (e.g., LM scores for sinus location) allow for indirect 
measurement of unobservable continuous latent constructs.17  We used maximum 
likelihood estimation for all models and oblique oblimin rotation to allow correlation 
among extracted factors. The number of extracted factors was chosen based on 




(SSABIC)18; and inspection of scree-plots17 (Supplemental material Figure 5.8.1 and 
Table 5.8.1). In addition to these base models, nasal cavity opacification was included 
as a binary variable (0 = score less than one; 1= score of at least one). To assess the 
influence of few, large mLM/LM scores, models were estimated using categorized 
versions of the original scoring approaches and polychoric correlations. mLM scored 
locations were collapsed into three categories: 0, 1, and > 1. LM scored sinus locations 
were dichotomized (0 and ≥ 1). 
5.3.5 Latent class analysis 
 We conducted latent class analysis (LCA) to identify potential subgroups of 
individuals based on sinus opacification patterns, as these subgroups may have clinical 
significance and inform pathogenesis as well as pathophysiology. LCA seeks to identify 
unobservable homogeneous subpopulations based on patterns of observed variable 
indicators17,19; whereas EFA determines how variables “cluster,” LCA determines how 
people “cluster.” For ease of model interpretability and identifiability, binary indicators of 
LM sinus scores were used in analyses (0 and ≥ 1). Increasing numbers of classes were 
fit and compared to guide the final LCA solution. We determined appropriateness of 
model fit using a variety of fit statistics, including standardized residuals, entropy, 
Akaike’s information criterion, Bayesian information criterion (BIC), SSABIC, Pearson 
chi-square, Lo-Mendell-Rubin likelihood ratio test (LRT),20,21 and bootstrapped LRT22. 
Posterior probabilities of opacification (π) were used to interpret the classes.17 
5.3.6 Risk factors for radiologic inflammation latent classes and symptom burden 
We obtained demographic information (i.e., age, sex, race/ethnicity), smoking status 
(never, former, current), and comorbidities used in the creation of the Charlson 
comorbidity index23 from the EHR. The continuous anxiety sensitivity index (ASI)24 
measures how much a person fears the symptoms of anxiety and was included to help 




determined migraine status at baseline using the Migraine ID questionnaire.25 Physician 
diagnosis of asthma and hay fever were ascertained by self-report at baseline. 
Questionnaire return dates were used to categorize the season in which symptoms 
occurred as previously described.14 We determined CRSS status as previously reported.13 
Briefly, all available questionnaires up to and including the CT questionnaire were used 
to classify subjects as: current (met CRSS criteria at time of CT), past (met criteria at prior 
timepoint but not at time of CT), or never (never met criteria). Lastly, a binary indicator 
was created for whether the self-reported symptoms were ascertained from a 
questionnaire greater than 90 days from time of CT (if the CT symptom questionnaire 
was not completed), a duration consistent with CRSS guidelines.1 
5.3.7 Other statistical analysis 
5.3.7.1 Risk factors for LCA group membership 
 In an effort to better understand what types of individuals comprised these classes, 
we used latent class regression to identify potential risk factors for latent class 
membership. We assessed four separate models using a standard (i.e. “one-step”) 
approach in which covariates can directly influence the makeup of the classes.26 Model 1 
included sex (female vs. male), ASI (z-transformed), self-reported physician diagnosis of 
hay fever (yes vs. no), age (z-transformed), and Charlson comorbidity index. Models 2 
through 4 had the same base covariates as model 1 but further included one of self-
reported physician diagnosed asthma, migraine status at baseline, or CRSS status, 
respectively. As a sensitivity analysis we assessed all models with fixed latent class 
membership logits ensuring latent classes in the regression model matched those from 
the marginal LCA, using a “three-step approach”.27 
5.3.7.2 Associations of LCA group membership with NSS 
 Latent class membership (most likely based on posterior probability) was used as an 




symptoms. For modeling associations of LCA and selected covariates with NSS, we 
used least absolute deviation regression of the conditional median (sometimes referred 
to as quantile or median regression).28,29 Model building included fitting unadjusted 
models for a pool of potential risk factors selected a priori based on our prior work with 
CRS.13,14,30-33 Variables were selected for the final model if they were theoretically and/or 
statistically associated with NSS burden or were a demonstrated confounder of the 
association of latent class with NSS. Standard errors as well as bias-corrected and 
accelerated 95% confidence intervals were estimated via bootstrapping, with 
acceleration correcting for skewness in the bootstrap distribution.34  
 For associations with individual symptoms we used multivariate (multiple outcome) 
ordered probit models.35-38 Probit regression is similar to logistic regression, however the 
former uses an inverse normal link function while the latter uses a logit link function.39 
Only four subjects reported nasal discharge in the highest frequency category (all of the 
time), so we combined that category with the one below (most of the time). We assessed 
potential influence of observations for each symptom’s unique model, from which three 
observations were deemed likely influential. As a sensitivity analysis, we assessed the 
final multivariate model with these observations removed, to better determine whether 
they had an impact on the final estimates.  
 EFA, LCA, and latent class regression were fit using Mplus v.8.1 (Muthén & Muthén, 
Los Angeles, CA) whereas all other models were fit using STATA v.15.1 (StataCorp, 
College Station, TX, USA).  
5.4 Results 
5.4.1 Overview of study sample 
In our sample of 646 subjects, 18.6% (n = 120) had radiologic evidence of prior sinus 
surgery. Comparing those with surgery (“surgical”) to those without (“non-surgical), 




meet current CRSS status, and have higher median LM and mLM scores (Table 5.4.1.1). 
Subjects with evidence of prior sinus surgery were excluded from subsequent analysis 
given the inability to determine whether prior sinus surgery affected 1) observed sinus 




Table 5.4.1.1. Study sample characteristics comparing subjects with and without evidence of prior sinus surgery on sinus computed 
tomography 
Variables 
Non-surgical (n = 526) Surgical (n = 120) 
Median (IQR, range) 
Age at baseline (in years) 56.4 (17.3, 19.1 – 85.7) 58.2 (15.3, 22.6 – 88.1) 
Body mass index (BMI; kg/m2) 30.0 (8.73, 17.5 – 59.3) 30.9 (7.62, 15.7 – 51.2) 
Charlson comorbidity index 2.00 (2.00, 0 – 7) 2.00 (3.00, 0 – 7) 
Anxiety sensitivity index (0 – 64) 12.0 (16.0, 0 – 64) 13.0 (17.5, 0 – 52) 
Lund-Mackay (0 – 24) 0.00 (2.00, 0 – 22) 3.00 (6.00, 0 – 22)*** 
Modified Lund-Mackay (0 – 44) 1.50 (3.00, 0 – 39.5) 4.50 (9.00, 0 – 42)*** 
 Column proportion (SE) 
Female sex, n = 431 0.69 (0.02) 0.56 (0.05)** 
Non-white race/ethnicity, n = 26 0.05 (0.01) 0.00 (0.00) 
Medical Assistance (ever received)a, n = 56 0.09 (0.01) 0.08 (0.02) 
CRSS statusb 
 Never, n = 73 
 Past, n = 249 









Self-reported physician diagnosis of asthma, n = 197 0.27 (0.02) 0.44 (0.05)*** 
Self-reported physician diagnosed of hay fever, n = 361 0.55 (0.02) 0.61 (0.04) 
Migraine headache statusc, n = 229 0.36 (0.02) 0.33 (0.04) 
***p-value < 0.001, **p-value < 0.01, *p-value < 0.05; p-values determined by Mann-Whitney-Wilcoxon U-test or 
Wald test. 
Abbreviations: CRSS = European Position Paper on Rhinosinusitis subjective symptoms definition for CRS 
classification; CT = computed tomography; EHR = electronic health record 
a Medical Assistance was determined from the EHR as a proxy for family socioeconomic status. 
b CRS status determined using self-reported symptoms relevant to CRSS at all observed time-points up to and 
including closest to time of CT scan; never CRS = never met CRSS criteria over follow-up; past CRS = met 
CRSS criteria at some point in lifetime or over follow-up, but did not meet criteria at time of CT scan; current CRS 
= met CRSS criteria at time of CT scan. 




5.4.2 LM vs. mLM scoring and nasal cavity opacification 
Analysis of location-specific opacification scores using EFA showed both LM and 
mLM measure just one underlying construct (Supplemental material Table 5.8.1 and 
Figure 5.8.1). No meaningful differences with respect to factor composition were 
observed (i.e. for LM and mLM, all sinuses contributed to the underlying construct); 
however, frontal and sphenoid locations had larger factor loadings (i.e. more strongly 
associated with the underlying construct) when measured via LM (Supplemental material 
Table 5.8.2). 
5.4.3 How should location specific scores be used? 
Given EFA models showed no differences between scoring approaches, LM was 
used for all subsequent analyses because of its widespread use in prior literature and 
clinical settings. LCA revealed that a three class model had superior fit to the one and 
two class models (Table 5.4.3.1). The three classes were identifiable as “no/mild 
opacification, “localized opacification,” and “diffuse opacification” with prevalence 
estimates of 63.0%, 21.5%, and 15.5%, respectively (Table 5.4.3.2). Descriptive 
characteristics of individuals assigned to each class showed substantial differences in 
median LM scores with the no/mild class having a score of 0, localized a score of 1, and 
diffuse a score of 7 (Table 5.4.3.2). Further, 94% of subjects assigned to the diffuse 





Table 5.4.3.1. Lund-Mackay sinus opacification patterns and latent class analyses fits (one to three classes) 
Lund-Mackay sinus opacification score 
(in order): OMC, maxillary (M), anterior 
ethmoid (AE), posterior ethmoid (PE), 
frontal (F), and sphenoid (S): None (0) or 
at least 1 (1)                                                            
 
  
Expected pattern frequency 
(standardized residual) 
OMC M AE PE F S 
Observed, 
n 1-class model 2-class model 3-class model 
8 most frequently observed patterns (84.8% 
of subjects) 
0 0 0 0 0 0 265 159.3 (10.0) 253.7 (0.99) 264 (0.09) 
0 1 0 0 0 0 94 100.9 (-0.76) 104.8 (-1.18) 94.7 (-0.08) 
0 1 1 0 0 0 26 31.1 (-0.95) 14.88 (2.92) 26 (0.10) 
0 0 1 0 0 0 19 49.1 (-4.51) 27.3 (-1.63) 19 (-0.09) 
1 1 1 1 0 0 12 0.67 (13.87) 11.3 (0.20) 10.7 (0.39) 
0 0 0 0 0 1 11 12.4 (-0.40) 8.06 (1.04) 10.8 (0.05) 
1 1 0 0 0 0 11 13.2 (-0.62) 3.44 (4.09) 10.3 (0.23) 
1 1 1 1 1 1 8 0.0 (117.5) 3.45 (2.46) 3.94 (2.05) 
Latent class model fit statistics     
 Entropy  NA 0.91 0.86 
 AIC  2664.4 2196 2172.8 
  BIC  2690.0 2251.4 2258.1 
  SSABIC  2671.0 2210.1 2194.6 
  Pearson chi-square  
1955.2 
(p < 0.0001) 
75.9 
(p = 0.01) 
36.8 
(p = 0.73) 
  Vuong-Lo-Mendell-Rubin LRT  NA 
482.5 
(p < 0.0001) 
36.4 
(p < 0.0001) 
  Bootstrapped LRT  NA 
482.5 
(p < 0.0001) 
37.2 
(p< 0.0001) 
 Latent class prevalence (estimated from model)     
  Class 1  100% 83.5% 63.0% 
  Class 2   16.5% 21.5% 




Abbreviations: AIC = Akaike’s information criterion; BIC = Bayesian information criterion; SSABIC = sample size-adjusted Bayesian 






Table 5.4.3.2. Latent class posterior probabilities of sinus opacification and class membership characteristics for selected variables 
Sinus and 
OMC 
Lund-Mackay sinus opacification 
scorea > 0 (overall %) 
Sinus opacification probability 
Class 1 Class 2 Class 3 
OMC 11.6 0.40 11.6 56.8 
Maxillary 38.8 6.60 100 85.0 
Anterior 
ethmoid 
23.6 6.70 22.2 93.9 
Posterior 
ethmoid 
14.1 3.50 0.00 76.5 
Frontal 8.20 1.10 2.00 45.5 
Sphenoid 7.20 3.90 0.00 30.5 
Class prevalence (%)b 63.0% 21.5% 15.5% 
Class name 
No/mild opacification Localized 
opacification 
Diffuse opacification 
Mean / median LM score (min, max) 0.18 / 0 (0, 4) 1.8 / 1 (1, 6) 7.2 / 7 (2, 22) 
% LM ≥ 2 3% 44% 100% 
% LM ≥ 3 0% 21% 94% 
% LM ≥ 4 0% 9% 89% 
% LM ≥ 5 0% 2% 78% 
% female sex 74% 60% 54% 
% migraine headache statusc 37% 38% 30% 
% self-reported physician diagnosis of hay fever 53% 59% 57% 
% self-reported physician diagnosis of asthma 27% 24% 33% 
% current CRSSd 49% 43% 54% 
% past CRSS 39% 44% 33% 





Abbreviations: CRSS = European Position Paper on Rhinosinusitis subjective symptoms definition for CRS classification; LM = 
Lund-Mackay; OMC = osteomeatal complex 
a Based on CT scoring by two otorhinolaryngologists blinded to CRSS status. 
b Based on estimated model. 
c Based on responses to four questions, at baseline, from the ID Migraine questionnaire. 
d CRS status determined using self-reported symptoms relevant to CRSS at all observed time-points up to and including closest to 
time of CT scan; never CRS = never met CRSS criteria over follow-up; past CRS = met CRSS criteria at some point in lifetime or 





5.4.4 Risk factors for latent class membership 
For all models (Supplemental material Tables 5.8.3 and 5.8.4 one-step and three-
step approaches, respectively), female sex was the only risk factor to cross an inferential 
boundary, with females (compared to males) having a 63-66% reduction in relative risk 
of being in the diffuse class (vs. no/mild) (Supplemental material Tables 5.8.3 and 
5.8.4). There were also elevated relative risks for self-reported physician diagnosis of 
hay fever for localized and diffuse (vs. no/mild), self-reported physician diagnosis of 
asthma for diffuse (vs. no/mild), and migraine headache for localized (vs. no/mild); 
however, these 95% confidence intervals included 1.0 (i.e. did not reach statistical 
significance) (Supplemental material Tables 5.8.3 and 5.8.4). 
5.4.5 Latent class membership informing LM score cutoff selection 
We compared the distributions of LM scores in each class using LM cutoffs of ≥ 4 
and ≥ 3 (Figure 5.4.5.1). LM ≥ 4 tended to exclude individuals in the diffuse class more 
severely than LM ≥ 3. While LM ≥ 3 still excluded individuals in the diffuse class (n = 5), 
Figure 5.4.5.1. Lund-Mackay distributions within latent classes using two 




it provided a balance of including subjects from the diffuse class (94%) while also 
excluding 99.7% of the no/mild class and 79% of localized.  
5.4.6 Associations of latent class with overall symptom burden and core CRSS 
symptoms 
The distribution of total NSS burden scores was shifted to higher values for the 
diffuse class (Supplemental material Figure 5.8.2). In adjusted analysis, diffuse 
opacification (vs. no/mild) was associated with more NSS, with a median index value 
increase of 1.15 (95% confidence interval: 0.29, 2.02) (Table 5.4.6.1). As an example, 
this represents subjects in the diffuse class reporting one of the four symptom groups at 
a frequency one category higher than the other two classes (e.g. most of the time vs. 
some of the time), on average.  
 For individual symptoms, diffuse opacification was positively associated with nasal 
blockage (β = 0.27; 95% confidence interval: 0.01, 0.53) and smell loss (β = 0.37; 95% 
confidence interval: 0.10, 0.63) (Table 5.4.6.2), conferring increased probability of 
reporting symptoms (Supplemental material Figure 5.8.3). Migraine headache modified 
associations of localized latent class membership with nasal discharge and post-nasal 
drip by reducing the probability of reporting these symptoms (Supplemental material 
Figure 5.8.4). In a sensitivity analysis, three potentially influential observations were 
removed prior to model estimation; effect estimates were not substantively changed 





Table 5.4.6.1. Associations of selected variables with CRSS symptom indexa at the 




(BCab confidence interval) 




0.01 (-0.74, 0.61) 
1.15 (0.29, 2.02)* 
Female sex (vs. male) -0.24 (-1.06, 0.31) 
Anxiety sensitivity index (z-transformed) 0.55 (0.22, 0.94)* 
Migraine headache status (vs. no)c 1.10 (0.56, 1.82)* 
Self-reported physician diagnosis of hay fever (vs. 
no) 
0.50 (-0.12, 1.12) 





0.50 (-0.42, 1.35) 
0.54 (-0.24, 1.30) 
0.18 (-0.63, 1.22) 
* Crossed inferential boundary (evidenced by confidence interval not crossing 
0.00); model additionally adjusted for smoking status (former or current vs. never) 
at baseline and binary indicator for whether symptoms taken from questionnaire 
occurred > 90 days from time of CT scan. 
Abbreviations: BCa = bias-corrected and accelerated; CRSS = European Position 
Paper on Rhinosinusitis subjective symptoms definition for CRS classification;  
a Sum of 4 core CRSS symptom groups (nasal blockage; nasal discharge and post-
nasal drip; smell loss; facial pain and facial pressure) self-reported at questionnaire 
closest to time of CT scan. 
b 95% bias-corrected and accelerated confidence interval based on bootstrap 
estimation; adjusted for skew of bootstrap distribution. 
c Based on responses to four questions, at baseline, from the ID Migraine 
questionnaire. 
d Fall = 22 September to 21 December; winter = 22 December to 21 March; spring = 




Table 5.4.6.2. Associations of selected variables with six core CRSS symptoms in multivariate (multiple-outcome) ordered probita 
regression 



























































































***p-value < 0.001, **p-value < 0.01, *p-value < 0.05; 
Abbreviations: CRSS = European Position Paper on Rhinosinusitis subjective symptoms definition for CRS classification; 
FPN = facial pain; FPR = facial pressure; NB = nasal blockage; ND = anterior nasal discharge; PND = post-nasal drip; SL 
= smell loss 
a Ordered probit regression yielded β-coefficients which represented a β-change in z-score of underlying outcome scale; 
all models adjusted for season, female sex, ASI, migraine status, and binary indicator for whether symptoms taken from 
questionnaire occurred > 90 days from time of CT scan. 
b Additionally included ASI2 and interactions for female sex by ASI and ASI2. 
c Additionally included self-reported physician diagnosis of hay fever, age, and interactions for female sex by ASI and by 
age. 
d Additionally included age, age2, Charlson comorbidity index, binary indicator for receipt of Medical Assistance, ASI2, and 
interactions for female sex by ASI and ASI2. 
e Additionally included self-reported physician diagnosed hay fever, age, and age2. 







Improving and standardizing measurement of sinus opacification is critical to 
advancing research in CRS as inconsistent or weakly-justified approaches to 
characterizing sinus opacification makes inferences across studies difficult. To the best 
of our knowledge, this is first study to evaluate LM vs. mLM, evaluate whether nasal 
cavity opacification should be included in the two scoring approaches, and identify other 
ways to classify location-specific scores, in a general population representative sample.  
LM has been recommended by the Task Force on Rhinosinusitis due to its simplicity 
and ease in interpretation5; although, inability to assess progression of disease prompted 
the development of modified scoring approaches including the mLM system.8 A previous 
study of LM, mLM, and Zinreich scoring approaches found no conclusive evidence that 
the modified approaches were an improvement to LM, vis-à-vis agreement between 
visual scoring by otorhinolaryngologists and computer calculated scoring (via soft tissue 
density rates).7 Yet, no prior studies had evaluated their comparative utility in a general 
population sample of non-surgical candidates representing a broad spectrum of disease. 
Since both EFA models found a single factor, to which all locations were associated, we 
found no advantage of using mLM over LM in research of sinus diseases.   
Neither mLM nor LM includes nasal cavity opacification as part of its scoring, but 
opacification in the nasal cavity might be indicative of nasal polyposis, an important 
pathology of CRSwNP.1 While we found no evidence that inclusion of nasal cavity 
opacification in scoring added information beyond that provided by the other sinus 
locations (all subjects with nasal cavity opacification were in the diffuse class), we had 
relatively few persons with any nasal cavity opacification in our sample (5.3% of the 




should be performed to more definitively address whether nasal cavity opacification 
should be included in scoring approaches.  
Whereas our EFA models showed all sinuses to measure the same underlying 
construct (i.e. inflammation), LCA identified three subpopulations of sinus opacification: 
no opacification or mild, isolated opacification; localized maxillary opacification; and 
diffuse opacification, almost always including the anterior ethmoid, indicating that 
patterns of radiologic inflammation differ among people. Therefore, current approaches 
to summing scores across all sinus locations may hide clinically useful information about 
the location and pattern of opacification. Our patterns of opacification share similarities 
with a prior study of sinus CT scans.40 In that study, five mutually inclusive patterns of 
sinonasal disease were observed among 500 patients from a tertiary care setting, whom 
were under evaluation for suspected sinus disease and possible candidates for surgical 
intervention. The patterns were: limited maxillary sinus disease; diffuse anterior disease; 
posterior sinus disease; sinonasal polyposis; and limited disease without involvement of 
the osteomeatal unit or sphenoethmoidal recess.40 Our study, however, addresses many 
limitations of that study: we used subjects selected from the general population, rather 
than a tertiary care population likely representing only the most severe end of the 
disease spectrum; we used a well-known and recommended scoring approach (LM) for 
quantifying sinus opacification; also, our study used formal statistical methods to 
discriminate patterns, identifying mutually exclusive subgroups of individuals. While our 
latent classes may appear hierarchical (i.e. represent points along disease progression), 
this cannot be determined without longitudinal CT information to assess whether 
individuals transition in or out of these latent classes. 
Risk factors for latent class membership provided insight into the clinical or 




larger LM scores,41 a finding supported by our latent classes in which males were over 
2.5 times more likely to be in the diffuse (vs. no/mild) class than females. Hay fever and 
asthma both trended towards an association with the diffuse class, both of which have 
previously been associated with the occurrence of diagnostic codes for CRS,30,31 CRS 
symptoms (CRSS),13,42 and sinus opacification on CT imaging.41,43 Future studies should 
explore whether latent class membership is associated with CRS endotypes and 
response to treatment as these classes could have relevance to disease management. 
These subgroups suggested that a different approach to the use of location-specific 
sinus opacification may offer advantages over a single-score cutoff. The current 
suggested guideline for objective evidence indicative of CRS is an LM cutoff of LM ≥ 4,6 
however there are several limitations with the study from which that guideline was 
established. That study used CT scans from subjects with indications requiring CT 
imaging, therefore they do not necessarily represent the general population. Further, 
individuals with suspected or confirmed CRS were excluded from the analysis, thereby 
making the distribution of LM scores in the target sample unavailable. However, if the 
standard approach to a single LM score cutoff is to be used a cutoff of LM ≥ 3 may be 
more appropriate, given its greater inclusion of individuals from the diffuse opacification 
class, which is taken to represent the most sinus diseased group of individuals.   
Lastly, we saw an opportunity to address the oft-cited lack of correlation between 
objective and subjective evidences of CRS. Our first novel insight to this dilemma came 
from an appreciation of the causal relation of inflammation and symptoms. NSS cannot 
cause sinus inflammation, but inflammation could cause NSS; as such, we reversed the 
directionality of our tested associations to allow sinus opacification latent classes to 
predict NSS. In adjusted analysis, diffuse latent class membership was associated with 




associations with nasal blockage and smell loss. Although this had never been 
evaluated in a general population representative sample across a broad spectrum of 
disease and in the appropriate causal direction, these findings are supported by prior 
studies in tertiary care settings. For example, a study using CT scans from subjects 
presenting with CRS symptoms at an otorhinolaryngology care clinic found subjects with 
LM ≥ 4 were more likely to report smell loss. 44 A similar finding was observed among 
subjects with non-CRS related indications requiring sinus CT imaging, in which LM ≥ 4 
was associated with more nasal blockage and smell loss.41  
Our study has several strengths. We used a population-based sample generalizable 
to the population in the region that included non-surgical patients representing a 
spectrum of individuals typically excluded from CT-based studies of CRS, to determine 
whether mLM offers advantages over LM; whether nasal cavity opacification should be 
included in scoring; and used novel approaches to categorizing location-specific CT 
opacification scores We also identified subgroups of sinus opacification that may have 
clinical and epidemiologic relevance. This study, however, is not without limitations. Due 
to sample size and model identifiability we were unable to assess LCA models beyond 
sinus opacification patterns based on presence/absence of opacification. Thus, we could 
not identify subgroups which also described severity of disease (e.g., unilateral vs. 
bilateral).  
5.6 Conclusion 
Overall, we found no differences between mLM and LM scoring approaches for sinus 
CT opacification and no additional benefit from including nasal cavity opacification as 
part of either scoring approach. We identified three subgroups of sinus opacification 
suggesting the use of a single-score cutoff as criteria for objective evidence of CRS is 
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5.8 Supplemental material 
Table 5.8.1. Fit of exploratory factor analysis models of modified Lun-Mackay (mLM) 
and Lund-Mackay (LM) scored sinuses. Models were performed on original and 
categorized (reduced) scales, with and without addition of binary (none vs. at least a 
score of one) nasal cavity opacification. 








mLM scale     
SSABIC     
 1 factor 6730.4 4342.3 6969.1 4407.6 
 2 factor - 4322.4 - 4390.0 
Eg > 1.0 1 1 1 1 
LM scale     
SSABIC     
  1 factor 2890.9 2196.4 2940.3 2240.7 
  2 factor - 2192.7 2929.9 2238.2 
Eg > 1.0 1 1 1 1 
Abbreviations: Eg = eigenvalue; LM = Lund-Mackay; mLM = modified Lund-Mackay; 





Figure 5.8.1. Example scree plot for exploratory factor analysis models. Scree plot from 
modified Lund-Mackay scored locations in the raw (uncategorized) scale and no nasal cavity 
opacification. All scree plots were similar to the one shown above. Larger eigenvalues indicate 




Table 5.8.2. One factor exploratory factor analysis models of modified Lund-Mackay (mLM) and Lund-Mackay (LM) scored sinuses. 
Models were performed on original and categorized (reduced) scales, with and without addition of binary (none vs. at least a score of 
one) nasal cavity opacification. 
Sinus 
location 
No nasal cavity included Nasal cavity included 
Original scale Categorized scale Original scale  Categorized scale 
Loading Communality Loading Communality Loading Communality Loading Communality 
mLM 
 OMC 
0.80 0.63 0.80 0.65 0.89 0.80 0.80 0.65 
 Maxillary 0.67 0.45 0.64 0.41 0.75 0.57 0.64 0.41 
 Anterior 
 ethmoid 
0.94 0.89 1.00 1.00 0.97 0.94 1.00 1.00 
 Posterior 
 ethmoid 
0.81 0.66 0.83 0.69 0.86 0.74 0.83 0.69 
 Frontal 0.71 0.51 0.75 0.56 0.77 0.60 0.75 0.56 
 Sphenoid 0.34 0.12 0.47 0.22 0.40 0.16 0.47 0.22 
 Nasal 
 cavity 








0.85 0.72 0.84 0.71 0.84 0.71 0.83 0.70 
 Maxillary 0.72 0.52 0.65 0.42 0.72 0.52 0.66 0.44 
 Anterior 
 ethmoid 
0.90 0.81 0.92 0.85 0.90 0.81 0.92 0.84 
 Posterior 
 ethmoid 
0.91 0.83 0.85 0.72 0.91 0.82 0.85 0.72 
 Frontal 0.85 0.73 0.86 0.74 0.85 0.73 0.85 0.72 
 Sphenoid 0.61 0.37 0.61 0.37 0.62 0.39 0.61 0.37 
 Nasal 
 cavity 
    0.87 0.75 0.93 0.86 




Table 5.8.3. Unadjusted and adjusted associations of selected variables with latent class membership using the one-stepa method 
Variables No/mild 
Relative risk ratios (RRR) and 95% confidence intervals 
Localized Diffuse 
Unadjusted Adjusted Unadjusted Adjusted 
Model 1      


















Self-reported physician diagnosis of hay 






























Model 2      
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Model 3      


















Self-reported physician diagnosis of hay 







































Model 4      


















Self-reported physician diagnosis of hay 






























CRSS status (vs. never CRSS)c 
 Past CRSS 
 
























***p-value < 0.001, **p-value < 0.01, *p-value < 0.05 
Abbreviations: CRSS = European Position Paper on Rhinosinusitis subjective symptoms definition for CRS classification 
a Did not fix measurement error associated with latent class membership allowing covariates to influence makeup of latent classes. 
b Based on responses to four questions, at baseline, from the ID Migraine questionnaire. 
c CRS status determined using self-reported symptoms relevant to CRSS at all observed time-points up to and including closest to 
time of CT scan; never CRS = never met CRSS criteria over follow-up; past CRS = met CRSS criteria at some point in lifetime or 




Table 5.8.4. Unadjusted and adjusted associations of selected variables with latent class membership using the three-stepa method 
Variable No/Mild 
Relative risk ratios (RRR) and 95% confidence intervals 
Localized Diffuse 
Unadjusted Adjusted Unadjusted Adjusted 
Model 1      















































Model 2      































































Model 3      
























































Model 4      















































CRSS status (vs. never CRSS)c 
 Past CRSS  
 
























***p-value < 0.001, **p-value < 0.01, *p-value < 0.05 
Abbreviations: CRSS = European Position Paper on Rhinosinusitis subjective symptoms definition for CRS classification 
a Fixed measurement error associated with latent class membership; allowed interpretation of latent classes to be unchanged with 
addition of covariates. 
b Based on responses to four questions, at baseline, from the ID Migraine questionnaire. 
c CRS status determined using self-reported symptoms relevant to CRSS at all observed time-points up to and including closest to 
time of CT scan; never CRS = never met CRSS criteria over follow-up; past CRS = met CRSS criteria at some point in lifetime or 




Figure 5.8.2. Box-and-whisker plot of CRSS symptom index within latent classes. The 
symptom index was created by summing frequency scores (0 to 4 from never to all of 




Table 5.8.5. Associations of six core CRSS symptoms with selected covariates in a multivariate (multiple-outcome) ordered probita 
model with three influential observations removed 























































































***p-value < 0.001, **p-value < 0.01, *p-value < 0.05; 
Abbreviations: CRSS = European Position Paper on Rhinosinusitis subjective symptoms definition for CRS classification 
a Ordered probit regression yielded β-coefficients which represented a β-change in z-score of underlying outcome scale; all 
models adjusted for season, female sex, ASI, migraine status, and binary indicator for whether symptoms taken from 
questionnaire occurred > 90 days from time of CT scan. 
b Additionally included ASI2 and interactions for female sex by ASI and ASI2. 
c Additionally included self-reported physician diagnosis of hay fever, age, and interactions for female sex by ASI and by age. 
d Additionally included age, age2, Charlson comorbidity index, binary indicator for receipt of Medical Assistance, ASI2, and 
interactions for female sex by ASI and ASI2. 
e Additionally included self-reported physician diagnosed hay fever, age, and age2. 





Figure 5.8.3. Marginal probabilities of self-reported symptoms at all frequency categories (in the past three months), by latent class. 
Estimates based on an adjusted multivariate ordered probit regression model. Nasal blockage (A), smell loss (B), facial pain (C), and 
facial pressure (D). Frequency categories were: never, once in a while (“once”), some of the time (“some”), most of the time (“most”), 





Figure 5.8.4. Marginal probabilities of self-reported symptoms at all frequency categories (in the 
past three months), by latent class and migraine status. Estimates based on an adjusted 
multivariate ordered probit regression model. Nasal discharge (A) and post-nasal drip (B). 
Frequency categories were: never, once in a while (“once”), some of the time (“some”), most of 
the time (“most”), and all of the time (“all”). The two highest frequency categories were 





Chapter 6: Miscellaneous results: CFA and MIMIC model of CRSS 
6.0 Introduction 
Chronic rhinosinusitis (CRS), is a prevalent and disabling condition characterized by 
inflammation of the paranasal sinuses.1-4 Several consensus groups operationalize 
clinical CRS by objective evidence of inflammation (e.g., sinus computed tomography 
[CT] scan, endoscopy, magnetic resonance imaging [MRI]) and subjective nasal and 
sinus symptoms (NSS).2-4 Given the difficulty in obtaining objective evidence of 
inflammation in epidemiologic studies, the European Position Paper on Rhinosinusitis 
and Nasal Polyps (EPOS) has recommended using the subjective symptoms component 
as the criterion for classification with CRS (CRSS).2 CRSS is defined by the presence of 
nasal blockage/congestion, anterior/posterior nasal discharge, smell loss, or facial 
pain/pressure; an individual must self-report two or more symptoms (one of which must 
be nasal blockage or discharge) lasting at least three months to be classified with 
current CRSS.2  
While CRSS has been used in several epidemiologic studies,1,5-7 no study has been 
done to confirm the construct validity of its operationalization. We have previously shown 
that the defining CRS symptoms – symptoms that could result from several overlapping 
conditions (e.g., CRS, asthma, allergic rhinitis, migraine headaches) – measure at least 
three different domains;8 however, the various approaches to summing symptoms for 
CRSS imply that the symptoms are equivalent and hence any underling symptom factor 
is unidimensional. Misclassification of symptoms for CRS could occur if symptom 
occurrence is truly multidimensional. Further, CRSS assumes exchangeability of anterior 
nasal discharge with post-nasal drip (i.e. posterior nasal discharge) as well as facial pain 
with facial pressure. However, we have previously shown differential associations of 
radiologic inflammation (measured by sinus CT) patterns with these symptoms, 




commonly reported in several conditions, including tension headache, migraine 
headache, vascular headache (e.g., hemicrania continua, cluster headache, and 
paroxysmal hemicrania), and orodental pathologies2; but, it is uncommon in CRS,9 
especially when nasal polyps are present (i.e. CRSwNP),10 and is usually only reported 
during onset of acute bacterial infection.2 Therefore, it is possible that certain CRSS 
symptoms may have different contexts (i.e. differential item functioning [DIF]), depending 
on an individual’s comorbidities, which could lead to bias in classification with CRSS. 
Given the possible multidimensionality of CRSS and DIF by comorbidities, we used 
self-reported NSS from a general population representative sample of individuals, across 
a broad spectrum of sinus disease, to answer the following questions:  
1) Is CRSS unidimensional or are multiple constructs identified by these six 
symptoms? 
2) Are there sex and comorbidity differences with respect to the underlying 
construct(s)? 
3) Is there DIF by sex and comorbidity status for any of the CRSS symptoms?  
6.1 Materials and methods 
6.1.1 Study overview and sample 
The details on the study design and sample have been published elsewhere.1,7,8 
Briefly, out of 200,769 individuals from the electronic health record (EHR) of Geisinger, a 
large healthcare system in central and northeastern Pennsylvania, 23,700 were selected 
to participate in a longitudinal epidemiologic study of CRS, NSS, and related symptoms 
and conditions based on International Classification of Diseases (ICD-9) and Current 
Procedural Terminology codes. Of the 23,700 selected, 7847 returned a baseline 
questionnaire which included (among other components) the six questions comprising 
CRSS and were subsequently followed through 16 months, with four questionnaires 




questions). After excluding individuals with missed questionnaires and excessive item-
level missingness (i.e. greater than five questions), 3535 individuals remained for 
subsequent analyses. 
6.1.2 CRSS symptoms 
CRSS symptoms, including nasal blockage/congestion, anterior nasal discharge, post-
nasal drip, smell loss, facial pain, and facial pressure were self-reported from all 
individuals at each questionnaire. The frequency of these symptoms in the past three 
months were reported using a five-point Likert scale (0 = never, 1 = once in a while, 2 = 
some of the time, 3 = most of the time, and 4 = all of the time).  
6.1.3 Selected covariates 
We chose sex, anxiety sensitivity index (ASI), and self-reported physician diagnoses 
of asthma, hay fever, and migraine as covariates in this study. We selected sex and the 
comorbidities as covariates given their prior associations with current CRSS in a 
separate study.1 We included ASI, a measure of a person’s fear of anxiety-related 
physical symptoms,11 as we hypothesized that individuals with greater ASI may either be 
more aware of their symptoms or overreport symptoms, thereby leading to differential 
measurement of these symptoms.  
6.1.4 Confirmatory factor and multiple indicator-multiple cause analyses 
Confirmatory factor analysis (CFA) is a measurement modeling approach in which 
dimensionality of an underlying construct is theoretically or empirically known (one of the 
key features distinguishing it from exploratory factor analysis [EFA]).12 CRSS arguably 
assumes a unidimensional construct based on responses to four symptom groups, 
therefore we set to use a CFA framework to statistically test this assumption. While 
CRSS assumes exchangeability of anterior nasal discharge with post-nasal drip and 
facial pain with facial pressure, we included these as separate questions on the 




operationalization, we included a priori paths between these pairs of symptoms to allow 
for residual correlation among these indicators, since conditional independence is an 
assumption in both EFA and CFA.12,13 This basic model became our base model. 
We tested for differences in means of the underlying factor identified in our base 
model by introducing indirect effects (i.e. paths from covariates to latent factor) of 
selected covariates. This model is known as the multiple indicator-multiple cause 
(MIMIC) model or sometimes called a CFA with covariates.14 We further assessed for 
DIF by including paths from selected covariates to CRSS symptoms. These direct effects 
were guided by modification indices (e.g., Lagrange multipliers15) and added one at a 
time, beginning with the most significant parameter.  
6.1.5 Statistical analysis 
CFA and MIMIC models were estimated in Mplus v.8.1 (Muthén & Muthén, Los 
Angeles, CA) using robust weighted least squares and fixing the factor loading for nasal 
blockage to one for model identification. Model fit was assessed by root mean square 
error of approximation (RMSEA),16,17 comparative fit index (CFI),18 Tucker Lewis index 
(TLI),19 and standardized root mean square residual (SRMR).20 Parameter estimates are 
presented in unstandardized form in path diagrams and standardized form in Table 
6.2.2.2. While our primary analyses were completed using baseline questionnaire 
responses, we reassessed all models using responses from the 16-month follow-up 
questionnaire, as a sensitivity analysis.  
6.2 Results 
6.2.1 Characteristics of sample 
Descriptive information on this sample can be found in the previously published 
Appendix (Cole et al. 2018).8 Briefly, males constituted 37.8% of the sample; the mean 




subjects self-reported physician diagnosis of asthma, hay fever, or migraine, 
respectively.  
6.2.2 CFA model with no covariates 
Our base CFA model fit the data well with a RMSEA of 0.035, CFI and TLI values of 
1.00 and 0.999 (respectively), and SRMR of 0.007 (Table 6.2.2.1). All six CRSS 
symptoms significantly loaded onto the factor (unstandardized parameters; Figure 
6.2.2.1). While the estimate for the correlation between facial pain and facial pressure 
was not significant, we retained this in the model since we specified it a priori as a key 
component of the model.  
Table 6.2.2.1. Selected fit metric for all CFA models, by questionnaire (baseline or 16-
month follow-up) 
As a sensitivity analysis, we estimated the CFA model using responses to the 16-
month follow-up questionnaire, to determine whether model results were replicable or 
 Base model Indirect effects added Direct effects added 
Fit metric Baseline 16-month Baseline 16-month Baseline 16-month 
RMSEAa 0.035 0.019 0.045 0.047 0.021 0.023 
CFIb 1.00 1.00 0.996 0.996 0.999 0.999 
TLIc 0.99 1.00 0.995 0.995 0.999 0.999 
SRMRd 0.007 0.006 0.032 0.038 0.009 0.012 
Abbreviations: CFI = comparative fit index; RMSEA = root mean square error of 
approximation; SRMR = standardized root mean square error; TLI = Tucker Lewis 
index 
a value < 0.08 generally indicates good model fit 
b value ≥ 0.95 generally indicates good model fit 
c value ≥ 0.90 generally indicates good model fit 




spurious. Absolute measures of model fit (Table 6.2.2.1) and factor loadings 
(unstandardized parameters; Figure 6.2.2.2) were comparable in the 16-month CFA 
model to those of the baseline model (Table 6.2.2.2).
  
Figure 6.2.2.1. 













Table 6.2.2.2. Standardized factor loadings and indirect and direct effects of covariates 
 Base model Indirect effects added Direct effects added 
Factor item Baseline 16-month Baseline 16-month Baseline 16-month 
Nasal blockage 0.90 0.81 0.91 0.82 0.91 0.82 
Nasal discharge 0.81 0.74 0.82 0.74 0.83 0.76 
Post-nasal drip 0.84 0.73 0.84 0.72 0.85 0.72 
Smell loss 0.66 0.62 0.67 0.64 0.67 0.64 
Facial pain 0.77 0.73 0.78 0.74 0.74 0.70 
Facial pressure 0.83 0.75 0.83 0.76 0.81 0.73 
Covariate effects, indirect       
Female sex   0.09 0.04 0.13 0.12 
Asthma   0.20 0.14 0.20 0.14 
Hay fever   0.39 0.42 0.41 0.45 
Migraine headache   0.36 0.41 0.26 0.30 
Anxiety sensitivity index 
(ASI, z-transformed) 
  0.16 0.23 0.15 0.22 
Covariate effects, direct       
Nasal blockage 
 Female sex 
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 Hay fever 
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6.2.3 CFA model with covariates 












but not the 
six CRSS 
symptoms directly (unstandardized parameters; Figure 6.2.3.1). Model fit was still 
acceptable with a RMSEA of 0.045, CFI and TLI of 0.996 and 0.995 (respectively), and 
SRMR of 0.032. All symptoms again significantly loaded onto the latent factor and all 
covariates were significantly associated with the factor as well (Table 6.2.2.2). These 
significant indirect associations indicated differences in means of the underlying factor 
by sex, ASI, or self-reported physician diagnoses. In absolute terms, self-reported 
physician diagnosis of migraine and hay fever as well as higher ASI were most 
associated with the latent factor.  
 
Figure 6.2.3.1. CFA model with indirect effects of selected covariates, using 
baseline questionnaire responses. ASI = anxiety sensitivity index; FPN = 
facial pain; FPR = facial pressure; NB = nasal blockage; ND = nasal 




In the CFA model using responses from the 16-month questionnaire, model fit was 
comparable to that of the baseline questionnaire model (Table 6.2.2.1), although sex no 
longer had a significant association with the latent factor (unstandardized parameters; 
Figure 6.2.3.2; Table 6.2.2.2).  
Lastly, to determine 
whether there was any 
DIF present vis-à-vis 
the selected 
covariates, we entered 
direct effects for these 
covariates, i.e. opened 
paths from the 




6.2.3.3). All covariates 
were again positively 
associated with the latent factor while DIF by sex, self-reported physician diagnosis of 
migraine and hay fever, and ASI were observed (Table 6.2.2.2). Considering the 
potential DIF, female sex was consistently associated with nasal blockage, anterior 
nasal discharge, smell loss, facial pain, and facial pressure; however, the direction of 
associations were dependent on the symptom. Female sex was negatively associated 
with nasal blockage, anterior nasal discharge, and smell loss, and positively associated 
with facial pain and facial pressure. Self-reported physician diagnosis of hay fever was 
 Figure 6.2.3.2. CFA model with indirect effects of selected 
covariates, using 16-month follow-up questionnaire 
responses. ASI = anxiety sensitivity index; FPN = facial pain; 
FPR = facial pressure; NB = nasal blockage; ND = nasal 




negatively associated with anterior nasal discharge while self-reported physician 
diagnosis of migraine 
was consistently 
positively associated 
with facial pain and 
facial pressure. 
Lastly, ASI was 
positively associated 





Figure 6.2.3.3. CFA model with indirect and direct effects of 
selected covariates, using 16-month follow-up questionnaire 
responses. ASI = anxiety sensitivity index; FPN = facial pain; FPR 
= facial pressure; NB = nasal blockage; ND = nasal discharge 




We reassessed this CFA model with responses from the 16-month questionnaire. 
Model fit (Table 
6.2.2.1), factor 
loadings, indirect 
effects, and direct 
effects were all 
comparable to 
those estimated 






Figure 6.2.3.4. CFA model with indirect and direct effects of selected 
covariates, using 16-month follow-up questionnaire responses. ASI = 
anxiety sensitivity index; FPN = facial pain; FPR = facial pressure; NB = 
nasal blockage; ND = nasal discharge (anterior); PND = post-nasal 





In this study, we used a general population representative sample of individuals 
across a broad spectrum of sinus disease, to address the following questions:  
1) Is CRSS unidimensional? 
2) Are there differences in association with CRSS by sex, ASI, and self-reported 
physician diagnoses? 
3) Is uniform DIF present in CRSS by the aforementioned covariates?  
To our knowledge, this is the first study to address the above questions, despite the 
common use of CRSS in epidemiologic studies.1,2,5-7 
CRSS is comprised of four major symptoms groups (six individual symptoms), 
including nasal blockage, anterior nasal discharge/post-nasal drip, smell loss, and facial 
pain/pressure, with nasal blockage and anterior/posterior nasal discharge serving as 
anchoring symptoms (i.e. at least one is required).2  While this operationalization is 
suggestive of a unidimensional construct, we have recently shown that these symptoms 
may be represented by as many as three latent constructs, when considered with 
additional NSS questions related to severity and bother, and while also including 
asthma, allergy, and constitutional symptoms in the model.8 Our base CFA models found 
a single factor model fit the data appropriately, suggesting that perhaps these four 
symptom groups do measure a single underlying construct, when only considered 
together (and not with additional NSS). Though, with only six indicators our ability to 
detect additional constructs is limited.  
It is important to note the insignificant correlation between anterior nasal discharge 
and post-nasal drip in all models tested. CRSS currently assumes that these symptoms 
are interchangeable, the same of which is true for facial pain and facial pressure; 




are not necessarily exchangeable with one another and should be considered as 
separate contributions to the operationalization. 
In the CFA models with indirect effects, female sex was positively associated with the 
latent factor as were ASI and self-reported physician diagnoses of asthma, hay fever, 
and migraine. These observations are congruent with those of a prior study of CRSS, 
though associations with ASI were not reported by the authors.1  
Considering our CFA models that allowed indirect and direct effects of covariates, we 
observed several of the CRSS symptoms to have DIF by one or more of the covariates. 
However, considering that these questions did not have any apparent difficult wording or 
phrasing, we do not consider the observed DIF associations to be “adverse,” but rather 
“benign.”21 Simply put, benign DIF occurs when a question identifies a different 
dimension in the construct that is not directly measured or manifests differently across 
subgroups of individuals. On the other hand, adverse DIF is essentially artifactual 
measurement error derived from the generation of the indicators used to measure the 
underlying construct.21 Females, while having a greater association with the underlying 
factor than males, exhibited systematic underreporting of nasal blockage, anterior nasal 
discharge, and smell loss while overreporting facial pain and facial pressure. This sex-
dependent item functioning has important implications for the validity of CRSS when 
applied uniformly to males and females. If certain types of symptoms (e.g. facial vs. 
nasal) are reported differentially by the basis of sex, then it is possible that CRSS may 
not have the same context across the sexes.  
ASI, a measure of a person’s fear of anxiety-related physical sensations (believing 
these sensations to be harmful),11 was positively associated with facial pain, meaning 
individuals with greater ASI were more likely to overreport this symptom than those with 




individuals with greater ASI have a lower pain threshold than those with lower ASI, 
thereby being more likely to report pain, even if biological inflammation resulting in that 
pain is comparable.  
We observed a negative association of self-reported physician diagnosis of hay fever 
with anterior nasal discharge, implying a systematic underreporting of this symptom 
among individuals with hay fever, compared to those without. This is as expected since 
our question pertaining to anterior nasal discharge asked about purulent (e.g., yellow or 
green in color) discharge specifically, which is not a common symptom of hay fever; 
mucous produced in response to allergens is usually clear and thin compared to that 
produced by infection.22,23 
Lastly, self-reported physician diagnosis of migraine headaches was positively 
associated with facial pain and facial pressure. This was as hypothesized considering 
our prior associations of CRSS with migraine headache, especially among individuals 
reporting these facial symptoms.1 While there are several explanations for this, the most 
likely is that these symptoms are manifested in a multitude of overlapping conditions, 
including CRS and migraine headache2; therefore, it is possible that these symptoms are 
really measuring a construct representing migraine headache when asked among 
individuals with this diagnosis, instead of the intended construct (i.e. CRS). 
In this study, we observed several instances of DIF in a CRSS construct by sex and 
various comorbidities. While we do not believe these are related to inappropriate 
question formation (i.e. adverse DIF), they do highlight the difficulties in creating a 
definition of symptom-based CRS, especially when there are likely pathogenic 
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Chapter 7: Discussion 
7.0 Summary of findings 
 The aims of this dissertation were to: comparatively assess multiple definitions of 
acute exacerbations of nasal and sinus symptoms (AENSS) and describe their 
respective risk factors; estimate the workplace impacts of nasal and sinus symptoms 
(NSS) and related symptoms and diagnoses; and develop a new approach to 
categorization of radiologic inflammation in chronic rhinosinusitis (CRS). As we became 
immersed in CRS research, we realized that the measurement of CRS symptoms, 
AENSS, and radiologic inflammation were all problematic. As such, the research 
presented in this dissertation became mainly about measurement of multidimensional 
constructs.  
 In our first study1 (Chapter 3), we directly addressed a call-to-action from the 
International Consensus on Allergy and Rhinosinusitis, wherein there was an expressed 
need for comparative assessments of several definitions for the acute exacerbations of 
CRS, especially in general population samples.2 We developed several 
operationalizations of NSS exacerbations, with varying degrees of specificity, including 
one related to antibiotic and oral corticosteroid use for worsened NSS (AENSS-Med); 
timing of symptoms (AENSS-Sx); and timing of symptoms with the requirement that one 
worsened symptom was mucopurulence (AENSS-Sx-Pur). We declined to refer to these 
definitions as AECRS, since we did not have objective evidence of inflammation and 
therefore could not classify individuals with clinical CRS (CRSC), only subjective 
symptoms CRS (epidemiologic definition; CRSS).  
 We found that NSS and AENSS were common in the general population, but 
exacerbations occurred more frequently in those with long-term CRSS status.1 Further, 
we observed a seasonal association with all AENSS definitions, though most 




treatment for viral or bacterial infections common during winter and increased allergen 
exposures in the spring.  
 Comparing the respective risk factors for each definition of exacerbation, we found 
several to be consistent across all definitions, including CRSS status, asthma (symptoms 
at baseline), self-reported physician diagnosed hay fever, and migraine headache.1 
These risk factors further support the concept of the unified airway disease model.3 
Ultimately, we reasoned AENSS-Sx-Pur to be the definition least influenced by medical-
seeking and -prescribing behaviors and was more specific than either AENSS-Med or 
AENSS-Sx. 
 In our second study4 (Chapter 4), we provided the first general population-based 
analysis of the workplace impacts of NSS and related symptoms. We also attempted to 
disentangle these relations from those of condition status (i.e. the presence and severity 
of current symptoms) and diagnosis, in an effort to better understand whether symptoms 
or other aspects of a condition were the major drivers of workplace lost productive time 
(LPT). 
 We took a novel approach to assessing symptoms and their associations with LPT, 
among individuals across the broad spectrum of sinus disease, by using symptom-based 
factor scores from exploratory factor analysis (EFA) models we developed in a separate 
analysis and subsequent publication from the same longitudinal study from which my 
dissertation data were derived.5 By doing so, we could better understand which sets of 
symptoms were most associated with to declines in workplace productivity. We found 
symptom factors relevant to nasal blockage and discharge; facial pain and pressure; and 
asthma and constitutional symptoms were most associated with increased LPT, after 




statuses (e.g., migraine headache, self-reported physician diagnosis of asthma, self-
reported physician diagnosis of hay fever, CRSS).4 
 While facial pain had previously been associated with increased workplace 
presenteeism, in a prior study,6 something we corroborated, it is interesting that facial 
pain (but not facial pressure) has been negatively predictive of being classified with CRS 
in clinical settings.7 This further demonstrates the complexity in defining CRS based 
solely on symptoms, especially when they overlap with several other conditions. 
Additionally, this iterates the possibility that individuals with classifiable disease (i.e. 
meets CRSS criteria) may not necessarily have the most severe symptoms or negative 
outcomes.  
 In a patient-centered care setting,8 these findings can be used to better educate 
patients and bring awareness to how these symptom groups can adversely impact daily 
functioning. Better management of these particular symptoms may also lead to improved 
workplace productivity. 
 Finally, our last study (Chapter 5) sought to extend the issue of measurement of 
CRSC components (i.e. CRSS and objective evidence-based CRS [CRSO]), which we 
began in our exploratory factor analyses of NSS and related symptoms (identifying three 
constructs relevant to CRS instead of the one theoretically implied by CRSS),5 by turning 
our focus to CRSO. Consensus groups,2,9,10 clinicians,11 and researchers12 have all used 
a single-score approach to quantify radiologic inflammation in sinus disease, obtained by 
sinus CT. We first compared a common scoring approach (Lund-Mackay [LM]) and its 
intended improvement (modified Lund-Mackay [mLM]) by using EFA models to 
determine whether both measured the same underlying constructs. Both approaches 
identified one underlying construct, i.e. sinus inflammation, with no noticeable 




scoring process to determine if any additional information could be gleaned by its 
inclusion, since nasal polyposis (identifiable as nasal cavity opacification) is a major 
component of one phenotype of CRS (CRS with nasal polyps [CRSwNP]).9 However, we 
saw no additional constructs emerge nor did factor loadings (i.e. associations of sinus 
locations with underlying construct) change by including nasal cavity opacification; 
though, we were likely underpowered to detect differences imparted by its inclusion.  
 We subsequently used a latent class approach to determine whether patterns of 
sinus opacification could discern mutually exclusive subgroups of individuals. We 
hypothesized that subgroups of individuals may opacify in different locations and 
patterns, which would be contrary to a single-score approach, which assumes all 
locations are exchangeable (i.e. opacification is random or sporadic). We identified three 
latent subgroups of individuals comprising a no/mild opacification class; localized 
opacification class, predominantly in the maxillary sinus; and a diffuse opacification 
class, almost always in the anterior ethmoid and always involving two or more sinus 
locations. Interestingly, these opacification patterns shared similarities with known 
otorhinological drainage routes.13 Additionally, we found differences by sex in the 
proportion of persons across these three classes, with males more likely to be in the 
diffuse class, compared to females. Also, there was a tendency for increased risk of 
being in the localized or diffuse classes if an individual self-reported physician diagnosis 
of asthma or hay fever and met symptom criteria for migraine headaches. 
 Another novelty of our study was the appreciation for causal directionality in the 
relation of radiologic inflammation with symptoms. While prior studies have assessed the 
two in the wrong causal direction (i.e. using symptoms as the independent variables to 
predict inflammation as the dependent variable, when the actual causal direction is that 




evaluate the associations of opacification latent classes with self-reported CRSS 
symptoms. By doing so, we observed the diffuse class was associated with nasal 
blockage and smell loss, but no other symptoms, while the localized class had no 
increased probability of CRSS symptoms, compared to the no/mild class.  
 While future studies are needed to elucidate the clinical relevance of these latent 
classes, our study suggests that a single-score approach to quantifying radiologic 
inflammation in sinus disease is incorrect; rather, location and patterns, as well as 
possibly severity, of sinus opacification should be considered. 
7.1 General population vs. tertiary care samples 
In all of our studies, we used a general population-based sample with individuals 
representing the broad spectrum of sinus disease. Nearly all prior studies of CRS have 
selected individuals from tertiary referral settings, were generally pre-surgical, and likely 
represent the most severe end of the disease spectrum. As such, our understanding of 
CRS has been limited to what was observed in this subpopulation, e.g., surgical 
candidates are often symptomatic (initially leading them to seek care) and have 
extensive radiologic inflammation.9,17-19 However, our CT study sample (Chapter 5) 
shows a more heterogeneous mix of symptoms and radiologic inflammation. We 
observed asymptomatic individuals across the entire LM score range and highly 
symptomatic individuals with no measurable opacification. Further, our average LM 
score was much lower than those reported in tertiary care studies.17,20-22 The shift in LM 
scores towards the lower end of the distribution was expected considering, again, that 
we selected individuals from a general population sample and selection was 
independent of radiologic inflammation (i.e. extent of sinus opacification was not known 




While studies of tertiary referral patients are important for understanding the late-
stage disease process and its implications, they are not suitable for studies earlier in 
disease progression. As such, general population samples with individuals across the 
disease spectrum are necessary, especially if studies aim to understand the intervenable 
points during pathogenesis and how varied etiologic agents relate to disease trajectory. 
7.2 Future research directions and implications for clinical practice and epidemiologic 
research 
 In this section, we discuss the future directions for CRS research in the context of our 
recent findings, their limitations, and what additional studies will be needed to address 
them. Specifically, we discuss the need for replication in our own source population; 
replication in other study populations; longitudinal studies to provide context to our three 
sinus opacification latent classes; longitudinal studies to evaluate disease progression; 
and detail necessary studies to build upon our findings relevant to measurement of 
CRSS and CRSO, with the aim of improving the definition for CRSC. 
7.2.1 Replication in source population 
In our studies, we selected individuals from the electronic health record (EHR) of 
Geisinger (a large healthcare system in predominantly northeastern and central 
Pennsylvania) to participate in our longitudinal, questionnaire-based, epidemiologic 
study of CRS. To validate our findings, it would be advisable to replicate our analyses in 
a new subset of individuals from this source population, following the same sampling 
strategy.23 This internal replication is useful in determining the extent to which our 
previous findings were dependent on subject selection and participation. 
7.2.2 Replication in other study populations 
 While our study sample was representative of the general population for the area, it is 
not representative of the general U.S. population. Replication in other U.S. geographies, 
especially those with greater racial/ethnic diversity, will be paramount to better 




highlighted the international geographic variation in prevalence and phenotypic and 
endotypic profiles of CRS. For example, Asian populations tend to display a T-helper 
1/T-helper 17 (Th1/Th17) mixed inflammatory profile with CRSwNP and Th2 with 
CRSsNP (CRS without nasal polyps), whereas the converse is generally true for studied 
populations in the U.S. and Canada.9,24-26 Therefore, it would be advisable to replicate 
our studies in not just other U.S. populations, but other countries, too.  
 Considering our analyses presented in Chapter 5, the latent class approach to 
categorization of radiologic inflammation should be replicated in other U.S. general 
population-based samples (i.e. not tertiary referral settings) to determine the external 
validity of our original findings, while replication in general population samples from other 
countries would elucidate its transportability.  
7.2.3 Longitudinal studies: context of our latent classes 
 While our latent classes share similarities with known otorhinological drainage 
routes,13 we have limited context to which we can understand the full clinical relevance 
of these subgroups. Further, the estimated latent classes may be sensitive to the range 
of individuals selected for participation in the study. While we selected individuals from 
the broad spectrum of disease, we may, for example, be able to detect subgroups of our 
diffuse opacification class if we assessed opacification patterns among a sample of the 
most severely diseased individuals only. This could potentially be more imperative to 
identification of discrete endotypes of CRS, considering the latent classes obtained in 
our general population sample may not all necessarily be CRS specific.  
 Without longitudinal (i.e. repeated) sinus CT measures, we cannot determine whether 
the three classes represent endotypes of CRS, different stages along the same disease 
process (i.e. different stages of severity), different conditions along the same broad 
process (i.e. acute rhinosinusitis [ARS] to CRS), or discrete pathologies (e.g., migraine 




progressive disease process, we would have likely expected the posterior probabilities of 
sinus opacification in all six locations (Chapter 5) to increase systematically as disease 
severity (i.e. extent of sinus opacification) increased, too.27 While we did not necessarily 
observe this progressive relation with out latent classes in the cross-sectional setting, a 
prior study of sinus CT scans among individuals presenting to primary care settings with 
ARS may give further insight to our localized latent class. 28 In that study, maxillary sinus 
opacification was more associated with ARS than any other sinus location,28 a finding 
which corroborated the first study of sinus opacification in the common cold (e.g., 
ARS).29 Given our localized latent class was driven primarily by isolated maxillary sinus 
opacification, it is possible that this latent class represents an ARS-dominant subgroup, 
while our diffuse latent class represents a CRS-dominant subgroup. 
7.2.4 Longitudinal studies to assess disease progression and identify endotypes of CRS 
 We previously discussed a framework for rhinosinusitis (Chapter 1) in which a subset 
of individuals with ARS transition into CRS and either remit or persist over time.30 Using 
a comparable sampling approach to that used in our studies – one in which a general 
population sample with individuals across the entire spectrum of disease is selected – 
our latent class approach could be extended to determine whether such a disease 
progression is plausible, given observed sinus opacification patterns. As mentioned 
above, different radiologic inflammation patterns could represent stages along a 
common disease continuum, discrete pathologies (i.e. representing different diseases), 
or different endotypes of the same disease state.  
 Previous studies of CRSICD (CRS classified by ICD codes) have suggested that 
individuals with CRSICD were more likely to have had a history of ARSICD31; therefore, it is 
plausible that some individuals with ARS, especially recurrent ARS (RARS), would 
transition into frank CRS.30 Ideally, future studies would enroll individuals across the 




the primary goal of identifying transition from an asymptomatic state to ARS (possibly 
RARS) and eventually CRS. Formally, this could be done using a latent transition 
analysis (LTA) approach in which probability of transitioning from one latent class to 
another, over time, is directly estimated.32 If individuals were most likely to stay within 
their original latent classes, then this would be evidence against disease progression 
and for discrete diseases or pathologies.  
 However, it is yet unclear as to the latency period for transitioning from acute to 
chronic sinus disease. Therefore, designing a prospective study of this sort would be 
difficult and expensive to sustain. Given the wealth of available longitudinal information 
provided by the EHR of Geisinger (which has had an EHR since 2001), a retrospective 
EHR study seems highly amenable to address research questions related to disease 
progression (over a possibly long period of time).   
7.2.4.1 Using biomarkers to identify type of progression 
 Biomarkers including cytokines (e.g., chemokines, interferons, growth factors), 
antibodies, and hormones as well as microbiology should be evaluated within individuals 
comprising our estimated latent classes and in future longitudinal studies of CRS and 
possible disease progression as well as natural history. If disease progression is 
evidenced, this could be a progression along a narrow (i.e. early CRS to late CRS) or 
broad (i.e. ARS to recurrent ARS to CRS) continuum. To differentiate between these two 
possibilities, the characterization of the inflammatory profiles, NSS, and microbiology 
would be crucial. For example, it has been suggested that microbiology of ARS differs 
from those with CRS,30 and therefore microbiology along with reported NSS (including 
frequency, duration, and severity) could aid differentiation.  
7.2.4.2 Using biomarkers to identify endotypes of CRS 
While biomarkers of inflammation would be useful in differentiating narrow or broad 




disease. For example, a prior study of CRSC collected 14 inflammatory biomarkers from 
tissue samples of participants undergoing sinus surgery, finding 10 clusters (i.e. 
endotypes) represented by these individuals.33 However, no prior studies have assessed 
inflammatory biomarkers in relation to disease progression (either from asymptomatic to 
ARS to CRS or from early-stage to late-stage CRS). Similarly, no prior studies have 
assessed differences in subsequent risks (e.g., worse prognoses, risk for subsequent 
morbidity, worse quality of life, workplace impacts) by inflammatory endotype.  
We could leverage our CT scans and other data from Chapter 5 to prospectively 
collect inflammatory biomarkers by readily accessible samples (e.g., nasal lavage fluid) 
and also perform additional CT scans, over follow-up. We could then use formal 
measurement models (e.g. latent profile analysis) to identify latent endotypes of 
inflammation, assess how these endotypes change over time (e.g., LTA), and how sinus 
opacification patterns relate to these endotypes (e.g., latent class regression).   
7.2.5 CRSC redefined 
 In our prior analysis using EFA, we identified as many as three CRS-relevant latent 
constructs measured by a set of 37 NSS and related symptoms.5 This would imply that 
CRSS, which theoretically measures one construct, is inappropriate given its 
encapsulation of several NSS domains. Further, our study of radiologic inflammation 
(Chapter 5) would suggest that the current approach to quantifying radiologic 
inflammation (and therefore operationalization of CRSO) is also incorrect, with location 
and patterns of opacification being important considerations that are currently not 
incorporated. Therefore, an improved operationalization of CRSC must contend with the 
multidimensionality of NSS commonly used in CRSS as well as the need to incorporate 
location and patterns of sinus opacification in CRSO.  
 One possibility is to extend these two components into a single structural equation 




determine whether any NSS factor or factors are predicted by radiologic inflammation 
patterns. Or, perhaps an approach more parallel to reality in which clusters of NSS (e.g., 
latent classes) are regressed on radiologic inflammation latent classes is warranted. 
Considering clustering of NSS may occur differentially in those with differing patterns of 
opacification, this approach would overcome limitations of the former, in which NSS 
factors are entered into latent class regression models as separate covariates 
(potentially missing complex interactions among the NSS factors).  
 However, the above approach may again only identify individuals with late-stage 
CRS. Therefore, multiple definitions of CRS may be necessary. For example, separate 
operationalizations could be used to identify individuals with early-, intermediate-, and 
late-stage disease, especially if future studies determine NSS to vary across the disease 
course (not just in severity, but in terms of which symptoms are reported).  
7.2.5.1 Implication for medical treatment and intervention  
 If disease progression is observed, then it may be possible to intervene earlier in the 
process to prevent individuals from transitioning into more severe disease states (e.g., 
frank CRS). One approach would involve the use of endotyping, which could guide 
medical therapies based on the inflammatory profile observed. If future studies show 
certain inflammatory endotypes nearly always transition from early-stage to late-stage 
CRS, or from ARS to CRS, then medical therapies targeting these inflammatory 
pathways may prevent further disease progression. Endotyping may also help tailor 
medical therapies for individuals with frank CRS. For example, individuals diagnosed 
with CRS who have normal or low IgE levels have been shown to have greater 




7.3 Final remarks 
 The studies described in this dissertation have contributed to the CRS literature in 
important and novel ways. We provided the first study to comparatively assess NSS 
exacerbation definitions relevant to CRS; the first study to quantify the workplace 
impacts of NSS from several related and overlapping conditions; and the first study to 
propose an approach to categorizing radiologic inflammation in sinus disease that takes 
into consideration location and patterns of opacification. Additional studies of CRS 
endotypes, resource utilization, and outcomes are necessary; however, our studies have 
shown that traditional approaches to defining CRSS and CRSO are likely incorrect. 
Therefore, it will be imperative to identify novel approaches to defining CRSC before we 
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7.5 CRISP longitudinal study questionnaires 






























































7.6 CRISP CT study questionnaire 




































































7.8 Cole M, et al. 2018. Longitudinal evaluation of clustering of chronic sinonasal and 
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